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ABG -arterial blood gas 
AC-autocycling asynchronous event 
AI-asynchrony index (all asynchronous breaths as a percentage of all breaths both requested and 
delivered) 
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CT-computer tomography 
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FVC-forced vital capacity 
HADS-hospital anxiety and depression score 
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ABSTRACT 
Introduction: Patient-ventilator asynchrony (PVA) can adversely affect the initiation of home 
mechanical ventilation (HMV).  The aim was to quantify the prevalence of PVA during HMV and 
determine the relationships between PVA and adherence to therapy, respiratory muscle loading, 
nocturnal gas exchange, health-related quality of life measures and sleep quality.   
Method: A pilot randomised control trial was conducted to compare a physiological led set-up of HMV, 
using neural respiratory drive to optimise ventilator set-up, to an expert led set-up.  Type and 
frequency of PVA were measured by surface parasternal muscle electromyography, thoraco-
abdominal plethysmography and mask pressure during initiation of HMV and 3 months post therapy.  
Severe PVA was defined as affecting ≥10% of breaths. 
Results: 40 patients (25 male) were enrolled with an age of 58±17years and a body mass index(BMI) 
of 33±10kg/m2.  Underlying diagnoses were neuromuscular ± chest wall disease (NMD-CWD,n=11), 
obesity-related chronic respiratory failure (ORRF,n=13) and chronic obstructive pulmonary disease 
(COPD, n=16).  Overall, PVA affected 25.6(16.4-35.7)% breaths at initiation of HMV, with ineffective 
efforts as the predominant type of PVA affecting 10.9(4.6-23.7)% breaths.  No difference was 
observed in the frequency of PVA between physician led and physiological led set-up of HMV at 
initiation or 3 months(28.4(17.4-37.6)%vs 25.6(14.0-30.4)%;p=0.6 and 22.4(13.3-37.1)%vs23.3(15.2-
41.5)%;p=0.7,respectively).  
No correlations were observed between PVA and ventilator adherence(rs=0.02,p=0.90), nocturnal 
oxygen saturations(rs =0.04,p=0.85), nocturnal carbon dioxide levels(rs=0.15,p=0.41), respiratory 
muscle unloading(rs=0.06,p= 0.76), patient perception of ventilator synchronisation(rs=0.03,p=0.9) at 3 
months of HMV therapy. 
10 patients (7 male) underwent polysomnography assessment of sleep quality. No further correlations 
were observed between PVA during sleep and sleep efficiency (rs=-0.6,p=0.1), wake after sleep 
onset(rs=0.5,p= 0.2) or total sleep time(rs=-0.4,p= 0.3) at 3 months of HMV therapy.  
Conclusion: Severe PVA was identified in the majority of patients irrespective of pathophysiological 
disease. This was not associated with inappropriate delivery of effective ventilation. These data 
suggest that elimination of PVA may not be required to successfully set-up HMV. 
  
- 26 - 
Chapter 1 Introduction 
 
1.1 A History of Patient Ventilator Interaction 
The first documented use of mechanical ventilation was as an aid to resuscitation in drowning victims 
in the early 1900s and patient ventilator asynchrony was therefore not considered. Negative pressure 
ventilation came into its own in the 1940s to 1950s with the Poliomyelitis epidemic and, interestingly, 
ventilatory support was considered sufficient if patients were unable to phonate during ventilation as 
the clinical conclusion was that inspiratory air flow into the thoracic cavity was adequate. 
Synchronisation with the ventilator was again of little concern as the ventilator was set at a fixed rate 
and the patient was not required to ‘trigger’ the ventilator but just patiently await the delivery of the 
mandatory breath.(1)  
It was not until 1953 when Lassen et al. reported the benefit of manual positive pressure ventilation in 
the treatment of poliomyelitis that the concepts of patient ventilator synchrony and ventilator triggering 
were considered.(2) The first description of the need to design a ventilator to match the needs of a 
patient was described by Harrison in 1964.(3) He observed the benefits of patient triggered ventilation 
to reduce work of breathing and improve patient comfort.(3)  Since then further research has detailed 
the importance of understanding the phases of ventilation produced by the ventilator and the impact 
of poor patient synchronisation with these phases, namely; the change from expiration to inspiration, 
the inspiratory phase, the change from inspiration to expiration and the expiration phase.(4-6)  Since 
the use of the earliest ventilators, many studies have now been performed to compare different 
ventilator performance characteristics and modes of ventilation with their impact on patient ventilator 
synchronisation, work of breathing and patient comfort.(7-10)   Overall these studies suggest that 
ventilator settings and performance may either enhance or adversely affect patient ventilation 
synchronisation but it remains unclear what the impact of poor patient-ventilator synchronisation on 
patient outcomes. The latter question will be addressed throughout this thesis.  
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1.2 Mechanisms of respiratory failure 
The respiratory system is made up of two main components; the respiratory muscle pump that 
facilitates airflow enabling ventilation and the lungs that support pulmonary gas exchange. The 
respiratory muscle pump itself is comprised of the inspiratory muscles, the diaphragm and chest wall 
intercostal muscles, and the expiratory muscles, principally the abdominal wall muscles.  Inspiration is 
an active process in which contraction of the diaphragm forces the abdominal contents in an 
anterocaudal direction and contraction of the intercostal muscles lifts the rib margins up and outwards 
which allows the volume of the chest cavity to increase.(11)  This, in turn, generates a negative sub-
atmospheric pressure to form a pressure gradient that drives air from the atmosphere into the 
lungs.(12) At rest, expiration is a passive process with the elastic properties of the chest wall and 
lungs providing the recoil forces that allow the lung volume to return to the functional residual 
capacity.  During spontaneous breathing the pressure generated by the respiratory muscles in 
inspiration must overcome the elastic and resistive forces that oppose inflation of the respiratory 
system. (13) This can be simply described by the equation of motion of the respiratory system: 
                                          Pmus = (Rrs x V. + PEEPi) + (Ers x Vt) 
Pmus is the pressure generated by the respiratory muscles, Rrs is respiratory system resistance, V. is 
inspiratory flow, PEEPi is intrinsic positive end expiratory pressure, Ers is respiratory system 
elastance and Vt is tidal volume..  
Breathlessness, alveolar hypoventilation and hypercapnic respiratory failure result from an imbalance 
between the respiratory muscle load and capacity.  In other words, the resistance and elastance of 
the airways, lung and chest wall plus the intrinsic positive end expiratory pressure associated with 
airflow limitation in chronic obstructive airways disease (respiratory muscle load) exceeds the strength 
and endurance of the respiratory muscle (respiratory muscle capacity).(14) This results in modification 
of the neural respiratory drive, which directly reflects the imbalance of the respiratory system.  An 
increase in respiratory muscle load occurs in patients with chronic obstructive airways disease, 
obesity and chest wall deformity. (Figure 1).  A reduction in respiratory muscle capacity occurs in 
patients with neuromuscular disease (e.g. motor neurone disease and muscular dystrophies) and 
chest wall deformity. 
  
- 28 - 
Figure 1: Types of Respiratory Muscle Load 
 
 
Non-invasive ventilation (NIV) is used to positively assist this load-capacity imbalance by unloading 
the respiratory muscles and augmenting alveolar ventilation.  This leads to a reduction in the patient’s 
work of breathing and improved gas exchange with the aim of resolving the respiratory failure.             
(Figure 2). 
During a pressure controlled mode of mechanical ventilation the patients respiratory muscle is 
completely off loaded i.e. Pmus= 0.  In this situation the pressure applied to the respiratory system to 
facilitate inspiration is solely from the ventilator.  The equation of motion of the respiratory system 
becomes (13): 
                      Pvent = (Rrs x V, + PEEPi) + (Ers x Vt) 
Pvent is the pressure applied by the ventilator.  
In assisted modes of ventilation such as pressure support ventilation both the patient and ventilator 
contribute to inspiratory pressure generation.(13)  
                   Pvent+ Pmus = (Rrs x V,+ PEEPi) + (Ers x Vt)  
THRESHOLD LOAD , 
respiratory muscle geometry 
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In addition to the manipulation of the load-capacity balance when using mechanical ventilation, 
multiple variables can be set on the ventilator to either decrease or if inappropriate increase a 
patient’s work of breathing.  The pressure support levels, inspiratory time, flow and volume settings of 
the ventilator dictated by the physician also have an effect on the patient’s respiratory pattern and 
synchrony with the ventilator.  Although increasing pressure support increases respiratory muscle 
unloading, very high levels of pressure support have been shown to both reduce neural respiratory 
drive to the respiratory muscles and increase intrinsic positive end expiratory pressure in obstructive 
airways disease adversely impacting on the triggering of the ventilator. (13, 15, 16) 
A similar effect is seen with a fixed inspiratory time, increasing flow in this setting leads to increased 
tidal volume, activating stretch receptors which results in a negative feedback on the brainstem, 
reducing neural drive to the respiratory muscles.(11)    
With high tidal volume or pressure support settings the ventilator will take longer to cycle into 
expiration and the ventilator inspiratory time may exceed the patients neural inspiratory time.(13)  The 
expiratory time will be reduced and in obstructed pulmonary mechanics ‘breath stacking’ or 
hyperinflation may result.(13)  Furthermore, high flow rates may induce tachypnoea through the 
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Figure 2: The interplay of the load-capacity balance and its relationship with the ventilator to 






1.3 Assessment of the patient in chronic respiratory failure 
1.3.1 Clinical Assessment 
 
History 
Clinical assessment should include a detailed focused history and examination.  The main aim is to 
identify an underlying diagnosis and the severity of symptoms affecting the patient. The speed of 
onset of symptoms may help guide the timing of initiation of ventilation particularly in the 
neuromuscular disease patient group.  In chronic ventilatory failure the onset may not be clear but 
clues can be gained from the history as to the course of events.  Often patients will describe 
dyspnoea on exertion but if peripheral muscle weakness precedes respiratory muscle weakness the 
patient may not be able to exert themselves sufficiently to produce dyspnoea.  Classical features of 
     + 
NON-INVASIVE 
VENTILATION 
    VENTILATORY SUCCESS     VENTILATORY FAILURE 
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diaphragm weakness are not always present in patients with generalised neuromuscular disease but 
may include dyspnoea on lying supine, on bending forward or on entering water where the depth 
reaches their waist.(19, 20)  In all cases of respiratory muscle weakness it is reasonable to enquire 
about symptoms which might suggest generalised neuromuscular weakness, in particular about the 
patient’s speech, swallowing and choking as well as weakness of the arms and legs.  Weakness of 
the abdominal muscles may result in difficulty achieving an effective cough to clear debris from the 
airways.  This leads to issues with sputum retention and greatly increases the risk of chest infection.  
Medication can exacerbate symptoms so common offenders such as corticosteroids and muscle 
relaxants should be identified and stopped where possible. Smoking history may help to support a 
diagnosis of chronic obstructive airways disease. 
If hypercapnic respiratory failure is present patients may describe symptoms of nocturnal 
hypoventilation, such as daytime somnolence, reduced concentration and morning headaches that 
resolve typically within 30 minutes of waking.(21)  
Examination 
Physical examination should be conducted to support the suspected diagnosis. In the case of obesity, 
kyphoscoliosis or chronic obstructive airway disease signs are usually self-evident..  Signs of 
underlying neuromuscular disease may be more subtle but examination may provide evidence of 
generalised muscle weakness in the form of muscle wasting and fasciculation or pseudohypertrophy.  
Scars of previous operations may indicate possible trauma to underlying neuromuscular structures.  
With severe diaphragm weakness abdominal paradox can be seen; where the diaphragm moves 
inwards on inspiration as opposed to outwards whilst the thorax expands. In more generalised 
weakness global loss of thoracic expansion on inspiration maybe seen. 
 
1.4 Clinical investigations  
1.4.1 Arterial blood gas (ABG) measurement 
ABG measurement is a useful first line investigation to detect acute, acute on chronic and chronic 
respiratory failure but the operator should be aware of its limitations. In particular, daytime PaCO2 
may be normal despite the presence of substantial inspiratory muscle weakness.  However, it is 
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essential to confirm the presence of chronic respiratory failure and defining the severity.  Chronic 
hypercapnic (type II) ventilatory failure is defined as a PaO2 of less than 8 kPa and a PaCO2 above 
6kPa.  Chronic ventilatory failure frequently presents insidiously and the patient may compensate for 
the increased acid load in the blood through renal retention of bicarbonate. Initial blood gases typically 
identify a picture of compensated chronic  ventilatory failure where the pH remains within the normal 
range (7.35-7.45).  In the event of rapid onset of neurological symptoms or in an acute deterioration of 
a chronic condition there is less time for renal buffering which takes in the region of a few days.  ABG 
result interpretation will therefore describe decompensated chronic hypercapnic ventilatory failure with 
a pH < 7.35 resulting directly from hypercapnia.  
 
1.4.2 Lung function tests 
Patients with respiratory neuromuscular weakness, chest wall disease and obesity present with 
features of a restrictive lung function pattern i.e. a low forced vital capacity (FVC) and an elevated 
forced expiratory volume in 1 second (FEV1) to FVC ratio, (FEV1/FVC > 80%).  Whereas, patients 
with COPD present with airflow obstruction that is a low FEV1 to FVC ratio (FEV1/FVC <70%). (22) 
Total lung capacity (TLC) and vital capacity (VC) are diminished in restrictive lung disease, however, 
the functional residual capacity (FRC) is preserved and may, in fact, increase.(23)  The residual 
volume (RV) is often increased especially if the expiratory muscles are involved.  In obstructive lung 
disease, the TLC and RV are usually increased.  
Although vital capacity (VC) has the advantage of simplicity, it is not very sensitive with significant 
muscle weakness being required (up to 50%) before an appreciable reduction is observed.(24)  The 
VC is, of course, also reduced in restrictive chest wall conditions and indeed often in obstructive lung 
disease.  A fall in VC on adopting the supine position is specific for respiratory muscle weakness and 
fall in VC of more than 20% indicates bilateral diaphragmatic weakness.(25)  Importantly, falls in VC 
within the normal range may occur with moderate degrees of weakness or hemi diaphragm weakness 
which can be more difficult to detect.  
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1.4.3 Non-invasive and Invasive Respiratory Muscle tests 
Respiratory muscle strength tests are used to confirm respiratory muscle weakness in those with 
suspected underlying impairment.  The commonly used non-invasive respiratory muscle tests can be 
easily performed with a handheld device and attached nasal bung or mouthpiece.  
Maximal inspiratory and expiratory pressures 
The maximal inspiratory pressure (MIP) is the maximal voluntary inspiratory pressure the patient can 
generate breathing in as measured the airway opening from FRC or RV.  If performed from FRC 
encompasses only the strength of the respiratory muscles whereas from RV a component of elastic 
recoil is also included. Disadvantages are the volitional aspect of the test which means that it is partly 
dependent on patient effort.(24)  Therefore while a high value (> 80 cm H2O in men and > 70 cm H2O 
in women) would confidently exclude inspiratory muscle weakness a low value is inconclusive.(24)  
The maximal expiratory pressure (MEP) is the maximal voluntary expiratory pressure the patient can 
generate breathing out; these are similarly measured from TLC or FRC. Challenges can be met in 
ensuring an adequate seal at the mouthpiece especially in patients with facial muscle weakness; a 
facemask may be preferred in this situation.   
Sniff nasal inspiratory pressure 
In order to negate issues of variability related to patient effort in performing maximal inspiratory 
manoeuvres, the maximal sniff nasal inspiratory pressures (SNIP) may be used as a more reliable 
outcome measure.  The SNIP is initiated at FRC and is taken as the maximal short, sharp inspiratory 
sniff a patient can perform.  It is usually measured through occlusion of one of the nasal passage with 
a nasal bung fitted with a small piece of tubing that connects to a handheld pressure transducer.(24, 
26)  Normal SNIP values would be >70 cm H2O in males and >60cm H2O in females.(27)  In view of 
the distance of the nose from the origin of the pressure generated at the active respiratory muscle 
pump, the pressure at the nose will be attenuated compared to the oesophageal or 
transdiaphragmatic pressures in patients such as those with airways disease.(24) To eliminate this 
problem it may also be necessary to measure transdiaphragmatic pressure during a sniff manoeuvre.   
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1.4.4 Peak Cough Flow 
Peak cough flow (PCF) is another simple non-invasive measure of expiratory muscle function which 
can be useful in the absence of obstructive lung disease.  It can be used as a marker of expiratory 
cough function and, consequently, the ability to clear respiratory secretions A PCF value less than 
160L/min is reported to be the cut-off value to predict an increased risk of chest sepsis (28). 
1.4.5 Invasive respiratory muscle tests 
Transdiaphragmatic pressure (Pdi) monitoring provides an assessment of diaphragmatic muscle 
strength and is derived from the gastric pressure (Pgas) minus the oesophageal pressure (Poes).(29) 
Pdi is assessed in combination with maximal inspiratory manoeuvres described above as to better 
identify inspiratory muscle weakness.  Pdi monitoring requires the ‘per nasal’ passage of a catheter 
with an oesophageal and gastric balloon attached to a pressure transducer to record the Pgas and 
Poes.  EMG pair electrodes can also be attached to the catheter to directly measure crural diaphragm 
electromyography as a marker of neural respiratory drive.(30)   
The phrenic nerve (originating from cervical nerve roots 3, 4 and 5) is selective in supplying the 
diaphragm only. To identify diaphragm muscle weakness the phrenic nerve can be activated by both 
an electric and magnetic stimulus, which is known as a ‘twitch’.(31)  The measurement of Pdi 
following supramaximal phrenic nerve stimulation currently provides the gold standard measurement 
for demonstrating unilateral or bilateral diaphragm weakness.(24)  Although this has the advantage of 
being a non-volitional test, measuring Pdi is an invasive test and maybe poorly tolerated by patients 
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Figure 3: Equipment required to measure twitch transdiaphragmatic pressure, diaphragm and 
simultaneous parasternal electromyography 
 
Written permission kindly received from the patient for this photograph 
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1.4.6 Imaging 
The chest radiograph is most helpful in identifying other reversible causes of respiratory failure.  It 
may also assist a diagnosis of COPD where evidence of hyperinflation may be seen.  However, an 
elevated hemi diaphragm as seen on plain chest radiography is often considered to indicate 
diaphragmatic paralysis but this in fact is only confirmed by diaphragmatic testing in approximately 
24% of cases.(32) 
Computerised tomographic (CT) scanning may have particular value in the assessment of pleural 
causes of restriction.  It is seldom helpful in obesity except to exclude thrombo-embolic disease 
although parenchymal lung disease may be an unexpected coincidental finding.  The chest 
radiograph of patients with scoliosis is often difficult to interpret and here CT scans may reveal new 
abnormalities when there is a clinical index of suspicion.. 
 
1.4.7 Overnight physiological monitoring 
Overnight oximetry and capnography is an essential part of the assessment to facilitate the early 
detection of nocturnal hypoventilation.  It is recommended in anyone with neuromuscular disease 
describing symptoms of sleep disordered breathing, such as daytime somnolence, early morning 
headaches, orthopnoea and a decline in cognitive functioning.  Some groups advocate the use of 
polysomnography to confirm arousals during apnoeas and hypopnoeas and therefore quantify the 
extent of sleep disturbance.(33, 34)  This is not routinely used in UK practice. In our unit, we typically 
titrate ventilatory support to the degree of hypercapnia identified irrespective of the sleep stage of the 
patient.  Surrogates for sleep fragmentation events can be crudely identified from transcutaneous 
capnography and oximetry alone.(35)  Respiratory inductance polygraphy (RIP) measures abdominal 
and thoracic excursion and may be used to differentiate obstructive and central apnoeas.  
 
1.5 The role of domiciliary non-invasive ventilation in chronic respiratory 
failure 
Mechanical ventilation has progressed over the last century from negative pressure ventilation to 
positive pressure ventilation and the development of non-invasive interfaces facilitating its use in a 
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domiciliary setting.   Initial demand for non-invasive respiratory support was driven by the increase of 
respiratory failure accompanying the poliomyelitis epidemics of the 1930-1940s. Non-invasive 
ventilation (NIV) has become one of most significant advances in treating hypercapnic respiratory 
failure over the last 20 years and with its substantial benefits its use has increased by 400% over the 
last 10 years for acute exacerbations of COPD alone.(36)   Recent demand is changing to include 
patients with chronic obstructive pulmonary disease and obesity hypoventilation syndrome with an 
emerging obesity epidemic.(1)  Although all these patients may present with a similar degree of 
respiratory failure, the aetiology differs widely and poses very different pulmonary mechanical 
challenges on the interaction between the patient and ventilator.  
1.5.1 Neuromuscular Disease (NMD) 
In patients with NMD, there is limited pressure generating capacity of the respiratory pump mainly as 
consequence of intrinsic muscle weakness.  There is substantial reserve in the respiratory muscle 
pump, such that inspiratory muscle strength must fall to one third of normal before the onset of 
respiratory failure occurs.(37)  On occasions, there can be relative preservation of vital capacity.  
However, in the context of a significant respiratory muscle load or poor orientation of the inspiratory 
muscles (e.g. kyphoscoliosis), dyspnoea and alveolar hypoventilation can develop.  An increased load 
applied to the respiratory system, such as an episode of pneumonia, or if the neural respiratory drive 
is modified with drugs (such as benzodiazepines, opiates and other anaesthetic agents during routine 
anaesthesia), may precipitate respiratory failure to be observed at an earlier stage.  Patients with 
respiratory muscle weakness, in particular diaphragm weakness and paralysis, often present with 
signs of hypoventilation during rapid eye movement (REM) sleep as the first sign of declining 
respiratory function due to a reduction in neural respiratory drive to the respiratory muscles during 
REM sleep.(37)   
Early studies identified that a majority of patients with progressive NMD such as Motor Neurone 
Disease and Duchenne Muscular Dystrophy died from respiratory failure, suggesting a role for long 
term non-invasive ventilatory support.(38)   Studies have since shown a significant improvement in 
gas exchange following 3 months use of non-invasive ventilation.  The mechanism of action has been 
associated with an improved hypercapnic ventilatory response seen as early as at 5 days with further 
improvement at 3 months.(39)  No changes in pulmonary mechanics defined by lung volume and 
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compliance measurements or respiratory muscle strength tests were seen.(39)   Data from previous 
studies have suggested that long term domiciliary non-invasive ventilation improved survival and 
quality of life for selected patients with NMD.  A randomised controlled trial (RCT) of NIV treatment 
compared to standard care, based on 41 patients with motor neurone disease, identified an overall 
survival benefit of 48 days and improved quality of life scores  following NIV use but no improvement 
in survival for those with severe bulbar dysfunction.(40)  These trials have been used to support the 
use of domiciliary NIV in NMD patients.  However, the optimum timing of NIV initiation remains 
unclear. Common clinical practice is to start NIV when the patient has symptoms of nocturnal 
hypoventilation, such as early morning headaches or increased daytime somnolence, or if there is 
profound respiratory muscle weakness with signs of orthopnoea or daytime hypercapnia.  An RCT 
comparing initiation of NIV pre-respiratory failure to standard care in 70 Duchenne Muscular 
Dystrophy patients did not show any protective effect of prophylactic NIV in delaying the onset of 
respiratory failure and a higher mortality in the early ventilated group.(41) However, other differences 
in the clinical management of the two groups call the findings of this study into question.  Often in 
chronic neuromuscular disease, respiratory muscle weakness requiring ventilatory support signifies a 
move towards considering end of life care.  This can be a challenging time for both patients and 
relatives, it is crucial that appropriate support and discussions are had in advance to anticipate 
concerns and tailor respiratory care to the patient.   Patients may need to adapt to the use of the 
ventilator and the timing initiation must be carefully planned so that the benefits of NIV outweigh its 
inconvenience. (42)  
Most of the studies of NMD have also included patients with chest wall disease (CWD) and shown a 
survival benefit of using NIV compared to home oxygen therapy.(43)  The mechanism of action of 
improved gas exchange is again thought to be due to an improved hypercapnic ventilatory 
response.(39) 
Primarily due to intrinsic muscle weakness in NMD or poor orientation of respiratory muscles in CWD, 
these patients have difficulties in optimising the respiratory pump function to generate negative 
pressure within the chest and so induce air flow into the lungs.  Most domiciliary non-invasive 
ventilators are triggered by changes in pressure or flow.(44)   Patients with NMD or CWD are unable 
to achieve this reliably and so will commonly experience triggering difficulties with the ventilator.  
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Facial muscle weakness can make interfaces prone to leak which may also interfere with ventilator 
triggering and cycling to expiration.  Persistent leak beyond leak compensation capacity of the 
ventilator is interpreted as patient inspiratory demand.  
 
1.5.2 Chronic Obstructive Pulmonary Disease (COPD)  
Patients with COPD exhibit expiratory airflow limitation as a consequence of airways resistance and 
reduced lung compliance.(45)  A complication is incomplete lung emptying, lung hyperinflation and a 
positive end expiratory pressure.(46) The positive end expiratory pressure acts as a threshold load 
that must be overcome to enable airflow during inspiration. In addition to this, the respiratory muscle 
pump capacity is reduced by the mechanical disadvantage of diaphragm muscle shortening that 
accompanies hyperinflation.(47)  Inflammation causes both airway and parenchymal destruction 
leading to increased dead space ventilation, ventilation perfusion mismatching, and inadequate 
ventilation.(47) 
The evidence for using NIV to treat acute exacerbations of COPD is well established.(48)  However, 
the evidence to support long term domiciliary ventilation is less clear. Long term oxygen therapy, 
when used for more than 15 hours a day, has shown a survival benefit in patients with severe COPD 
but does not control nocturnal hypoventilation.(49)  As with the neuromuscular patients, the use of 
nocturnal NIV to support patients who are symptomatic from nocturnal hypoventilation would seem 
appropriate. Previously, there was little evidence to suggest that non-invasive ventilation has a 
significant survival benefit or reduction in exacerbation rate over long term oxygen therapy alone.(50-
52)  These studies have been criticised for using small numbers of patients that have had insufficient 
acclimatisation to NIV before starting the study and for using insufficient pressure support to control 
hypercapnia.(53)  A  study by Windisch et al. in 2009 suggested that using higher pressure support 
(mean IPAP of 28cmH20, mean EPAP 4cmH20) improved daytime hypercapnia, lung function and 
haemocrit, plus perhaps reduced mortality and the frequency of exacerbations compared to previous 
data.(54)  Most recently, Murphy et al. have demonstrated a 3 month improvement in admission free 
survival over a 12 month period following an exacerbation with hypercapnic respiratory failure with the 
use of HMV.  Patients recruited in this study had persistent hypercapnia (PaCO2 >7kPa, >53mmHg) 
2-4 weeks post the resolution of respiratory acidaemia following an exacerbation of COPD.(55) This 
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would suggest that identifying and targeting the subset of patients with COPD that have chronic 
respiratory failure are most likely to benefit from HMV. Patients that are unable to tolerate long term 
oxygen therapy without becoming significantly hypercapnic may also find some improvement. COPD 
patients with frequent admissions to hospital in hypercapnic respiratory failure may be another 
subgroup who could be considered for home non-invasive ventilation. These principles are used to 
provide non-invasive ventilation for COPD patients in our respiratory high dependency unit. 
The mechanism of ventilatory improvement with NIV in COPD patients  was studied by Nickol et al. 
(56) This demonstrated an improvement in the patients ventilatory response to breathing carbon 
dioxide from just 5 days use of NIV. Patients were followed for a total of 3 months.  Hyperinflation 
reduced, suggesting improvements in pulmonary mechanics, but no change in respiratory muscle 
strength was observed.   
Due to altered pulmonary mechanics, COPD patients can develop a number of difficulties in co-
ordinating with the ventilator.  Frequently, the patient can experience inspiratory efforts that are not 
successful in triggering the ventilator. Unlike the neuromuscular patients, this is thought to be related 
to positive end expiratory pressure, which must be overcome to generate a negative pressure change 
in the thorax and facilitate inspiratory flow to trigger the ventilator.(13, 15)  The combination of breaths 
that are unable to trigger the ventilator and the added load of breaths that do trigger the ventilator 
markedly increases the patient’s work of breathing and may lead to an underestimation of the 
respiratory rate.  Increasing the trigger sensitivity may not assist in improving triggering of the 
ventilator.  Instead, prior studies have suggested that adding an external end expiratory pressure 
(EPAP) can reduce the number of ineffective breaths and the work of breathing.(57, 58)  Another 
approach is to reduce the pressure support applied to the patient.   This has been shown to reduce 
ineffective patient breaths by limiting the delivery of excessive tidal volume, reducing dynamic lung 
hyperinflation and improving positive end expiratory pressure in obstructed patients.(8, 18) 
COPD patients may also experience poor synchrony when the ventilator changes from inspiration to 
expiration by a reduction in the inspiratory pressure applied. This is known as ‘ventilator cycling’.  The 
ventilator is usually triggered to change into the expiratory phase by a reduction in inspiratory flow 
commonly when inspiratory flow has decreased to 25 percent of the peak flow rate achieved during 
the breath.(13)  In obstructed airways, lower peak flow rates are achieved and the flow rates take 
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much longer to reach 25 percent of the maximal flow rate. A patient with severe COPD may take a 
second longer to reach 25 percent of maximal flow rate compared to a subject without obstructed lung 
disease.(13) If the ventilator continues to provide inspiratory support which the patient no longer 
requires, this will reduce the time available for expiration, reduce lung emptying capacity and may 
therefore lead to worsening dynamic hyperinflation and positive end expiratory pressure.  As 
described above, this may consequently impair triggering of subsequent breaths and increase the 












1.5.3 Obesity Hypoventilation Syndrome (OHS) 
Obesity hypoventilation syndrome is defined as a combination of Obesity (BMI >30 kg/m2), daytime 
hypercapnia (PaCO2 > 6kPa) and sleep disordered breathing.(60)  It is hypothesised that 
breathlessness and alveolar hypoventilation in obese patients results from an imbalance between the 
respiratory muscle load, capacity and neural respiratory drive, although the exact pathophysiological 
details are yet to be determined.  Fat distribution has a significant effect on pulmonary mechanics with 
central obesity placing the largest load on the respiratory system. Respiratory muscle capacity, albeit 
estimated using volitional MIP and MEP measurements, was found to be reduced in hypercapnic 
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obese patients compared with eucapnic obese patients.(61)  However, direct measurement of 
diaphragm strength, using Pdimax, demonstrated no difference between eucapnic and hypercapnic 
obese patients indicating that diaphragm weakness does not contribute to the development of 
ventilatory failure in obese patients.(62)  In contrast, there is a difference in respiratory muscle load 
between hypercapnic obese patients and eucapnic obese subjects with greater upper airways 
resistance in both sitting and supine position and reduced respiratory system compliance.(63, 64)  
This increasing load on the respiratory muscles results in a reduction in lung volumes, with a 
reduction in FEV1 and FVC and an elevated FEV1/FVC ratio confirming a restrictive defect.(64)  In 
addition, TLC, expiratory reserve volume (ERV) and FRC are all reduced.  Interestingly, these 
reductions are more marked in obese patients with hypercapnic respiratory failure compared with 
eucapnic obese subjects with a matched BMI.(64)  This indicates that in addition to absolute fat load 
the distribution of the fat is important in determining the severity of lung restriction.  The reduction in 
lung and chest wall compliance results from the obese patient breathing at a lower lung volumes..(65) 
Breathing at a lower lung volume also results in closure of the small airways during early expiration 
causing expiratory airflow limitation and development of intrinsic positive end-expiratory pressure 
(PEEPi).(64)  This phenomenon is exacerbated by an obese patient adopting a supine position, such 
as occurs during sleep.(66)   
Work by Piper et al. has demonstrated that non-invasive ventilation in OHS does improve 
physiological parameters such as gas exchange, sleep quality, daytime somnolence and health 
related quality of life measures.(67)  Nowbar et al. have suggested a survival benefit with NIV use but 
there have not been any studies to compare treatment against standard care.(68)  A prospective RCT 
comparing NIV with CPAP therapy did not suggest any additional benefit of NIV however the patients 
recruited to this study did not have severe nocturnal hypoventilation.(67)  Ventilatory benefit of NIV in 
OHS is again thought to be mediated by an improved hypercapnic ventilatory response.(69)   
Very few studies have been performed looking at patient ventilator synchrony in obese patients.  
Potential problems related to an elevated positive end expiratory pressure may be predicted to 
manifest as difficulties in triggering the ventilator similarly to that seen in COPD.  Upper airways 
obstruction that often accompanies hypoventilation in these patients may also impact on ventilator 
triggering making it difficult to generate flow against this obstruction.  A study by Guo et al. identified 
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poor synchronisation with the ventilator affecting more than half of the 20 obese patients studied 
predominantly in sleep stages 1 and 2.(70)  The authors also demonstrated that the asynchronous 
events occurring in sleep stages 1 and 2 were more likely to result in arousals.(70)   
 
1.6 Non-invasive ventilation (NIV) failure  
Despite the benefits of NIV, a significant number of patients still fail to comply with NIV.  NIV failure 
rates for acute exacerbations of COPD, pulmonary oedema and all cause acute respiratory failure are 
quoted between 5 and 38%.(71, 72)  Late NIV failure (more than 48 hours post initiation) confers a 
much higher mortality risk and recent data published by Chandra et al, based on 7.5 million COPD 
admissions in the United States of America, suggests that this group of patients is increasing.(36)  A 
recent BTS audit (2013) into adult non-invasive ventilation in the United Kingdom identified that 
‘general intolerance’ was the cause of a third of patients failing acute NIV.(73) 
Similarly to acute NIV, a proportion of patients fail to adhere to domiciliary non-invasive ventilation. 
Data from our own high dependency respiratory unit has quoted an average failure rate of 38% at one 
year. The failure rates vary across disease groups with 13.8% of COPD patients, 22.8% of NMD and 
chest wall disease (CWD) patients and 41.6% OHS patients failing long term NIV at one year.(74)  
After death, the commonest cause for NIV failure was poor tolerance of ventilation. 
Potential causes of NIV failure have been suggested as poor-patient selection, progression of the 
underlying disease process, poor patient tolerance of interfaces and the ventilator strategy used.  
Whilst some factors are not modifiable such as the severity of pathology affecting the patient, the 
appropriate set up of the ventilator is physician dependent and could be manipulated to improve 
patient-ventilator synchrony. Improved synchrony may lead to complete respiratory muscle unloading, 
improved patient comfort and therefore better tolerance and adherence to ventilation.  To date, a 
direct relationship between poor patient ventilator synchrony and NIV failure has not been 
demonstrated.  However, poor patient-ventilator synchrony has adversely affected gas exchange, 
respiratory muscle unloading, sleep quality and patient comfort. (18, 75, 76)   
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1.7 Patient-Ventilator Interaction in Mechanical Ventilation 
 
1.7.1 Defining patient-ventilator synchrony 
Patient ventilator synchrony describes the co-ordination between the patient’s respiratory effort and 
the mechanical breaths delivered by the ventilator. The ideal situation would be for both the patient’s 
neural inspiratory phase to match the ventilator inspiratory time (Ti) and the patient’s expiratory phase 
to match the ventilators cycling into expiration.  
In other words: Neuralinspiration = Ventilatorinspiration and Neuralexpiration = Ventilatorexpiration. This is 
often referred to a neuroventilatory coupling.  . 
Figure 5: An example of adequate patient ventilator synchrony 
 
Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- second intercostal parasternal electromyography 
signal, Rectified RMS Signal- rectified root mean square of the parasternal electromyography signal. 
 
When patient and ventilator matching is incomplete, ‘patient-ventilator asynchrony’ occurs.  Patient-
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1.7.2 Difficulties in assessing the prevalence of patient-ventilator asynchrony 
Previous work has assessed the prevalence of patient-ventilator asynchrony (PVA) predominantly in 
association with invasive ventilation in the intensive care unit.  When describing the prevalence of 
asynchrony the reader must be cognisant of the observation period.  As asynchrony is an intermittent 
phenomenon, very short observation periods may fail to detect and capture the quantity and type of 
PVA that is actually present.  As patient factors, such as disease progression or improvement, may 
change on a daily basis different amounts of asynchrony may be seen in the first 24 hours compared 
to that seen a few weeks post initiation of ventilation.  One would also predict that differences in the 
asynchrony levels may relate to the changes in neural drive and breathing pattern between when the 
patient is awake or asleep.  The current literature has reported PVA over a range of time from 1 
minute to 120 minutes, which, although useful, provides only a PVA snapshot.  (Tables 1-3). 
The asynchrony detection method may also affect the reported prevalence of events. The current gold 
standard detection method is the measurement of the oesophageal pressure (a negative pressure 
indicating the start of inspiratory flow) and a measure of the electrical activity of the respiratory 
muscles (indicating the precise start of neural inspiratory and expiratory time).  This is commonly 
measured by per nasal placement of a pressure monitoring catheter with a multiple array of 
electrodes attached to measure the crural diaphragm muscle electromyogram (EMGdi). The 
oesophageal and gastric pressures (Poes and Pgas) are measured via balloons mounted on the 
same catheter and connected to 2 pressure transducers as described in Section 1.4.5.  
Using simple markers of pressure, flow or ventilator waveforms without respiratory muscle 
electromyography may underestimate or overestimate the number of asynchronous events.  In 
patients with obstructive pulmonary mechanics and positive end expiratory pressure or 
neuromuscular disease, the respiratory muscle contraction may be insufficient to result in a detectable 
change in pressure or flow and so the patient’s respiratory effort would be under reported.  
Conversely, in the presence of extrinsic factors such as airway secretions, interface leak or cardiac 
oscillations, interruptions in pressure or flow signals may falsely be attributed to patient effort.  This 
would lead to an overestimation of certain types of PVA. (Tables 1-3). 
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1.7.3 Difficulties in reporting the prevalence of patient-ventilator asynchrony 
To date, studies reporting asynchrony data lack a uniform approach describing PVA as the 
percentage of patients with asynchrony or the percentage of breaths that are defined as 
asynchronous. Others have described PVA as the percentage of total asynchronous breaths only and 
as the number of asynchronous events occurring per minute or per minute per individual patient.  This 
ambiguity has made it difficult to compare the prevalence of asynchronous events between different 
studies and different disease groups. In order to improve on these discrepancies, Thille et al. 
developed an asynchrony index.(77)  This ratio was expressed as a percent defined as the number of 
asynchronous events divided by the total respiratory rate.  The total respiratory rate was calculated as 
the sum of all the ventilator delivered breaths (triggered and non-triggered) plus the wasted inspiratory 
efforts demanded by the patient without triggering the ventilator (ineffective efforts).  Work by Vitacca 
et al. based solely on ineffective efforts (a single type of patient ventilator asynchrony) evaluated the 
effect of different ventilator pressure support settings on PVA.(18)  When pressure support was 
removed and a PEEP (positive end expiratory pressure) of 5 cmH20 was applied to the patient, the 
mean plus the standard deviation of the percentage of ineffective efforts did not exceed 10% of 
breaths per minute.  Thille et al. defined an asynchrony level with an asynchrony index less than 10% 
of breaths affected as acceptable.  Subsequent studies have focused on this cut off level of 10% of all 
breaths (both delivered and requested) to investigate consequent clinical outcome measures.(77, 78)   
1.7.4 Critique of the current asynchrony index 
Using a 10% cut off level for the asynchrony index as a measure to describe the prevalence of PVA 
may not be translatable across all types of asynchrony because it was based on a single type of 
asynchrony (ineffective efforts).  The asynchrony index reported by Vitacca et al was developed 
based on 36 patients receiving invasive ventilation in the intensive care setting.  It is not yet clear if 
using a 10% cut off for this index provides any useful clinical information in patients receiving non-
invasive ventilation.  Furthermore, as the asynchrony index is a categorical rather than a continuous 
variable, the current 10% cut off does not provide the clinician with an appreciation of the magnitude 
of the problem as the asynchrony index could range from 11% to 100% for which the clinical 
implications may be wholly different.  The current asynchrony index was based on data measured 
over a one minute period, which may not provide an accurate reflection of the PVA occurring over the 
many hours that mechanical ventilation is used. 
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Despite these criticisms, in the invasive ventilation setting an asynchrony index greater than 10% has 
been associated with important patient outcomes such as increased duration of mechanical 
ventilation, reduced ventilator free survival, increased hospital length of stay and a reduced likelihood 
of discharge home.(78)   
 
1.7.5 Prevalence of patient-ventilator asynchrony in invasive ventilation 
 Studies of PVA during the first 24 hours of invasive ventilation in the intensive care setting 
demonstrated asynchronous events affecting 27% to 42% of patients. (Table 1). In studies of patients 
on invasive mechanical ventilation for more than 24 hours, PVA were identified over a wider range 
affecting 11% to 72% of patients. (Table 2). 
Table 1: A summary of the amounts of asynchrony reported during invasive ventilation for 
acute respiratory failure (<24hrs) in pressure support mode 











Prevalence of asynchrony 
described 
Jubran et al. 
(1995) 
12 10  Flow, Paw, Pes Delayed cycling 5/12 patients (42%) 
Younes et al. 
(2007) 
21 60 Transdiaphragamatic 
pressure, Flow, Paw 
Severe Ineffective efforts (>10% breaths) 
affected 7/20 patients (35%) 
Mulqueeny et al. 
(2009) 
23 10-20  Flow, Paw, 
transdiaphragmatic 
pressure 
10% breaths were ineffective efforts 
(combined data with non-invasive 
ventilation) 
De Wit et al. 
(2009) 
60 10 Ventilator pressure 
and flow waveforms 
27% patients  AI ineffective efforts > 10% 
breaths 
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Table 2: A summary of the amounts of asynchrony reported during invasive ventilation for 















asynchrony described  
Fabry et al. 
(1995) 
11 Mean 3.8 days 
(range 1-10)  
5 (taken at 
intervals over 
25-150 hrs) 
Paw, Flow and Pes Ineffective efforts mean 
range 0-40% of all ventilator 
delivered breaths. 
Nava et al. 
(1997) erj 
24 >48hrs 5 Flow and 
transdiaphragmatic 
pressure 
Ineffective efforts affected 
54.2% patients. 
Chao et al. 
(1997) 
174 Range 3 to 
371 days 




10.9% patients demonstrated 
ineffective efforts  
Leung et al 
(1997) 
11 n/a (9 via 
tracheostomy) 
1 Paw, Flow, Pes Ineffective efforts 2-6/ per 
minute (higher with higher 
PS, 26% of breaths) 
Vitacca et al. 
(2004) 
36 Range 22 to 
57 days 
5 Ventilator flow and 
pressure 
waveforms 
Ineffective efforts observed in 
72% patients (affecting a 
mean approx 10% 
breaths/minute) 
Thille et al. 
(2006) 
62 >24hrs 30  Paw and Flow 24% patients AI > 10% 
Mulqueeny et 
al. (2007) 





30% patients AI> 10% 
Ineffective efforts 15.1% 
breaths 
Double triggering 1.2 % 
breaths 
Colombo et al. 
(2008) 
14 Range 2 to 19 
days 
60  Paw, Flow and 
Diaphragmatic 
EMG 
36% patients had and AI> 
10%. 
Piquilloud et al. 
(2011) 
22 3days +/- 2  40  Paw, Flow and 
Diaphragmatic 
EMG 
60% patients had an AI > 10 
%. (Equivalent to approx 3 
/min) 
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Gutierrez et al. 
(2011) 
110 Range 1 to 5.8 
days 
120 Flow and Paw 50.9% patients AI> 10%. 
Ineffective efforts 70.2% of 
asynchrony.  Double 
triggering 29.8% of 
asynchrony. 
 




1.7.6  Prevalence of patient-ventilator asynchrony in non-invasive ventilation 
Non-invasive ventilation includes the added complications of an open circuit with an interface which is 
prone to air leak interfering with the synchrony of the patient and ventilator. In addition, the patients 
themselves are also less likely to be sedated or paralysed which will impact on the patient’s neural 
ventilatory drive and respiratory patterns. Despite this, perhaps related to improvements in leak 
compensation mechanisms of the non-invasive ventilators, asynchronous events were identified in 
0% to 43% of patients. (Table 3). 
Table 3: A summary of the amounts of asynchrony reported during non-invasive ventilation in 
pressure support mode 
 











Prevalence of asynchrony described 
Fanfulla et al. 
(2007) 




Ineffective efforts affected approx. 4% breaths. 
Moerer et al. 
(2008) 
7 (healthy) 2  Flow, Paw, Pes Mean range 5 to 55% of the total breath 
duration. (variable PS and RR applied) 
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Vignaux et al. 
(2009) 
60 30 Paw, Flow and 
surface diaphragm 
EMG 
 43% patients AI> 10% 
 -Delayed cycling  23% patients 
-Double triggering  15% patients 
- Ineffective efforts 13% patients 
- Auto-triggering 13% patients 
-Premature cycling 12% patients 
Mulqueeny et al. 
(2009) 
23 10-20  Flow, Paw, 
transdiaphragmatic 
pressure 
10% breaths were ineffective efforts 
(combined data with invasive ventilation) 
VIgnaux et al. 
(2010) 
65 30 Paw, Flow, surface 
diaphragm EMG 
38% patients AI >10% ICU ventilator with NIV 
algorithm (commonest asynchrony premature 
cycling) 
46% patients AI> 10% ICU ventilator without 
NIV algorithm (commonest asynchrony 
premature cycling) 
 
Carteaux et al. 
(2012) 
15 20 Flow, Paw, neck 
surface EMG and 
surface diaphragm 
EMG 
0% patients had AI >10% using domiciliary 
NIV (no asynchrony seen) 
13% patients had AI >10% using ICU 
ventilator with NIV algorithm (commonest 
asynchrony auto-triggering) 
27% patients had AI>10% using ICU ventilator 
without NIV algorithm (commonest asynchrony 
auto triggering) 
Abbreviations: Paw-airway pressure, Pes-oesphageal pressure, AI-asynchrony index,                  
EMG-electromyogram, NIV- non-invasive ventilation, PS-pressure support, RR-respiratory rate. 
 
1.8 Types of patient-ventilator asynchrony 
PVA can occur at any point of the breathing cycle and is best explained by examining the ventilator 
pressure waveform. (Figure 7).  A patient can have difficulties in triggering the ventilator ‘ineffective 
effort’ or conversely the ventilator may trigger automatically without any patient demand 
‘autotriggering’ (a single event). These events may occur twice in quick succession ‘double 
triggering’, or in multiples ‘autocycling’.  Following successful triggering of the ventilator a patient 
may have difficulties with the ventilator cycling appropriately into expiration, cycling may be too early 
whilst the patient is still in active inspiration ‘premature expiratory cycling’ or too late when the 
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patient has already tried to breathe out against inspiratory pressure ‘delayed expiratory cycling’.  I 
will explain the individual asynchrony further with an example from my own observations in the 
methods section (Section 2.5) which have been peer reviewed and published.(79) 
 
Figure 6: An example of different asynchronous events as they affect the ventilator delivered 




1.9 Extent of the problem –a survey of patient opinion on patient-
ventilator asynchrony 
In order to examine the prevalence of PVA and gain an understanding of patient awareness of this 
issue, a survey was undertaken in non-selected patients with chronic respiratory failure established 
on non-invasive ventilation whilst awaiting their routine outpatient appointment. (See Appendix 6 for a 
copy of the survey used). 
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110 patients (37 female) took part in the survey. The majority of patients had neuromuscular disease 
(38 patients) or obesity related respiratory failure (ORRF) (36 patients) reflecting the patients requiring 
non-invasive ventilation in our unit. Fewer patients had COPD (7 patients), COPD/OSA overlap (18 
patients) and chest wall disease (CWD) (11 patients). Patient characteristics as described below in 
Table 4 with ventilator settings for the different disease groups reported in Table 5.  PVA was frequent 
with 61% of patients aware of asynchronous breaths delivered by the ventilator. The commonest type 
of PVA’s described were ineffective efforts affecting 43% of patients followed by autotriggering events 
reported by 40% of patients. Cycling asynchrony were less common with premature cycling affecting 
38% of patients and delayed cycling affecting 30% of patients. 
Table 4: Patients surveyed demographics 
Results are presented as mean and standard deviation Abbreviations: BMI- Body Mass Index, FEV1- 
Forced expiratory volume in 1 second, FVC- Forced vital capacity, COPD-chronic obstructive 
pulmonary disease, CWD-chest wall disease, NMD-neuromuscular disease, ORRF-obesity related 
respiratory failure, COPD/OSA overlap-combination of chronic obstructive pulmonary disease and 




 COPD          
(7) 
CWD     
(11) 
NMD         
(38) 
ORRF         
(36) 
COPD/OSA 
Overlap         
(18) 
Age (yrs) 6111 6214 4421 5710 659 
BMI (kgm-2) 3112 254 2812 4411 406 
FEV1 (L/s) 0.80.3 0.70.2 0.80.4 1.91.0 1.20.5 
FVC (L) 1.60.7 0.90.3 1.10.7 2.41.2 1.80.8 




905 9010 952 952 926 
  





Table 5: Ventilator settings in different patient groups on HMV 
 COPD                 
(7) 
CWD               
(11) 
NMD         
(38) 





IPAP (cmH2O) 26   (20-
28) 
20  (16-30) 20  (16-23) 21  (18-24) 27  (24-30) 
EPAP (cmH2O) 5   (3-6) 3   (3-7) 5   (3-7) 10  (8-12) 10  (8-12) 
BUR 
(breath/min) 
16   (12-
18) 
14   (10-16) 14  (14-16) 12   (10-14) 14  (10-16) 
Results are expressed as median (interquartile range) Abbreviations: IPAP= inspiratory positive 
airway pressure, EPAP= expiratory positive airway pressure, BUR=back up rate 
 
Patients with COPD/OSA overlap were most likely to describe PVA which affected 83% of patients 
surveyed whereas patients with CWD were least likely to report PVA affecting 46% of patients 
surveyed. (Figure 8).  Ineffective efforts were most frequently reported in patients with COPD/OSA 
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Figure 7: Proportion of patients reporting awareness of PVA in different disease groups 
 
Abbreviations: COPD-chronic obstructive pulmonary disease, CWD-chest wall disease, NMD- 
neuromuscular disease, ORRF- obesity related respiratory failure, Overlap-combined chronic 
obstructive pulmonary disease with obstructive sleep apnoea. 
Differences were observed in PVA between the different domiciliary ventilators used reflecting the 
variability in operating characteristics. PVA was most frequently reported by patients using the A30 
BIPAP (Philips Respironics, Murrysville, Pa, USA) (78%) followed by S9 VPAP S (ResMed, San 
Diego, Ca, USA) (72%), NIPPY 3+ (B&D Electromedical, Stratford-upon –Avon, UK) (58%), BiPAP 
Harmony (Philips Respironics, Murrysville, Pa, USA)(52%). 
PVA was most commonly reported in patients (82%) who had started domiciliary ventilation within the 
last year. There was a gradual decline in patients reporting PVA with time on ventilation with 60% of 
patients affected having used NIV between 1-3 years and only 38% of patient affected who were 
established on NIV between 4-8 years. A further increase in patients reporting PVA was observed in 
the long term group (>10 years) (62%) although this may be in part related to this group containing 
the fewest patients surveyed (19). 
In summary, we found that patient reported awareness of PVA is higher than PVA levels described in 
the literature and affects a majority of patients requiring long-term non-invasive ventilation.(18, 75, 80)  
A limitation of this survey is that there was not an objective physiological measure of PVA to compare 
with the self-reported PVA by the patients, but importantly these data highlight that the patients 
perceive this as a clinical problem. 
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1.10 Potential consequences of patient-ventilator asynchrony 
1.10.1 Ultrastructural injury to respiratory muscles 
Ventilator delivered breaths during expiration i.e. respiratory muscle relaxation and lengthening may 
force sudden respiratory muscle contraction that is thought to lead to muscle damage.  In animal 
models contraction of skeletal muscle during lengthening can lead to muscle fibre injury and 
decreased ability to generate force.(81, 82)  Evidence from ventilation in acute lung injury has 
suggested that ventilator settings must be balanced to prevent total muscle inactivity resulting in loss 
of muscle mass and strength on the one hand and sustained increased work of breathing causing 
structural damage and inflammation on the other.(83-85)  
1.10.2 Increases work of breathing 
Patient inspiratory efforts that fail to trigger the ventilator results in wasted work of breathing, as the 
respiratory muscles contract, consume oxygen but do not generate an effective tidal volume or gas 
exchange. This may prevent respiratory muscle unloading and in fact increase the work load on the 
respiratory muscles.  Work by Nava et al. measured work of breathing of the diaphragm using the 
pressure-time product of the diaphragm (PTP).(86) The PTP was described by Fields et al, calculated 
as the mean transdiaphragmatic pressure multiplied by the duration of diaphragmatic muscle 
contraction and closely correlated with the oxygen consumption of the inspiratory muscles.(87)  Nava 
et al, observed a higher PTP to be associated with more ineffective efforts and that these occurred 
with higher pressure support levels in patients with COPD.(8, 86)   Leung et al. found the PTP of the 
diaphragm to be 38% higher during wasted patient efforts compared to triggered breaths.(8)  Thille 
and colleagues identified that wasted patient efforts accounted for more than fifteen percent of the 
total work of breathing per minute in patients with difficulties weaning from mechanical ventilation.(88) 
1.10.3 Impairs pulmonary mechanics and gas exchange 
Double triggering and auto-triggering occurring during patient expiration may lead to effective ‘breath 
stacking’ and increased inspired tidal volume.  As explained above (1.5.2), in patients with expiratory 
airflow limitation this may lead to dynamic hyperinflation, increased end expiratory positive pressure 
and therefore an increased threshold load for the patient to work against in order to trigger the 
ventilator.(13, 82)  A similar phenomenon occurs with delayed cycling, where the ventilator continues 
to deliver inspiratory support whilst the patient is breathing out.  This also decreases the patient’s 
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expiratory time and may lead to gas trapping and dynamic hyperinflation, in those with airflow 
obstruction.(13)  Both of these mechanisms may adversely affect gas exchange through increased 
dead space ventilation and ventilation- perfusion mismatching. Work by Fanfulla et al. demonstrated 
that ineffective efforts seen overnight were correlated with an increased time spent with saturations 
below 90% in patients with chronic respiratory failure receiving domiciliary ventilation. (76) 
Frequent auto-triggering may effectively hyperventilate the patient leading to hypocapnia and 
respiratory alkalosis.(82)  
1.10.4 Induces patient discomfort  
PVA may induce patient discomfort; clinical experience has shown that patients poorly tolerate 
situations where they appear to be ‘fighting the ventilator’.  In invasively ventilated patients, Vitacca et 
al. identified increasing proportions of ineffective efforts and discomfort with high levels of pressure 
support although a significant correlation was not seen.(18)  In a study of 65 non-invasively ventilated 
patients, Vignaux and colleagues demonstrated a significantly improved comfort measured by a visual 
analogue score in patients with an asynchrony index (AI) less than 10 percent of breaths (p=0.027). 
(89)  Work by Moerer et al. comparing neural triggering of non-invasive ventilation against pneumatic 
triggering in healthy subjects found a significant correlation between subject comfort scores and the 
amount of asynchrony in pneumatic triggering.(90) 
1.10.5 Increases sleep disruption  
PVA may lead to microarousals and increased sleep fragmentation.  Work by Fanfulla et al. 
performed in neuromuscular disease patients receiving domiciliary non-invasive ventilation 
demonstrated that more frequent ineffective efforts was associated with less time spent in rapid eye 
movement (REM) sleep.(75)  Bosma et al. studied PVA in patients weaning from invasive mechanical 
ventilation. This study identified that PVA per hour were more frequent during pressure support 
ventilation compared to proportional assist ventilation and these correlated significantly with the 
number of arousals per hour (r2=0.65, p=0.0001).(91)  A further detailed study performed by Guo et 
al. in  20 patients with obesity hypoventilation syndrome suggested that patient ventilator asynchrony 
was associated with fragmented sleep and  a reduction in slow wave and REM sleep.  A majority (2/3) 
of the microarousals were seen in stage 1 and 2 non-REM sleep which may reflect the enhanced 
neural drive to the respiratory muscles observed in lighter stages of sleep.(70) 
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1.10.6 Increases time spent on mechanical ventilation 
Clinicians frequently use the respiratory rate as a parameter to assess a patient’s ability to wean from 
invasive mechanical ventilation.  Respiratory rate is often measured by the ventilator, as ineffective 
efforts are not detected by the ventilator the true respiratory rate may be much higher than the 
measured respiratory rate and impact on weaning decisions. (92) The presence of asynchrony has 
also been shown to reduce the likelihood of successful weaning from mechanical ventilation and 
increase sedation levels. (93) Chao et al. demonstrated that 16% of patients with ineffective efforts 
successfully weaned from invasive ventilation after 30 days of ventilation compared to 57% of patients 
without ineffective efforts.(58)  Those that managed to wean from ventilation took an average of 72 
days to wean compared to 33 days in those without ineffective efforts.(58)  Thille et al. identified 
similar results in patients with an asynchrony index more than 10% who had a longer duration of 
mechanical ventilation and were more likely to require a tracheostomy.(77)  Work from de Wit et al. 
describes a significant association between increased ineffective efforts and longer time spent on 
mechanical ventilation.(78)  This also translated into an increased ICU and hospital stay as well as a 
reduced likelihood of being discharged home. However, overall no differences in mortality outcomes 
have been observed. 
1.11 Summary 
 It remains to be explained whether PVA is simply a reflection of patients with complex pulmonary 
mechanics preventing synchronous interaction with the ventilator or if it is PVA that directly affects 
patient outcomes whereby correcting these is a worthwhile endeavour.  In this thesis I will attempt to 
identify the prevalence of PVA in patients on HMV and identify the relationship to important patient 
outcomes such as gas exchange, patient adherence to HMV therapy, patient quality of life measures 
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Chapter 2 Material and Methods 
 
2.1 Ethical Approval 
The studies in this thesis were approved by the Harrow National Research Ethics Service, London 
and the research and development at Guys and St. Thomas’ NHS Foundation Trust.  The studies 
were performed in the Lane Fox High Dependency Unit of St. Thomas’ Hospital.  All subjects were 
provided with information leaflets regarding the study and gave their written consent to participate.  
When written consent was not possible due to neuromuscular weakness verbal consent was obtained 
that was countersigned by an independent member of the research team or a patient advocate.  
2.2 Subjects 
Healthy subjects were recruited from Guy’s and St. Thomas’ Hospital staff, research colleagues from 
the London Respiratory Muscle Group and their friends or relatives.  
Patients with hypercapnic respiratory failure related to chronic obstructive pulmonary disease 
(COPD), obesity hypoventilation syndrome (OHS), neuromuscular disease (NMD) and chest wall 
disease (CWD) were screened and recruited from referrals to the Lane Fox High Dependency Unit, 
St. Thomas’ Hospital for the initiation of home mechanical ventilation.  
2.3  Anthropometrics 
After informed consent, the subject’s date of birth and gender were recorded.  Height was measured 
using a portable Leicester height measure (Invicta Plastics Limited, Oadby, Leicester, range 14-
210cm) where height measurement was not possible (for example in patients with Duchenne 
muscular dystrophy) an arm span measurement by a flexible standard medical tape measure was 
made.  Weight was measured using a medical scale (SECA, maximum capacity 160kg).  Body-Mass-
Index (BMI) was calculated as weight (kg) / (height (m))2.  Waist measurements were obtained at the 
midpoint between the lower costal margin and the iliac crest and hip measurements were obtained at 
the point of maximal lateral protrusion of the hips with a standard medical tape measure.  Waist-to-hip 
ratio was calculated as waist (cm) / hip (cm).  
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2.3.1  Measurement of Fat Free Mass 
Single frequency bioelectrical impedance (Bodystat 1500, Douglas, UK) was used to calculate the fat 
free mass of study participants.  The technique involves passing a small current at 50Hz between 
surface electrodes placed on the dorsal aspect of the hand and foot.  The Bodystat calculates the 
voltage drop between the electrodes and therefore the total body impedence.  The test assumes that 
adipose tissue has a low water content and is therefore of high electrical impedance whereas the fat 
free mass has a high water content and has a lower electrical impedance.  Predictive equations that 
incorporate age, heights, weights and genders are used to calculate the fat free mass of a subject 
from an impedance value.  Regression equations exist to optimise accuracy and have been validated 
against alternative methods for measuring body composition such as dual energy x-ray 
absorptiometry (DEXA) in COPD patients. (94) 
2.4 Arterial blood gases 
Arterial puncture was obtained by manually palpating the radial pulse and performing an arterial blood 
gas using a Roche MICROSAMPLER PROTECT (Roche Diagnostics Ltd, Indianapolis, IN, USA) 
needle and self-filling syringe.  A full aseptic technique was employed. Patients were seated at rest 
and on room air. The blood samples were analysed on a Cobas b221 (Roche Diagnostics Ltd, 
Indianapolis, IN, USA) benchtop arterial blood gas analyser that was calibrated on a daily basis by the 
technical services team on Lane Fox Unit as for routine clinical care.   
2.5  Questionnaires 
Questionnaires were filled out by the subjects with the investigator ensuring that the whole 
questionnaire was completed.  Occasionally either the investigator or a relative read out the questions 
if the patient was unable to read or had forgotten their glasses.  Where patients were unable to 
manually complete the questionnaire the appropriate response was verbalised by the patient and 
noted by the research investigator.  There was no time limit within which the patient was required to 
complete the questions.  
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2.5.1  Epworth Sleepiness Scale (ESS) 
Tiredness and fatigue are common symptoms but daytime somnolence maybe a marker of underlying 
sleep disordered breathing leading to frequent arousals and sleep disruption.  The Epworth 
sleepiness scale was validated to differentiate between pathologically sleepy states associated with 
diseases such as obstructive sleep apnoea, narcolepsy and idiopathic hypersomnia from snoring or 
healthy matched subjects.(95)  The values are weakly correlated to sleep latencies during 
polysomnography and sleep latency testing.  The ESS is commonly used to monitor a patient’s 
response to treatment of sleep disordered breathing associated with respiratory failure.(39)  The scale 
consists of eight questions each with a score of 0 to 3 points.  
2.5.2  Fatigue Severity Score (FSS) 
The FSS consists of 9 items each with a 7 point scale to measure fatigue severity in neurological and 
medical conditions.  A higher score relates to more severe symptoms of fatigue and has been 
validated against a visual analogue score.(96)  
2.5.3 Hospital anxiety and depression score (HADS) 
The HADS is a 14 item scale with a score ranging from 0-42, where a higher score represents more 
severe symptoms.   The questionnaire was initially developed as a screening tool to detect anxiety 
and depression in patients with physical symptoms.(97)  Seven items of the HADS relate to 
depressive symptoms and seven items relate to anxiety each item has a possible score of 0-3.  The 
HADS has now been validated to grade the severity of anxiety and depression of a patient from 
normal to severe.  The data returned from the HADS is ordinal.(97) 
2.5.4 Severe Respiratory Insufficiency Questionnaire (SRI) 
Patients with respiratory failure arising from many underlying pathologies receive domiciliary 
ventilation.  Although the underlying mechanisms leading to ventilatory failure may differ, the impact 
on respiratory patterns during sleep and the symptoms experienced by the patients may be similar 
across different diseases.    The SRI questionnaire comprises of 49 questions producing a summary 
and 7 sub-domain scores.  The higher the total score, the better the quality of life (range 0-100).  The 
questionnaire has been validated in patients with a range of disorders using home mechanical 
ventilation and has been shown to be reproducible  and correlates to other generic measures of 
health related quality of life.(98) 
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2.5.5 St. George’s Respiratory Questionnaire 
The St. George’s respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire 
developed to measure the health status of patients with airways obstruction.(99) It is a 50 item 
questionnaire that assess 3 domains of symptoms, activity and impacts providing a total score. 
Scores are expressed as a percentage of the overall impairment with 0 representing no impairment 
and 100 representing maximal impairment.  Subjects are requested to recall their symptoms over the 
previous 3 month period for the assessments used in this thesis.   The questionnaire has been 
validated in a number of clinical trials and has demonstrated both repeatability and reliability.(100, 
101) The SGRQ has correlated well with markers of disease activity such as cough, dyspnoea, 6-
minute walk test and FEV1. (102, 103)  A minimum change in score of 4 has been demonstrated to be 
clinically relevant.(104) 
2.5.6 36-Item Short Form Health Survey (RAND-36) 
The RAND-36 is a health related quality of life questionnaire developed by the RAND Corporation as 
part of the Medical Outcomes Study (MOS).(105)  It is comprised of 36 items that assess eight health 
sections: physical functioning, role limitations caused by physical health problems, role limitations 
caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and 
general health perceptions.  Each section is scored on a scale from 0-100 with a higher score 
reflecting a better quality of life.  
2.5.7 Visual Analogue Scores (VAS) 
A VAS is a horizontal line 100 millimetres in length that is anchored by opposite word descriptors at 
each end of the line used to measure an opinion or symptom that is a continuum.  An example is 
measuring pain, which may be considered to have a continuous dimension of severity  and could 
be anchored by no pain against severe pain.  The patient marks along the line the point that 
represents their perception of their current status.  The VAS score is measured along the line in 
millimetres to the point where the patient makes a mark.  There is a possible score of 0-100 with a 
higher score representing an improvement in symptoms.(106) The VAS has been shown to be 
superior to some other measures of health related scores.(107) In this thesis, the VAS was used to 
assess participants comfort receiving non-invasive ventilation and their perceived co-ordination with 
the ventilator. 
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2.6 Pulmonary function and respiratory muscle testing 
Spirometry tests were performed using a handheld spirometer (Williams Medical, Rhymney, UK) by a 
trained health care professional in accordance with the ATS/ERS consensus statement (2005).(22)  
The study participants were asked to maximally inspire and then to exhale forcibly, as hard and as 
fast as possible through the mouthpiece until there was nothing left to expel.  The spirometer then 
recorded the forced expired volume over the first second (FEV1) and the forced vital capacity (FVC), 
i.e. the total volume expired.  The procedure was repeated three times or until there were two 
readings within 100ml.  The best result was used for the studies.  The result was compared to the 
predicted normal values that are adjusted for age, gender and height to provide the percent predicted 
value.  The ratio of FEV1 to FVC was compared in all subjects. A cut off <70% was used to identify 
patients with obstructive airways disease and >70% to identify patients with restrictive lung disease.   
2.6.1  Pneumotachography flow assessment  
A heated pneumotach (PNT Series 3830, Hans Rudolph, Shawnee, KA, USA) manufactured for flow 
rates between 0-400 litres/minute was attached to the face mask of patients on non-invasive 
ventilation to assess flow. The flow signal was processed integrated into the LabChart v 7.3 using the 
spirometer software. From this we could calculate the tidal volume (as the area under the curve of the 
flow signal) achieved for each breath when interacting with the ventilator. For safety reasons with the 
heating system this was only used for studies under the direct observation of the research team.  To 
ensure accuracy calibration checks were performed prior to each study using a fixed volume 3 litre 
syringe discharged and different flow rates between 0.5L/s and 12L/s as per the American Thoracic 
Society/European Respiratory Society (ATS/ERS) Task Force standardisation of lung function 
guidelines.(22)  The volume at each flow rate was checked to ensure any discrepancy was kept below 
3.5%.  
 
2.6.2 Respiratory Muscle Strength 
Non-invasive assessment of respiratory muscle strength including maximal inspiratory pressure (MIP), 
sniff nasal inspiratory pressure (SNIP) and maximal expiratory pressure (MEP) were carried out using 
a handheld device (Micromedical Ltd, Kent, UK) in accordance with ERS/ATS guidelines.(24)  In the 
neuromuscular patient group, cough peak flow was also obtained using a handheld peak flow meter.  
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A mask interface was used and patients were asked to cough into the peak flow meter.  For all tests 
the best of three were obtained, further tests were performed until there were two results within 5 
percent of each other.   
 
 
2.7 Measures of Neural Respiratory Drive 
2.7.1 Measurement of surface parasternal EMG (sEMGpara) 
The second intercostal parasternal space was identified using bony landmarks (the sternal notch and 
the angle of Louis) and the skin was prepared using EMG contact gel (Nuprep, DO weaver and Co, 
USA).  Silver-silver chloride wet gel electrodes (Neuroline 720, Ambu, Denmark) were placed 
adjacent to the sternum in the second intercostal spaces. (Figure 9). The signal was amplified and 
processed using two high differential amplifiers with band pass filters set at 10Hz and 2000Hz 
(Bioamp, ADInstruments, Chalgrove, UK).  Additional adaptive mains filters were applied and AC 
coupling was used.  Amplified signals underwent analogue to digital conversion (Powerlab, 
ADinstruments, Chalgrove, UK) and passed to a desktop computer.  Further digital filtering occurred 
at 20Hz after data acquisition and signals were analysed using signalling software (Labchart v7.3, 
ADInstruments, Chalgrove, UK).  sEMGpara signals were recorded with the subject relaxed in a semi-
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Figure 8: Positioning of second intercostals surface parasternal EMG electrodes (sEMGpara) 
 
sEMGpara signals for maximal manoeuvres and tidal breathing were recorded post 10 minutes of 
stable breathing at the beginning of the overnight traces.  To normalise the signals facilitating 
comparison of results between patient groups the signal was expressed as a percentage of the 
maximal signal obtained during maximal inspiratory manoeuvres (sEMGpara%max).  This normalised 
sEMGpara%max signal reduces the effect of between patient and between occasion variation in skin 
preparation, electrode placement and subcutaneous tissue impedance.  (Figures 10 and 11).   
sEMGpara signals were analysed using the breath-by-breath maximal root mean squared (RMS) of 
the raw sEMGpara signal with a moving window of 40ms averaged over a 2 minute period.  This was 
then normalised to the maximum RMS sEMGpara value obtained during a maximal inspiratory 
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Figure 9:  A representative trace of a raw sEMGpara signal with rectified RMS signal 
 
Abbreviations: ECG- electrocardiogram, EMG-electromyogram, RMS- root mean square of the raw 
parasternal electromyogram signal. 
 
Figure 10: A representative trace of a raw sEMGpara signal during tidal breathing and a 
maximal inspiratory manoeuvre that is used to normalise the measurement 
 
 
Abbreviations: Snip-sniff nasal inspiratory pressure, EMG-electromyogram, RMS-root mean square of 
the raw electromyogram signal. 
 
2.7.2 Difficulties encountered in using surface parasternal EMG measurements for continuous 
monitoring 
Ensuring reliable signals that are free from artefact is paramount to work with surface EMG and its 
utility to detect patient inspiratory effort.   Surface EMG measurements are known to be easily 
contaminated from cross-talk signals from adjacent muscle activity.(30)   Signals are also affected by 
the impedance of both skin and subcutaneous fat that reduces the signal strength.(30)  This can 
Raw EMG signal 
Snip inspiratory manoeuvre                   Tidal breathing 
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partially be improved with the use of good skin preparation to remove dead skin cells and any 
moisture but makes signals in obese patients more difficult to detect above noise levels.  Surface 
EMG recording can also be affected by mains noise and external electrical interference.(30)  Filtering 
the signal helps to guard against these artefacts.   
Initial signals were filtered using a 50Hz analogue notch filter in addition to the band pass filters set at 
10Hz and 2000Hz to eliminate the noise from the mains power supply which runs at 50Hz.    We 
found however that this filter produced an interference termed ‘ringing’ at fixed intervals either side of 
50Hz and degraded the signal that arose in the 50Hz range that includes muscle unit firing 
frequencies. The signals were assessed with a spectral frequency analysis to confirm or exclude 
artefact. (Figure 12). In addition, due to slight variations in the power supply to the hospital, the noise 
signal may contain harmonics of the noise and the exact frequency of the noise may vary. 
Subsequently we used an adaptive mains filter which identifies both the patient signal and signals 
from the power supply directly.  The adaptive filter is then able to track the actual frequency of the 
noise as it fluctuates and improves the signal quality. 
Before recruiting for the randomised control trial, I performed studies in nine subjects in order to 
optimise the EMG signal I obtained.  I spent time practising skin preparation, electrode placement 
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Figure 11: An example of notch filter artefact affecting sEMGpara signals 
           
 
 
Abbreviations: sEMGpara: surface second intercostal parasternal electromyogram signal, Hz-hertz 
2.7.3 Measurement of Diaphragm EMG 
A disposable multipair electrode catheter (Yinghui Medical Technology Co., Ltd, Guangzhou, China) 
was inserted per-nasally. (Figure 13).  The oesophageal catheter consists of five pairs of electrodes. 
The catheter was positioned based on the amplitude of the crural diaphragm EMG (EMGdi) recorded 
from five pairs of electrode. Optimal position was characterised when the largest EMG amplitude 
recorded from pairs 1 and 5 and the smallest EMG signal recorded from pair 3 and was then fixed at 
the nose to ensure consistency.(30, 108, 109)  The EMGdi signals were amplified and band-pass 
filtered between 20 Hz and 1 kHz (Bioamp, AD Instruments, Chalgrove, UK).   Amplified signals 
underwent analogue to digital conversion (Powerlab, ADinstruments, Chalgrove, UK) and were 
passed to a desktop computer.  After data acquisition, signals were analysed using signalling 
software (Labchart v7.3, ADInstruments, Chalgrove, UK).   
The mulitpair electrode catheter has two 9.5cm long balloons with an uninflated circumference of 
1cm. The gastric balloon is attached 5cm from the tip of the catheter and is separated from the 





50Hz Notch filter 
artefact  
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positioned the balloons were connected to a pressure transducer (GM Instruments Ltd, Kilwinning, 
UK) to simultaneously measure the oesophageal and gastric pressures (110).  The connection was 
secured with a 3 way tap to ensure the balloons could be inflated post being swallowed by the 
subject. The position of the catheter balloons were assessed by reviewing the pressure tracing 
obtained from each balloon.  Distal balloon placement in the stomach was confirmed by a positive 
pressure reading which is confirmed by gently compressing the abdomen leading to an increase in 
positive pressure reading on the manometer (Pgas). The oesophageal balloon placement was 
ascertained by reviewing the pressure reading that corresponds to a negative deflection with 
inspiration and maybe confirmed by the presence of cardiac oscillations (Poes). The Poes provides a 
marker of pleural pressure (111), the Pgas provides a marker of abdominal pressure (112) and from 
these the transdiaphragmatic pressure (Pdi), a measurement of diaphragmatic strength can be 
calculated (Pdi=Pgas-Poes)(113).    
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Figure 13: A representative trace acquired from simultaneous diaphragm and parasternal 
electromyography 
 
Abbreviations: Pdi-transdiaphragm pressure, Poes-oesphageal pressure, Pgas-gastric pressure, 
sEMGpara-surface second intercostal electromyogram, EMGdi- diaphragm electromyography, 
multipair- pairs of diaphragm electromyogram electrodes according to the configuration demonstrated 
in Figure 13. 
 
2.7.4 Pressure-volume characteristics of the nasogastric catheter balloons 
The accuracy of the catheter balloons in recording pressure measurements depend on their 
compliance and the volume of air they are filled with. The balloons were filled with 0.1ml aliquots of air 
in a stepwise fashion between 0.0ml and 3.0ml and the pressure that was transmitted was measured 
using a handheld pressure meter (Fisher Scientific UK Ltd, Loughborough, UK).  Figures 15 & 16 
identify an optimal range of balloon filling pressures between 0.5ml and 1.4ml for the oesophageal 
balloon and 0.2-0.8ml for the gastric balloon.  Below 0.2ml for the gastric balloon and 0.5ml for the 
oesophageal balloon the pressure measurements become more negative due to the initial balloon 
properties that must be overcome to expand. Above 0.8ml for the gastric balloon and 1.4ml for the 
oesophageal balloon measurements become positive non-linear measurements due to contracting 
forces.  The best volume to assess negative pressures like Poes was to fill the balloon with 0.5ml 
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preferred volume for positive pressure measurements like Pgas was 0.8ml because of the 
compression by the external positive pressure.  
 
Figure 14: Pressure-Volume characteristics of the oesophageal balloon catheter. Optimal 
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2.7.5 Pressure Transducer calibration 
Pressure transducers (GM Instruments Ltd, Kilwinning, UK) were used for obtaining SNIP, MIP, MEP 
measurements, identifying the phases of tidal breathing and the ventilator output in response to the 
subject’s respiration.  These were provided with a manufacturer’s certificate of accurate measurement 
over a pressure range (+/- 200cmH20).  The pressure transducers readings were also checked prior 
to each study against a hand held pressure transducer (Fisher Scientific UK Ltd, Loughborough, UK) 
and calibrated with the Labchart (v7.3) (AD Instruments, Chalgrove, UK) software readings. 
 
2.7.6 Testing for intrinsic delays between pressure and flow responses 
A 50ml eccentric cone medical syringe (Beckton, Dickinson and Co Ltd, Co.Louth, Ireland) was 
attached to a heated pneumotach (PNT Series 3830, Hans Rudolph, Shawnee, KA, USA) and a glass 
bottle and sealed to prevent air leak. (Figure 17). The plunger was advanced with a maximal force to 
evoke a change in pressure and flow across the pneumotach (PNT Series 3830, Hans Rudolph, 
Shawnee, KA, USA) attached to a spirometer (AD Instruments, Chalgrove, UK)  and generate a 
pressure signal that could recorded by the pressure transducer (GM Instruments Ltd, Kilwinning, UK) 
simultaneously.  The onset of the force applied was the same and so any delay observed between the 
onset of the flow or pressure signal would represent a true delay in the acquisition recording system. 
The test was repeated 10 times at the maximal time difference recorded between the 2 readings was 
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Figure 17: Raw Labchart data file demonstrating the accuracy of our pressure and flow 
recordings (time delay between signals <0.006s) 
 
 
2.7.7 Frequency Response of the Recording System 
To test the response of the nasogastric catheter balloon to sudden changes in pressure we carried 
out a ‘pop-test’.  The oesophageal balloon was filled with 0.5ml of air and the gastric balloon was filled 
with 0.8ml of air and each was independently placed inside a larger balloon with an external pressure 
applied. The external balloon was then popped with a needle and the time taken for the balloon to 
detect the atmospheric pressure of 0cmH2O was recorded. The response time (t10-90) of the slope of 
the pressure decay between 90% and 10% of the initial pressure was calculated. The t10-90 was 
0.007s for the oesophageal balloon and 0.005s for the gastric balloon.  The frequency response (Fr) 
was derived from the equation (Fr= 3x t10-90)-1.  The frequency response of the equipment including 
the balloon catheter, pressure transducer, amplifier, AD- converter and computer was 47.6Hz for 
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Figure 18: Frequency response recording from a ‘pop-test’ using the gastric balloon (Yinghui 
Medical Technology Co., Ltd, Guangzhou, China) filled with 0.8ml of air.  
 
 
2.8 Assessment of Sleep disordered Breathing 
2.8.1 Overnight oximetry and capnography 
A combined oximeter-capnometer device (Tosca500, Radiometer, Crawley, West Sussex, UK) was 
used to record oxygen saturations (SpO2) and transcutaneous carbon dioxide (TcCO2) during sleep.  
Capnometer probes were calibrated at the start and end of sleep monitoring and the data was 
outputted in real time to the software (Labchart v7.3, ADInstruments, Chalgrove, UK) as well as being 
uploaded to a personal computer using Download 2001 (Stowood Instruments, Beckley, Oxford, UK). 
This facilitated the calculation of 4% oxygen desaturation index, mean SpO2, minimum SpO2, mean 
TcCO2, maximum TcCO2, time spent with SpO2 <90% and time spent with TcCO2 >7kPa. 
2.8.2 Respiratory Inductance Plethysmography 
Respiratory inductance plethysmography (RIP) bands (Embla, Broomfield, USA) attached to 
Respitrace Plus Monitor (Sensormedics, Miami Beach, Florida) were used to assess chest wall and 
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wide, lightweight elastic and adhesive bands. The RIP bands are placed around the rib cage at the 
level of the nipple line and around the abdomen at the level of the umbilicus. They are connected to 
an oscillator to obtain digital waveforms. During normal, orthodox, inspiration the cross-sectional area 
of the rib cage and abdomen increases. This alters the inductance of the coils and the frequency of 
their oscillation, with the increase in cross-sectional area proportional to the change in lung 
volumes.(116) This was used as a second marker of patient effort to identify inspiration that was 
incorporated into our definitions of asynchronous events to improve accuracy.  The RIP bands were 
also used to confirm movement artefact affecting the sEMGpara signals.   
2.8.3 Mask or nasal Pressure monitoring 
Pressure signals were measured by attaching small calibre tubing from nasal cannulae or the mask 
interface to a differential pressure transducer (GM instruments, Kilwinning, Scotland). The pressure 
transducer was checked and demonstrated linearity across our range of testing (-150cmH20 to 
150cmH20).  The signals from the pressure transducer are amplified, converted from analogue to 
digital and displaced on commercial software (Labchart v 7.3, ADInstruments, Chalgrove, UK).  Prior 
to each overnight tracing the calibration of the pressure transducer was checked against a handheld 
manometer (Fisher Scientific, Loughborough, UK) delivering a fixed pressure measurement to the 
circuit via a 20ml syringe.   
2.8.4 Respiratory Polygraphy 
The combination of parasternal, sternocleidomastoid and abdominal surface EMG with respiratory 
inductance plethysmography and either nasal pressure monitoring (self-ventilation nights) or mask 
pressure monitoring (nights on non-invasive ventilation) formed our overnight respiratory polygraphy 
montage.  
 
2.8.5 Overnight Polysomnography 
Polysomnography was performed using Alice 5 ® equipment (Respironics ®, Murrysville, PA, USA). 
Electrical activity of the brain (EEG) was recorded using surface electrodes (Gold) according to the 
ten-twenty system.  Skin preparation was performed using Nuprep ® gel (Weaver & Co, Colorado, 
USA) and the gold cup electrodes were filled with Ten20 ® conductive paste (Weaver & Co, 
Colorado, USA). The electrodes were then fixed to the scalp with skin adhesive Tensive (Biopac 
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Systems Inc, Goleta, CA, USA) and secured with tape.  We recorded EEG activity using the 
recommended configuration (F4M1, F3M2, C4M1, C3M2, O2M1,O1M2), according to the AASM 
Manual for Scoring Sleep, 2007; Figure 20.(117) F represents frontal electrical activity, C represents 
central electrical activity and O represents occipital activity.  M1 and M2 refer to the reference 
electrodes over the left and right mastoid processes. Electro-oculography (EOG) was measured using 
Ambu® neuroline single-use surface electrodes (Ambu Inc, Ballerup, Denmark) to detect rapid eye 
movement (REM) sleep staging. The electrodes were placed 1 cm below the outer canthus of the eye 
on the left and 1 cm above the outer canthus of the eye on the right as per the recommended EOG 
derivations.(117) The same Ambu® neuroline electrodes were used to detect chin EMG movements 
with one electrode placed in the midline 1cm above the inferior edge of the mandible and another 
electrode placed 2cm below the inferior edge of the mandible and 2cm lateral to the midline.(117)   
Figure 19: An example of the electroencephalography montage configuration according to the 








     
Abbreviations: M1-reference electrode over left mastoid process, M2- reference electrode over right 
mastoid process, F3-left frontal electrode, F4-right frontal electrode, C3-left central electrode, C4-right 
central electrode, O1-left occipital electrode, O2- right occipital electrode. 
 
2.8.6 Scoring sleep stages 
Sleep and respiratory events were scored using standard scoring terminology for adults.(117, 118).  
Sleep stages were identified by convention as Stage W (Wakefulness), Stage N1 (NREM1), Stage N2 
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(NREM2), Stage N3 (NREM3), Stage R (REM) according to the standard criteria.(117)  Sleep stages 
were scored in 30 second sequential epochs from the start of the study with each epoch assigned a 
stage as appropriate from those listed above.  If 2 or more stages were observed within the same 
epoch then this was scored as that which occupied the majority.(117)  
Stage W, is observed if more than 50% of the epoch has alpha rhythm (8-13Hz activity) over the 
occipital regions or periods of eye blinks, reading eye movements associated with normal or 
increased chin muscle tone.(117)  
Stage N1, is reported if alpha rhythm becomes attenuated and is replaced by low amplitude (4-7Hz 
activity) and mixed frequency activity for more than 50% of the epoch.  There is frequently the 
presence of vertex sharp waves lasting less can 0.5 seconds over the central region and slow eye 
movements.(117)  
Stage N2 is defined by K complexes, a well-delineated negative sharp wave immediately followed by 
a positive component lasting more than 0.5 seconds, along with the presence of sleep spindles 
(distinct waves with a frequency of 11-16Hz) lasting more than 0.5 seconds.(117) 
Stage N3 is scored when more than 20% of an epoch contains slow wave activity (0.5-2Hz) with a 
peak amplitude of more than 75µV over the frontal cortex. Sleep spindles may persist but eye 
movements are rarely seen.(117)  
Stage R is characterised by rapid eye movements which are irregular, sharply peaked eye 
movements with an initial deflection lasting less than 0.5 seconds. Sawtooth EEG waves may be 
observed, which are often triangular waves, occurring at a frequency of 2-6Hz and maximal in 
amplitude over the central regions.  These features are often observed in combination with low chin 
EMG tone.(117) 
2.8.7 Scoring arousals 
The scoring of arousals from sleep was defined as a rapid shift of EEG frequency lasting for at least 3 
seconds during any stage of sleep (N1, N2, N3 or R) preceded by a minimum of 10 seconds of stable 
sleep.(117) The arousal index (AI) was defined an average of the number of arousals occurring per 
hour of sleep throughout the analysis overnight. Normal AI is <10-24 with a wide variation related to 
aging where an increased in arousal frequency is observed as we age.(119)  
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2.8.8 Sleep quality measures 
Total sleep time (TST) was identified as the total time sleep stages were identified from all the epochs 
examined overnight described in minutes.  The total sleep efficiency (SE) was defined as the total 
sleep time as a percentage of the total sleep opportunity (i.e. between lights off and lights on). Normal 
SE is described as greater than 80%.(117)  Markers of sleep disruption were identified as the amount 
of time spent awake in the night after the first onset of sleep (WASO) measured in minutes and the 
time it took to first fall asleep termed the sleep latency. Normal SL is described as <30 minutes.(117)  
2.8.9 Scoring respiratory events 
Respiratory events on NIV were scored in accordance with the guidance published by the SomnoNIV 
group in Thorax in 2010.(34)  Obstructive events were classified as period of cessation in flow with an 
initial reduction and then exaggerated abdominal RIP movements whilst the ventilator switches to the 
back-up rate. (Figure 21). A central apnoea was identified by a cessation in flow without respiratory 
effort detected from the RIP bands and a switch to the back-up rate.  A mixed apnoea was identified 
as combination of both events. It is characterised by an absence of flow at the mask initially 
associated without inspiratory effort followed by resumption of inspiratory effort in the second portion 
of the event without airflow. A hypopnea was defined as a reduction in flow at the mask but not 
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Figure 20: Example of respiratory events identified from overnight traces as defined by the 
SomnoNIV group. A) An example of an obstructive apnoea with preserved respiratory effort 
but reduction in flow. B) An example of central apnoea with an absence in respiratory effort 
















2.9 Non-invasive detection of patient-ventilator asynchrony  
In order to identify PVA, the physician must have a marker of both the patient’s inspiratory and 
expiratory effort to breathe and the ventilator delivered breath. As discussed previously the current 
accepted method of measuring a patient’s breathing effort involves the use of a catheter with a multi-
pair electrode placed in the oesophagus for measuring crural diaphragm electromyography (EMGdi) 
and pressure measuring balloons placed in the stomach (Pgas) and oesophagus (Pes).  EMGdi 
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provides a real time breath-by-breath measurement of neural respiratory drive (NRD) and reflects the 
load on the respiratory muscles.  EMGdi has been shown as a useful method of monitoring 
respiratory disease severity, the effect of mechanical ventilation on the respiratory muscle unloading, 
as well as acting as a direct trigger for mechanical ventilation in neurally adjust ventilator assist mode 
(NAVA).(23, 120) 
However, these catheters are invasive and poorly tolerated in the awake, non-sedated patient which 
limits their clinical application to assess non-invasive ventilation, particularly in an elective setting.  
The catheters may be required for monitoring over days whilst ventilatory therapy is administered and 
would be impractical to maintain in a feeding, ambulatory patient. In addition, neuromuscular patients 
represent a significant proportion of patients requiring domiciliary ventilation for respiratory failure in 
our high dependency unit.  These patients often have poor bulbar function at the initiation of 
domiciliary ventilation; the use of these oesophageal, gastric catheters requires good swallow function 
to pass the tube and would be unfeasible in such patients placing them at risk of aspiration of gastric 
contents.    
The intercostal muscles are obligatory inspiratory muscles and act to stabilise the chest wall against 
the downward movement of the diaphragm during inspiration.(70) Previous work by Gandevia 
identified that there was a diminishing cranio-caudal distribution of inspiratory neural respiratory drive 
to the intercostal muscles which mirrors the mechanical inspiratory advantage of these muscles.(121) 
Parasternal muscles in the second intercostal space have maximal inspiratory mechanical advantage 
with associated phasic inspiratory activity, minimal postural tonic activity and demonstrate similar 
activity to the diaphragm.(121, 122)  Previous work using surface electrodes to measure second 
intercostal parasternal muscle electromyogram (sEMGpara) has demonstrated a direct relationship 
with respiratory muscle load reflecting NRD.(123)  sEMGpara has also been used as a clinically 
useful alternative monitoring tool in patients with acute COPD, asthma and cystic fibrosis that reflects 
disease severity and is sensitive to respond to acute changes in disease state.(124-127)     
We therefore used sEMGpara as a non-invasive marker of patient inspiratory effort to identify patient 
ventilator asynchrony.  We combined sEMGpara with RIP as a marker of the translation of patient 
inspiratory effort into chest wall excursion and to identify upper airway obstructive respiratory events 
overnight.   Surface EMG measurements of sternocleidomastoid and abdominal muscles were also 
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obtained as a further visual marker of the recruitment of accessory inspiratory muscles and muscles 
of active expiration.  Ventilator delivered breaths were identified using the mask pressure (Pmask). 
Examples of this technique in identifying individual patient ventilator asynchrony are shown below.       
(Figures 22-28).  
I firstly inspected the overnight studies to identify the asynchrony occurring in non-invasive ventilation 
using our non-invasive technique.   I then set rules for these asynchronous events so that they could 
be easily characterised and reliably identified between different observers. The overnight polygraphy 
data were analysed manually examining each breath over 2 minutes for every 10 minutes of recording 
overnight excluding periods of movement artefact. Below are my definitions for each of the 
asynchrony in turn with an example, these have now been published. (79)  
2.9.1 Trigger asynchrony- Ineffective efforts 
An ineffective effort is an asynchronous event where the patient exhibits inspiratory effort demanding 
a breath without a corresponding breath being delivered by the ventilator.   
Visual data definition: sEMGpara activity (neural respiratory drive) and associated thoraco-abdominal 













Figure 21: A representative trace identifying an ‘ineffective effort’ asynchronous event 
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Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal. 
 
2.9.2 Trigger asynchrony- Autotriggering 
Autotriggering represents an inappropriate ventilator delivered breath that is not triggered by the 
patient.  This mainly occurs as a pressure support delivered breath without corresponding EMGpara 
activity plus delayed abdominal and chest RIP activity post the onset of the ventilator delivered 
breath. (Figure 23).  It can also occur as a pressure control delivered breath identified by a fixed 
inspiratory time without sEMGpara activity and delayed abdominal and chest RIP activity post the 
change in the pressure signal.  For the breath to be auto-triggered as a pressure control breath it 
must be delivered at an inappropriate time when compared to the set back up rate.  For example at a 
back-up rate of 6, a pressure control ventilator delivered breath would be expected every 10 seconds. 
If a breath was delivered at the preset inspiratory time, 4 seconds after the previous breath without 




Figure 22: A representative trace demonstrating an ‘autotriggered’ asynchronous event 
s 
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Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal, Rectified RMS Signal- rectified root mean square of the parasternal 
electromyography signal, Ti-inspiratory time, PSV-pressure support ventilation delivered breath. 
 
2.9.3 Defining double triggering 
Double triggering is an asynchronous event where a patient demands a single breath but 2 breaths 
are delivered by the ventilator.  We defined double triggering as 2 breathing cycles of the ventilator 
delivered separated by a short expiratory time (defined as up to 1 second).  The first cycle must be 








Figure 23: A representative trace of a ‘double triggering’ asynchronous event 
s 
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Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal, Rectified RMS Signal- rectified root mean square of the parasternal 
electromyography signal. 
 
2.9.4 Defining multiple triggering 
Multiple triggering is an asynchronous event where a patient makes a single continuous demand for a 
breath that triggers multiple breaths from the ventilator. This requires sEMGpara activity representing 
neural respiratory drive to be continuously present throughout all the delivered breaths. A single 









Figure 24: A representative trace of a ‘multiple triggering’ asynchronous event 
s 
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Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal, Rectified RMS Signal- rectified root mean square of the parasternal 
electromyography signal. 
 
2.9.5 Defining premature expiratory cycling asynchrony 
Premature expiratory cycling represents a patient ventilator asynchronous event, the patient’s neural 
inspiratory time continues whilst the ventilator cycles into expiration. (Figure 26).  To identify this from 
our traces we have defined it as occurring when the following rules are present: 
1. The ventilator cycles to expiration seen by a reduction in the pressure signal towards the baseline 
whilst sEMGpara activity continues. 
2. Thoraco-abdominal band movement continue outwards in the direction of inspiration whilst the 
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Figure 25: A representative trace of a ‘premature expiratory cycling’ asynchronous event 
 
Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- second intercostal parasternal electromyography 
signal, Rectified RMS Signal- rectified root mean square of the parasternal electromyography signal. 
 
2.9.6 Defining extended expiratory cycling asynchrony 
Extended expiratory cycling represents the patient’s neural inspiratory time finishing but the ventilator 
remains in inspiration i.e. the patient tries to expire but the ventilator continues to give an inspiratory 
support breath. (Figure 27). We have defined this as being present with the following rules:  
1. sEMGpara activity stops 20ms prior to the expiratory phase  
2. A small increase in the pressure wave may be seen, representing the patient trying to forcibly 
expire i.e. ‘fighting the ongoing inspiratory manoeuvre’. 
3. Abdominal EMG signal may be visible indicating forced expiratory muscle recruitment.  
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Figure 26: A representative trace of a ‘delayed expiratory cycling’ asynchronous event 
 
Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal, Rectified RMS Signal- rectified root mean square of the parasternal 
electromyography signal. 
 
2.9.7 Defining autocycling 
Autocycling is defined as multiple cycles of ventilator breaths being delivered in quick succession. 
More than 2 breaths must be delivered each separated by a short expiratory time of less than 1 
second. These breaths are not triggered by the patient but occasionally sEMGpara activity is seen in 
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Figure 27: A representative trace of an ‘autocycling’ asynchronous event 
 
Abbreviations: Chest RIP- chest wall respiratory inductance plethysmography, Abdo RIP- abdominal 
wall respiratory inductance plethysmography, Sum RIP- Sum of both the chest wall and abdominal 
inductance plethysmography bands, sEMGpara- surface second intercostal parasternal 
electromyography signal, Rectified RMS Signal- rectified root mean square of the parasternal 
electromyography signal. 
 
2.10 Inter-rater reliability in detection on patient ventilator asynchrony 
Two assessors (MR and SM) were blinded and independently scored 10 randomly selected one hour 
sections of recorded data from 10 patients.  Asynchronous events were manually assessed according 
to the a priori definitions. (Figures 22-28). 
10 patients (4 COPD, 4 ORRF, 2 NMD-CWD) were included in this sub-study.  A total of 4,603 
breaths were analysed by two independent scorers with PVA reported in 812 (35%) and 891 (39%) 
breaths, respectively.  The Inter class correlation coefficient (ICC) between the scorers was 0.84 
(0.74-0.90).  The predominant asynchrony reported was ineffective efforts, for which there was the 
closest inter-observer agreement with an ICC of 0.94 (0.79-0.99).  The agreement for triggering and 
cycling PVA are shown in Table 6 and Table 7.  The lowest agreement was observed in the 
autocycling asynchrony (0.22; -0.54-0.74), albeit this had a very low frequency and was observed in 
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n (% breaths) 
Scorer 2 
n (% breaths) 
ICC 
(95% CI) 
Bland- Altman  
Analysis 
Bias (95% Limits of 
Agreement) 
Ineffective effort 484 (21%) 466 (21%) 0.94 (0.79-0.99) 1.8 (-30.1, 33.7) 
Auto-triggering 164 (7%) 231 (10%) 0.77 (0.19-0.94) -6.7 (-25.4, 12.0) 
Double 
Triggering 
22 (<1%) 11 (<1%) 0.67 (0.11-0.91) 1.1 (-1.9, 4.1) 
Multiple 
Triggering 
4 (<1%) 4 (<1%) 1.00 0.0 (0.0, 0.0) 
 




n (% breaths) 
Scorer 2 
n (% breaths) 
ICC 
(95% CI) 
Bland- Altman  
Analysis 




88 (4%) 124 (5%) 0.73 (0.26-0.92) -3.6 (-18.7, 11.5) 
Extended 
Cycling 
45 (2%) 50 (2%) 0.76 (0.31-0.93) -0.5 (-8.6, 7.6) 
Auto-cycling 5 (<1%) 5 (<1%) 0.22 (-0.54-0.74) 0.0 (-2.3, 2.3) 
A total of 4603 breaths were analysed with patient ventilator asynchrony reported in 812 and 891 
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Figure 28: Bland-Altman comparison of (A) Ineffective efforts and (B) Auto-triggering 
asynchrony 
   
PVA can be reliably identified using the above technique. The predominant PVA’s were ineffective 
efforts for which there was the greatest agreement. This analysis could be automated to provide a 
simple approach to assessing PVA. 
2.10.1 Scoring PVA in association with sleep and wakefulness during the overnight study 
I took a pragmatic approach to scoring events during our overnight analysis and comparing these with 
the polysomnography data. Both the respiratory polygraphy data and the overnight polysomnography 
were synchronised and analysed as 2 minutes every 10 minutes of data, excluding movement 
artefacts. The terms used to describe the events analysed were described as follows.  
PVA is defined and reported throughout this thesis as the percentage of breaths out the total breaths 
analysed that demonstrated PVA, including type of asynchrony, unless stated otherwise.  PVAwake 
was defined as the total number of PVA observed per hour during periods of wake during the 
overnight analysis. PVAsleep was defined as the total number of asynchronous events observed per 
hour during periods of sleep as determined by PSG. 
The arousal index (AIpsg) was defined as the number of EEG identified arousals from sleep lasting > 3 
seconds that occurred per hour from the complete PSG analysis.  The arousal index (AItotal) was 
defined as the calculated arousal index per hour, this was targeted on the detailed 2 minute epochs 
that were examined for PVA throughout the overnight study.  The patient-ventilator asynchrony 
arousal index (AIpva) was defined as the number of patient ventilator asynchronous events that 
A B 
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preceded an arousal within 3 seconds  per hour of sleep overnight calculated from the 2 minute epoch 
assessments,   
 
2.10.2 Acquisition and storage of Data 
All data acquisition took place in the Lane Fox Unit, St. Thomas’ Hospital, London. The data were 
anonymised, stored and analysed in the Lane Fox Unit, in locked rooms when unoccupied on 
password protected laptops (HP Inc UK Limited, Bracknell, Berks, UK).  
 
2.10.3 Statistical Analysis  
Anthropometric data, were normally distributed and are presented as mean and standard deviation 
(SD).  Unpaired t-tests were used to compare baseline characteristics between both the patient 
groups and; patient and healthy subjects.  A one way analysis of variance (ANOVA) with a Dunn’s 
multiple comparisons correction test were performed to compare baseline characteristics between the 
disease groups and identify where significant differences occurred.   
All other data were non-parametric and are presented as median value with the inter-quartile range. 
Comparisons between the sEMGpara signals in different postures were performed using an ANOVA. 
Whereas comparisons between healthy subjects and Duchenne Muscular Dystrophy (DMD) patients 
in Chapter 3 used Mann-Whitney U t-test analysis.  Spearman correlation was applied to assess the 
relationship between changes in sEMGpara%max and EMGdi%max in different postures. The same 
correlations were used to assess the sEMGpara%max and measures of spirometry or body mass 
index in DMD patients. 
Similar comparisons between the physician led set up and the physiological led set up in Chapter 4 
were also performed using a Mann-Whitney U t-test.  Comparisons between the disease groups were 
performed using a Kruskal-Wallis test with a Dunn’s multiple comparison correction test.  To assess 
changes in outcome measures over time in either the ventilator set up groups or the disease groups a 
repeated measures Friedman test was applied.   Correlations between PVAs and outcomes 
measures were performed with a Spearman correlation.  
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In chapter 5, sleep quality measures were compared over time with the Wilcoxon-matched pairs test.  
Comparisons of PVA levels in the same patient between different sleep stages were performed with a 
repeated measures Friedman test.  The frequency of PVAs occurring in different sleep levels and 
leading to arousals were compared using a Kruskal-Wallis test with a Dunn’s multiple comparison 
correction test.  Correlations between PVAs and sleep efficiency measures were again performed 
with a Spearman correlation. 
Comparison of data between healthy subjects and COPD patients in Chapter 6 was performed using 
Mann-Whitney t-test. Spearman correlations were performed between trigger delay settings and 
participant outcome measures such as respiratory muscle loading or comfort scores. 
To assess the inter-rater reliability of identifying PVA using our technique, described earlier in 
Methods section 1.10, intraclass correlation coefficient (ICC) was analysed.  This was based on 2-
way random effects model with absolute agreement to measure reliability.  The agreement between 
each pair of observations was also assessed using Bland and Altman plots. 
For all analyses, a p-value <0.05 was considered statistically significant.  Data analysis was 
performed using IBM SPSS Statistics v22 (IBM Corporation, Portsmouth, UK) and GraphPad Prism 6 
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Chapter 3 The effect of posture on neural respiratory drive to 
parasternal intercostal and diaphragm muscles in healthy 
subjects and Duchenne Muscular Dystrophy patients 
 
3.1 Background  
Neural respiratory drive has previously been quantified by measuring diaphragm EMG (EMGdi) using 
a multi-pair oesophageal electrode reflecting the load and capacity balance of the respiratory system.  
EMGdi, measured continuously during sleep on a breath-by-breath basis, may be a useful method of 
monitoring respiratory disease severity and the effect of mechanical ventilation.(125, 128)   In the 
upright position, the rib cage expands more than the abdomen whereas in the supine position, most 
normal healthy subjects are ‘abdominal breathers’.(129) During resting tidal breathing normal healthy 
subjects have shown greater activation of the rib cage inspiratory muscles and of the diaphragm in an 
upright posture compared to a supine posture.(130) The increased electrical activity of the diaphragm 
in the upright position is considered a mechanism for counterbalancing the adverse effects produced 
by the upright posture on the length-tension state of the diaphragm and facilitates the generation of a 
constant transdiaphragmatic pressure.(129) sEMGpara is usually acquired seated in a 45 degree 
position but has been previously used to assess neural respiratory drive in both asthmatics and 
healthy controls overnight.(124, 125)  If sEMGpara is to be used to continuously monitor the 
respiratory system it is important for the operator to be understand the effect of posture on the signal 
acquisition in health subjects which is the focus of the first part of the study.  The second part of this 
study was to ensure that sEMGpara could be measured in patients with Duchenne muscular 
dystrophy, where the signal size may be affected both by posture as well as the underlying muscle 
wasting disease process preventing recruitment of the chest wall inspiratory muscles. 
 
3.1.1 Study hypothesis: There is a change in neural respiratory drive accompanying changes 
in body position from 45º upright. 
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3.2 Material and Methods 
Healthy subjects and Duchenne Muscular dystrophy patients were recruited for this study to validate 
sEMGpara acquisition in different postures.  
Baseline data 
Following enrolment, healthy subjects performed spirometry to exclude significant underlying 
obstructive or restrictive lung disease.  Height and weight measurements were also performed to 
calculate body mass index. Duchenne muscular dystrophy patients also performed spirometry to 
characterise the severity of their restrictive deficit.  The weight in these patients was similarly recorded 
on weighing scales, height was estimated by measuring the arm span to calculate the body mass 
index.  
sEMGpara Measurement 
Five different postures were examined; 45 degrees, 90 degrees upright, flat horizontal, lying on the 
right hand side and lying on the left hand side. The sequence of the positions was randomised 
between subjects. sEMGpara measurements were obtained during tidal breathing with the subject 
fully supported by the bed in each different posture to minimise signal artefact.  sEMGpara was 
measured during two minutes of tidal breathing post 10 minutes of relaxed breathing in each posture.  
Resting sEMGpara was normalised to the maximal inspiratory manoeuvre performed in each position 
(sEMGpara%max) as described in the Material and Methods section 1.7.1.   
Data and Statistical Analysis 
Baseline characteristics are expressed as mean (± standard deviation (SD)). sEMGpara tabulated 
data are expressed as median and interquartile range unless otherwise stated. sEMGpara data are 
expressed as median, interquartile range and total range in all figures.  The sEMGpara data were not 
normally distributed as defined by the Kolmogorov-Smirnov test and so non-parametric tests were 
applied.  Differences in sEMGpara%max between the standardised 45 degree position and different 
postures were analysed using a Kruskal-Wallis One-Way ANOVA test with a Dunns correction to 
compare all data points. Bland-Altman tests were used to compare sEMGpara and EMGdi results and 
a spearman correlation was used to compare the changes in both values with different postures. The 
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neural drive of Duchenne Muscular dystrophy patients and healthy controls were compared using 
Mann-Whitney t-tests. Spearman correlation was used to correlate measures of sEMGpara%max with 
spirometry values and body mass index results.  A p-value <0.05 was considered as statistically 
significant.   
3.3 Results 
3.3.1 Subject demographics 
Seventeen healthy subjects were recruited (12 female). Mean (SD) age was 39 (±13) years with a 
mean body mass index (SD) of 23.0 (±3.5)kg/m2. The mean FEV1 predicted (SD) was 99 (±13)% and 
FVC predicted (SD) was 106 (±21)% consistent with normal spirometric values. Phasic inspiratory 
neural drive was reliably recorded in all postures for 11 healthy subjects (65%).  Adequate inspiratory 
sEMGpara signal was demonstrated in the right and left lateral postures in 12(71%) subjects. The 
inspiratory sEMGpara signal was inadequate in the flat posture in 2(12%) subjects. There was no 
statistical difference in the baseline characteristics between those healthy subjects that had adequate 
sEMGpara recorded in all 5 postures and those who did not; to account for this (Table 8). 
Five healthy subjects (3 females) consented to simultaneous EMGdi measurements of which four (3 
females) subjects demonstrated an adequate sEMGpara signal in all 5 postures.  Mean (SD) age was 
40 (±11) years with a mean body mass index (SD) of 23.0 (±3.4)kg/m2. The mean FEV1 predicted 
(SD) was 104 (±9)% and FVC predicted (SD) was 117 (±8)% consistent with normal spirometric 
values.  
Four Duchenne muscular Dystrophy patients (all male) were also studied to confirm that an 
sEMGpara signal was obtainable in the 5 different postures.  Mean (SD) age was 26 (±2) years with a 
mean body mass index (SD) of 20.0 (±2.4)kg/m2. The mean FEV1 predicted (SD) was 16 (±4)% and 
FVC predicted (SD) was 15 (±3)% consistent with restrictive spirometric values. Duchenne patients as 
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Table 8: Healthy subjects demographics for the total enrolled and for those with adequate 
signal in all 5 postures 
Subject Characteristics Total group (n=17) Adequate signal 
acquisition (n=11) 
p-value 
Age (yrs) 39 (±13) 40 (±14) 0.9 
BMI (kg/m2) 23 (±4) 24 (±4) 0.6 
FEV1 (%pdt) 99 (±13) 103 (±14) 0.5 
FVC (%pdt) 106 (±21) 112 (±24) 0.5 
FEV1/FVC (%) 80 (±7) 79 (±7) 0.6 
Abbreviations: yrs-years, BMI- body mass index, FEV1-forced expiratory volume in 1 second, FVC- 
forced vital capacity 
 
Figure 29: The proportion of patients in whom an adequate phasic inspiratory sEMGpara 
signal was detected in each posture 
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3.3.2 sEMGpara measurements in healthy subjects 
Excluding the sEMGpara signals where clear phasic inspiratory activity was not seen in all postures 
11 subjects’ data were amenable to analysis.  sEMGpara%max was statistically significantly lower in 
the right and left lateral positions, the median sEMGpara%max difference was -0.9% (-3.2 to -0.2) and 
-1.5% (-3.7 to -0.8) respectively.    No statistically significant difference was seen between the 
sEMGpara%max signals in the 90 degree upright position and lying flat compared to the standardised 
45 degree position. 
Table 9: sEMGpara%max signals obtained in the 5 different postures including the change 
from the standardised 45 degree posture 
Subject 45 degrees,% Flat,% (change 
from 45 degrees) 
RHS,% (change 
from 45 degrees) 
LHS,% (change 
from 45 degrees) 
90 degrees,% (change 
from 45 degrees) 
1 6.6 7.0  (0.4) 6.4  (-0.2) 5.8  (-0.8) 4.4  (-2.2) 
2 3.9 5.0  (1.1) 2.9  (-1.0) 1.9  (-2.0) 5.3  (1.4) 
3 4.0 5.1  (1.1) 4.1  (0.1) 1.5  (-2.5) 3.2  (-0.8) 
4 6.9 7.0  (0.1) 6.3  (-0.6) 5.4  (-1.5) 6.8  (-0.1) 
5 23.2 24.2  (1.0) 14.9  (-8.3) 17.4  (-5.8) 23.6  (0.4)  
6 7.8 7.8  (0.0) 5.8  (-2.0) 6.6  (-1.2) 5.8  (-2.0) 
7 11.3 7.8  (-3.5) 6.4  (-4.9) 6.0  (-5.3) 10.4  (-0.9) 
8 6.0 6.7  (0.7) 6.1  (0.1) 6.7  (0.7) 4.9  (-1.1) 
9 9.1 6.0  (-3.1) 5.9  (-3.2) 5.4  (-3.7) 8.9 (-0.2) 
10 7.4 6.1  (-1.3) 6.5  (-0.9) 6.5  (-0.9) 7.1  (-0.3) 
11 9.5 8.1  (-0.4) 8.4  (-0.2) 8.8  (0.2) 9.4  (0.9) 
Median 
(IQR) 
7.4                    
(6.0-9.1) 
7.0                                 
(6.0-7.8) 
6.3                             
(5.8-6.5) 
6.0                                       
(5.4-6.7) 
6.8                                                 
(4.9-9.4) 
Abbreviations: 45- sitting at a 45 degree posture, flat-lying flat on the back RHS- lying on the right 
hand side, LHS- lying on the left hand side, 90- sitting at a 90 degree posture. 
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Figure 30: Change in sEMGpara%max with 5 different postures A) Actual sEMGpara%max 





























































Abbreviations: 45- sitting at a 45 degree posture, flat-lying flat on the back RHS- lying on the right 
hand side, LHS- lying on the left hand side, 90- sitting at a 90 degree posture, sEMGpara%max- 
normalised surface parasternal electromyogram reading to a maximal inspiratory manoeuvre. 
 
It was observed that the sEMGpara%max signal reliability was frequently related to the signal 
amplitude, with smaller signals more prone to difficulties in detecting a physiological signal above a 
noise signal in the different postures. The sEMGpara%max signal amplitude between subjects that 
were interpretable across all the 5 postures and those that were non-interpretable were compared.  A 
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Table 10: Comparison between baseline sEMGpara%max signals obtained at 45 degrees in 
healthy subjects that had reproducible and non-reproducible signals in all 5 postures studied. 
Subjects   Reproducible sEMGpara%max (%) Non-reproducible sEMGpara%max (%) 
1 6.6 1.8 
2 3.9 4.3 
3 4.0 2.7 
4 6.9 4.1 
5 23.2 3.9 
6 7.8 3.4 
7 11.3  
8 6.0  
9 9.1  
10 7.4  
11 8.5  
Median 
(IQR) 
7.4                                                                
(6.0-9.1) 
3.7                                                                                           
(2.5-4.2) 
Abbreviations: sEMGpara%max- surface second intercostal parasternal signal normalised to a 
maximal inspiratory manoeuvre. 
 
3.3.3 EMGdi signal measurement in healthy subjects 
Concurrent EMGdi was measured in 5 healthy subjects (3 females). A phasic inspiratory signal was 
obtained in all individuals in the 5 postures examined.  To compare the subjects EMGdi was recorded 
as a percentage of a maximal inspiratory manoeuvre (EMGdi%max) either a SNIP or MIP whichever 
provided the greater EMGdi recruitment.  Comparing the EMGdi%max signal obtained in the 5 
different postures using a Friedman repeated measures test, no significant difference was observed 
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between the different postures (p=0.17).  The lowest median EMGdi%max value was recorded in the 
supine posture however there were very variable responses to the different postures between two 
individuals in this study (Figure 32).(129)  
Table 11: EMGdi%max signals obtained in the 5 different postures in healthy subjects 
including the change from the standardised 45 degree posture 
Subject 45 degrees, % Flat,% (change 
from 45 degrees) 
RHS, % (change 
from 45 degrees) 
LHS, % (change 
from 45 degrees) 
90 degrees, % (change 
from 45 degrees) 
1 8.2  6.9  (-1.3) 8.0  (-0.2) 11.9  (3.7) 11.3  (3.1) 
2 9.5  8.5  (-1.0) 9.2  (-0.3) 9.9  (0.4) 10.4  (0.9) 
3 12.0  7.1 (-4.9) 13.1  (1.1) 5.4  (-6.6) 6.1  (-5.9) 
4 9.3  8.4  (-0.9) 7.8  (-1.5) 7.6  (-1.7) 9.8  (0.5) 
5 12.1 11.8 (-0.3) 12.0  (-0.1) 11.4  (-0.7) 12.6  (0.5) 
Median            
(IQR) 
9.5                       
(8.8-12.1) 
8.4                              
(7.0-10.2) 
9.2                               
(7.9-12.6) 
9.9                              
(6.5-11.7) 
10.4                                         
(8.0-12.0) 
Abbreviations: 45- sitting at a 45 degree posture, flat-lying flat on the back RHS- lying on the right 
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Figure 31: Change in EMGdi%max in healthy subjects with 5 different postures A) Actual 






























































Graph A) data are represented by Box-whisker plots demonstrating median, IQR and minimum-
maximum values.  Abbreviations: 45- sitting at a 45 degree posture, flat-lying flat on the back RHS- 
lying on the right hand side, LHS- lying on the left hand side, 90- sitting at a 90 degree posture, 




3.3.4 Comparison between sEMGpara%max and EMGdi%max in healthy subjects 
4 healthy subjects had reproducible EMGdi%max and sEMGpara%max recorded simultaneously.  In 
all postures examined there was no statistically significant difference between the EMGdi%max and 
the sEMGpara%max obtained in these healthy subjects. Although as described previously, 
EMGdi%max was consistently a higher than sEMGpara%max (Figure 33).(131) The values obtained 
for both sEMGpara%max and EMGdi%max were similar to those previously published for healthy 
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Figure 32: Comparison between EMGdi%max and sEMGpara%max obtained in 4 healthy 
individuals during 5 different postures (45 degrees semi-recumbent, lying flat, lying on the 
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Abbreviations: 45- sitting at a 45 degree posture, flat-lying flat on the back RHS- lying on the right 
hand side, LHS- lying on the left hand side, 90- sitting at a 90 degree posture, sEMGpara%max- 
normalised parasternal electromyogram reading to a maximal inspiratory manoeuvre, EMGdi%max- 




Figure 33: Bland-Altman analysis of agreement between sEMGpara%max and EMGdi%max 
signals in all 5 postures in 4 healthy subjects (A-45 degrees semi-recumbent, B-flat, C-lateral 
right hand side, D-lateral left hand side, E-90 degrees sitting).   
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Graph A: bias-2.7%,SD of bias 2.9%,95% limits of agreement -8.4 
to 3.0% 
Graph B: bias-1.8%,SD of bias 2.5%,95% limits of agreement -6.8 
to 3.1%          
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These data suggest that the value obtained from the sEMGpara%max is lower than that from 
EMGdi%max in all postures.  No direct relationship was observed between the change in 








Graph C: bias-3.9%,SD of bias 1.8%,95% limits of agreement -7.3 
to -0.4% 
Graph D: bias-2.6%,SD of bias 4.1%,95% limits of agreement -
10.5 to 5.4% 
Graph E: bias-2.5%,SD of bias 4.5%,95% limits of agreement -
11.4 to 6.3% 
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Figure 34: Relationship observed between the change in sEMGpara%max and EMGdi%max 
from a standard (45 degree posture) across the 4 other postures.  
                             














Abbreviations:sEMGpara%max- normalised surface parasternal electromyogram reading to a 
maximal inspiratory manoeuvre, EMGdi%max- normalised diaphragm electromyogram reading to a 
maximal inspiratory manoeuvre. 
 
3.3.5 sEMGpara signals in Duchenne Muscular Dystrophy patients 
Clear phasic inspiratory activity of sEMGpara signals was observed in all 4 patients analysed with 
Duchenne Muscular Dystrophy (DMD) in each of the 5 postures.   The mean sEMGpara%max 
obtained was higher in DMD patients than healthy controls in all five postures but this did not reach 
statistical significance (Figure 36).  No significant difference was seen in the sEMGpara%max 
obtained in any of the 5 postures in DMD patients (p=0.11); Figure 37). 
sEMGpara%max was not significantly correlated with age, BMI, FEV1% predicted or FVC% predicted 
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Figure 35: Neural respiratory drive measured by sEMGpara%max in A) 45 degrees (semi-
recumbent) posture, B) Flat posture, C) Right hand side posture, D) Left hand side posture, E) 














































































































































The horizontal bar delineates the median value for each group. Abbreviations: Healthy- healthy 
subjects, DMD- Duchenne muscular dystrophy patients, sEMGpara%max- normalised parasternal 






C D p=0.23 p=0.14 
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Figure 36: Changes in sEMGpara%max signals measured in Duchenne Muscular Dystrophy 






























































                    
A- Box and whisker plot representing the median sEMGpara%max and maximum and minimum 
values obtained in each of the 5 postures. B- Demonstrates the change in sEMGpara%max from the 
gold standard posture of 45 degrees in each of the 4 DMD subjects. Abbreviations: 45- sitting at a 45 
degree posture, flat-lying flat on the back RHS- lying on the right hand side, LHS- lying on the left 
hand side, 90- sitting at a 90 degree posture, sEMGpara%max- normalised parasternal 
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Figure 37: Relationships between sEMGpara%max and A) Body mass index (BMI), B) Forced 
expiratory volume in 1 sec percentage predicted (FEV1%pred), C) Forced Vital Capacity 
percentage predicted (FVC). 















































    
                                                























Abbreviations:sEMGpara%max- normalised parasternal electromyogram reading to a maximal 
inspiratory manoeuvre, BMI-body mass index, FEV1-forced expiratory volume in 1 second, FVC-








rs=-0.8, p=0.33 rs=-0.6, p=0.42 
rs=-0.7, p=0.17 
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3.4 Discussion 
The sEMGpara%max signal was obtained in over 70% of healthy subjects recruited in all 5 postures. 
However, in a small proportion of healthy subjects with low levels of resting drive the signal was not 
analysable.  sEMGpara%max did not significantly change between 45, 90 and lying flat in these 
subjects but there was a reduction observed in the signal obtained in the lateral postures.   
Our study was concordant with previous values obtained in healthy subjects for EMGdi%max and 
sEMGpara%max and also demonstrated as previously observed that values for EMGdi%max were 
consistently greater than sEMGpara%max.(66, 127, 131, 132) EMGdi%max did not change 
significantly between the 5 different postures.  
This is the first study to describe the levels of NRD in Duchenne Muscular Dystrophy patients 
quantified by sEMGpara%max demonstrating that it was both obtainable and reliably observed in all 5 
postures.   No significant difference in NRD was observed in these patients between the different 
postures although variation between individual responses was noted.   
3.4.1 Critique of the method 
The goal of this physiological study was to provide pilot data to demonstrate the feasibility and clinical 
utility of using sEMGpara as a continuous monitoring tool where different postures maybe adopted 
such as during sleep.  The small number of participants that were monitored in the awake state may 
not represent the findings in a patient population that would be monitored clinically overnight. 
The issues of surface EMG recording and contamination from other chest wall muscles are 
described.(30) Every attention was given to ensure good skin preparation and electrode placement 
was optimised but we found artefact to affect mainly the lateral postures. This is likely to be related to 
changes in the chest wall configuration, impedance of the skin and displacement of the electrode 
further away from the underlying parasternal muscle. Despite this, 88% of subjects had a reliable 
phasic inspiratory signal identified in all but lateral postures.  Needle electrode technique could be 
used to isolate parasternal muscle activity but this is an invasive technique and would not be suitable 
for overnight monitoring.(121)   
Examining the lack of statistical significant difference between the healthy subjects and the Duchenne 
muscular dystrophy patients it is observed that there is a clear outlier who consistently recruits more 
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than 15% of the maximum during tidal breathing in the different postures. When examining this 
individual further they are young at 27 years with a low BMI 19.4 although not the lowest in the co-
hort. Spirometry is within the normal range FEV1 (90% predicted) and FVC (94% predicted).  The raw 
EMG signal is similar to the other healthy subjects at 7.8µV, however, the maximal EMG signal is 
lower than the other healthy subjects at 34µV. Therefore the percentage of maximum muscle 
recruited during tidal breathing is higher. This highlights the difficulties with the EMG technique and 
the importance of familiarising subjects with the normalising techniques that have previously been 
discussed in the literature.(127) Despite making every effort to ensure that the SNIP was repeated at 
least 5 times, until three reproducible efforts with less than 10% variance were obtained as per the 
ATS/ERS guidelines (24), maximal inspiratory manoeuvres are non-the-less voluntary and so 
dependent upon the effort made by the subject.  
We chose not to use the raw signal only as DMD patients are substantially weaker than healthy 
subjects as indicated by the intrinsic muscle wasting that occurs with this condition. The maximal raw 
EMG signal was significantly reduced in all DMD patients compared to healthy controls which is a true 
reflection of their underlying disease process (SNIP rawEMG at 45 degrees; healthy subjects 82 (60-
114)µV vs DMD patients 32 (15-40)µV; p<0.01).  The significance of their weakness is best 
expressed by the amount of muscle recruitment required for tidal breathing as a percentage of the 
maximum they can achieve, indicating the low reserve capacity available.  
 
3.4.2 Significance of findings 
Importantly, neural respiratory drive (NRD), as measured by sEMGpara%max, does not significantly 
change on lying flat or sitting 90 degrees upright in healthy subjects.  Neural respiratory drive falls 
when adopting the left hand side and right hand side postures.  Caution should be taken to ensure 
that the sEMGpara%max signal is of adequate quality. If future automated monitoring were to be used 
a visual criterion with an appropriate signal to noise level would need to be set for an individual 
patient.  sEMGpara%max can be considered as an overnight monitoring tool but attention must be 
paid to body position and combining sEMGpara%max and a body position accelerometer sensor 
would assist interpretation of the signal.  Indeed, an automated system could exclude those 
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measurements that are acquired when the patient is lying on their side and aim to include all 
measurements in positions between 90 degrees and horizontally lying flat. 
In this physiological study, we did not find a statistical difference between the changes in 
sEMGpara%max between the sitting and lying postures examined in either healthy or Duchenne 
muscular dystrophy patients. Furthermore, no difference was observed in the EMGdi%max of healthy 
subjects in any of the 5 postures, although I acknowledge that there was variability in the individual 
responses observed. Previous work has suggested in healthy subjects that the activation of the rib 
cage and diaphragm muscles is greater in the upright than in the supine position during tidal 
breathing.(130) However, under conditions of ventilatory stress evoked by CO2 rebreathing the supine 
posture required higher activation of these muscles (129). Different proportions of ventilatory stress 
may have been experienced by healthy subjects due to subtle differences in their BMI and pulmonary 
mechanics.  Work by Steier et al. has previously demonstrated that obese subjects have elevated 
neural respiratory drive which increases in a supine posture (66).  Although the majority of our healthy 
controls had a BMI in a normal range, 5 participants would be categorised as overweight with a BMI 
between 25 kg/m2 and 30kg/m2.  Surface EMG may also be affected by underlying subcutaneous fat 
which may increase the distance between the electrode and the underlying parasternal intercostal 
muscle and this may change further with the body position adopted.  Although every effort was made 
to ensure that skin preparation was optimal and the electrodes were seated correctly, this may explain 
some of the drop in the sEMGpara%max in the lateral posture in healthy subjects.  
Our findings are concordant with previous studies indicating that NRD as measured by EMGdi%max 
in healthy subjects was between 8.4(±4.0)% and 10.0 (±7)%.(66, 131, 132)  Similarly 
sEMGpara%max values observed in our study were comparable with previously work, 
sEMGpara%max values in healthy subjects were reported as 5.8 (±3)% and lower than the 
EMGdi%max values simultaneously recorded.(127) Unlike previous studies we did not demonstrate a 
strong correlation between the changes in EMGdi%max and sEMGpara%max in the 5 postures.  
However, the current study, unlike previous studies, investigated the effect of differing posture alone 
on neural respiratory drive rather than previous studies that have investigated both posture and 
external respiratory muscle loading.  Although variability was observed, the majority of changes seen 
in the EMGdi%max measurements were less than 1% with only a single healthy subject 
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demonstrating more than a 5% change.  Similarly, with sEMGpara%max only a single subject 
demonstrated more than a 2% change in NRD between the different postures. These data represent 
the breath-by-breath variability between some individuals. 
This is the first study to demonstrate that NRD, as measured by sEMGpara%max is obtainable in 
patients with Duchenne muscular dystrophy.  Furthermore, NRD was observed in all postures studied 
and did not significantly change on lying flat or in the lateral postures in this group of patients. From 
observation of the raw traces the clarity of the signal was mainly due to the absence of tonic postural 
interference rather than an increase in the raw EMG signal.  There was however a marked reduction 
in neural drive in the supine and lateral postures in a single DMD patient.  On further review this 
patient had severe disease characterised by an FVC of only 13% predicted, with the highest tidal 
sEMGpara%max in a 45 degree posture of 16%. The reduction in neural respiratory drive may be 
explained by respiratory muscle wasting and loss of muscle mass in this individual leading to reduced 
respiratory muscle recruitment suggesting some variability in patient responses to posture depending 
on the capacity of the respiratory muscle pump.  However, as mentioned earlier, Druz et al. have 
described greater activation of the respiratory muscles in the upright posture in healthy subjects and 
so this may represent normal variation, whereas, the other patients do not drop their neural 
respiratory drive due to decreasing efficiency of the respiratory muscles.(130).  Indirect correlations 
were observed, albeit with only 4 patients and so lacked statistical significance, between neural 
respiratory drive and lung function and body composition.  In the Duchenne Muscular Dystrophy 
patients, a lower BMI and lower FVC was associated a higher level of neural respiratory drive.  
Further work investigating neural respiratory drive in in a larger sample of Duchenne muscle 




sEMGpara%max provides a  useful, non-invasive alternative measurement of NRD in both healthy 
subjects and Duchenne muscular dystrophy patients. The sEMGpara%max signal is most easily 
measured in healthy subjects in postures of 45 degrees, 90 degrees and lying flat and importantly 
neural respiratory drive did not change significantly in these positions.  sEMGpara%max is less easily 
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measured in healthy subjects in the lateral posturing. However, the lateral posture sEMGpara%max 
measurement is possible if the subject has a higher level of sEMGpara%max (>4%) when measured 
during tidal breathing seated at 45 degrees.  Alternatively, EMGdi%max can be employed as this is 
more reproducible albeit a more invasive monitoring technique.  Finally, NRD can be reliably 
measured using sEMGpara%max in all postures in patients with Duchenne muscular dystrophy.  
sEMGpara%max may therefore be used as useful non-invasive monitoring tool to assess the changes 
in NRD in these patients during sleep overnight.  
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Chapter 4 Pilot randomised controlled trial of physiological 
surface second intercostal parasternal electromyography 
(sEMGpara) set up of home mechanical ventilation compared to 
standard physician led set up 
 
4.1 Introduction 
Home mechanical Ventilation (HMV) has been shown to improve respiratory muscle unloading, gas 
exchange, health related quality of life and confer a survival benefit in certain patient groups with 
chronic ventilatory failure.(39, 40, 51, 67, 133)   Increasing patient numbers and increasing physician 
experience with non-invasive ventilation has led to widespread HMV use as a treatment.(134)   
Poor patient ventilator synchronisation may adversely impact on the benefits obtained from HMV in 
terms of respiratory muscle unloading, gas exchange, sleep quality, patient comfort and adherence to 
HMV.(8, 75, 76, 89, 135)  Furthermore, Thille et al. have demonstrated an association with the 
frequency of patient ventilator asynchrony (PVA) and ventilator settings such as pressure support 
levels, trigger sensitivity and inspiratory time.(77)  
When initiating HMV for patients in chronic hypercapnic ventilatory failure, ventilator settings have 
traditionally either been protocolised or titrated to correct arterial blood gases in combination with 
reports of patient tolerability.  Previous studies have suggested that titrating ventilator settings to a 
detailed physiological assessment of the patient could improve upon standard HMV set ups by 
enhancing patient ventilator interaction.(75, 136)  The ventilator manipulations performed in these 
studies were titrated to reduce measurements of transdiaphragmatic pressure and intrinsic end 
inspiratory positive airway pressure.(75, 136)  An alternative marker of measuring patients’ inspiratory 
effort has been to assess the neural drive to the diaphragm using crural diaphragm electromyogram 
(EMGdi).(30)   Ventilatory pressures have been titrated to maximally unload the diaphragm reducing 
the EMGdii signal and synchronise the ventilator to the patients’ neural inspiratory time with a modality 
of ventilation called neurally adjust ventilator assist (NAVA).(120, 137-140) 
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These methods of physiological assessment require the insertion of a nasogastric catheter.  The 
invasive nature of this procedure is challenging in awake, non-sedated patients and therefore its use 
has been limited outside an intensive care environment.  A study assessing its applicability  in 
patients receiving non-invasive ventilation in an acute setting demonstrated that it was often poorly 
tolerated and signal acquisition was difficult to achieve.(141)   
The parasternal intercostal muscles are obligate inspiratory muscles that act to stabilise the chest wall 
from the descent of the diaphragm and contract in concert during inspiration.(121, 122, 142)  The 
peak rectified surface electromyogram signal from the second intercostal space parasternal muscles 
(sEMGpara) has been found to be similar to the diaphragm and hence sEMGpara measurements 
have been used as a reliable non-invasive alternative to EMGdii in assessing neural respiratory 
drive.(143, 144)  sEMGpara has been correlated with markers of breathlessness and shown to be 
sensitive to change, both in a research setting following threshold loading, hypercapnic ventilator 
responses and clinically as a predictor of changing disease severity.(124, 127, 131, 145)  
Furthermore, the sEMGpara signal has previously been used overnight as a reliable breath by breath 
marker of neural respiratory drive in asthmatics and healthy subjects.(125)   These factors suggest 
sEMGpara may act as a suitable measure of respiratory muscle unloading and patient ventilator 
synchronisation during the application of nocturnal HMV.  This is the first study to examine the role of 
sEMGpara in the titration of ventilator settings in mechanical ventilation.  
 
4.1.1 Study Hypothesis 
We hypothesised that using sEMGpara as a novel non-invasive physiological marker to titrate 
individualised ventilatory pressures, identify and correct patient ventilator asynchrony will improve 
patient adherence to HMV at 3 months compared to a standard protocolised physician led set up of 
HMV.  
We also aimed to examine the effect of the sEMGpara titration of HMV on secondary outcomes such 
as gas exchange, respiratory muscle unloading, health-related quality of life measures, patient 
perception of HMV and the length of hospital stay for initiation of HMV as secondary outcome 
measures.  
  




All patients provided written consent prior to enrolment.  The study was approved by the Harrow 
National Research Ethics Service, London and the research was conducted in accordance with the 
Helsinki declaration.  The study was registered prospectively on a public database (ClinicalTrials.gov - 
NCT01371149). 
Patients were recruited from referrals to the Lane Fox Respiratory Unit, St. Thomas’ Hospital requiring 
initiation of non-invasive ventilation. 
Patients with chronic ventilatory failure (awake daytime PaCO2 > 6kPa) secondary to chronic 
obstructive pulmonary disease (COPD), obesity related respiratory failure (ORRF) or neuromuscular 
and chest wall disease (NMD-CWD) were enrolled.  Patients with an overlap of COPD and ORRF, 
including obstructive sleep apnoea, were categorised based on the predominant disease pathology as 
assessed by obstructive or restrictive pulmonary mechanics (e.g. FEV1/FVC < 0.7 obstructive; 
FEV1/FVC > 0.7 restrictive).  
4.2.2   Detailed Patient Eligibility Criteria 
 
Inclusion Criteria 
1) Patients with confirmed neuromuscular disorders, chest wall disease, chronic obstructive 
pulmonary disease or obesity hypoventilation syndrome. 
2) Patients with evidence of nocturnal hypoventilation with an arterial carbon dioxide partial pressure 
of >6.0 kPa on waking in the morning. 
3) Patients with evidence of hypercapnic respiratory failure with an arterial carbon dioxide partial 
pressure of >6.0 kPa during the day. 
4) Age over 16 years old. 
5) No prior domiciliary ventilation. 
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Exclusion Criteria 
1) Patients with other life threatening co-morbidities e.g. cancer or severe cardiac failure. 
2) Patients with an unconfirmed diagnosis of neuromuscular disease, obesity hypoventilation 
syndrome or chronic obstructive pulmonary disease. 
3) Patients who have had an acute illness within the last 4 weeks prior to starting assessment for 
ventilation. 
4) Patients who have an abnormal bleeding tendency (INR >1.4 or platelets <100). 
5) Patients with a psychological, social or geographical situation that would impair compliance with 
the project. 
 
4.2.3 Study Design  
The study was a prospective pilot randomised controlled trial.  Patients were randomly allocated via 
minimisation to either standard clinical care using overnight oximetry and capnography to titrate NIV 
settings or physiological sEMGpara led set up to optimise NIV settings through identification and 
correction of patient ventilator asynchrony.   Minimisation criteria were based on spirometry values 
FEV1/FVC more or less than 0.7, BMI more or less than 25 kg/m2 and an age above or below 50 
years. (See trial schematic in appendix 3).  
 
4.2.4 Primary Outcome 
The primary outcome was adherence to non-invasive ventilation at 3 months.  Secondary exploratory 
outcomes included PVA, NRD, gas exchange, health related quality of life, patient perceived comfort 
and length of hospital set up. 
 
4.2.5 Home mechanical ventilation set up  
HMV was set up in pressure support mode and provided by a portable home ventilator, the NIPPY3+ 
ventilator (B&D Electromedical, Stratford-upon-Avon, UK).  Ventilation was delivered to all patients 
  
- 117 - 
using an oral-nasal mask (Mirage Quattro, ResMed, San Diego, CA, USA) on the first night of HMV.  
Subsequently, 1 patient with NMD with compatible pressures was issued a nasal mask (nasal swift 
FX, ResMed, San Diego, CA, USA) at 6 weeks, 3 patients were issued with a total face mask (Philips 
Respironics, Murrysville, PA, USA) at 6 weeks (1 NMD patient, 1 COPD patient and 1 ORRF patient) 
for management of pressure sores.   The back-up rate was set at 2 breaths below the resting 
respiratory rate for both groups.  
 
Physiological sEMGpara set up   
Ventilatory pressure support was titrated during the daytime prior to the first night of HMV according 
to the sEMGpara levels with the aim of reducing the sEMGpara  by more than 50% or until pressure 
tolerability was reached by the patient.  
Once an optimal pressure support was achieved the patient was left on ventilation for 30 minutes 
whilst PVA was assessed. Ventilator trigger settings were manipulated to minimise patient ventilator 
asynchrony using a pragmatic standardised approach to addressing common causes of PVAs (See 
appendix 2).  
Safety parameters were applied to further manipulate the ventilator settings overnight if the 
transcutaneous carbon dioxide (TcCO2) rose 2 kPa from the baseline values or the patients oxygen 
levels measured by pulse oximetry (SpO2) fell below 80% for more than 10 minutes (TOSCA 500, 
Radiometer, Crawley, West Sussex, UK).   
 
Physician led set up  
Ventilatory pressure support was titrated overnight to optimise nocturnal SpO2 and TcCO2.  
Protocolised titration was performed by nursing staff according to the patients underlying disease 
group as is standard practice in our unit.  No overnight assessment of patient ventilator 
synchronisation occurs and alterations of ventilator trigger settings are not routinely performed.  (See 
appendix 1)(79). 
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Nursing staff performed hourly observations on all patients’ overnight recording ventilator settings, 
sleep status, SpO2 and TcCO2 measurements which was presented to the physician along with the 
overnight download from the TOSCA 500 (Radiometer, Crawley, West Sussex, UK) the following 




Patients underwent baseline height and weight measurements, arterial blood gases, baseline 
spirometry (Microplus handheld spirometer, Cardinal Health, OH, USA), non-invasive respiratory 
muscle strength tests (Micromedical Ltd, Kent, UK) and sEMGpara measurements during 2 minutes 
of tidal breathing and maximal inspiratory manoeuvres (MIP and SNIP).  Duchenne muscular 
dystrophy patients, Becker muscular dystrophy and spinal muscular atrophy patients who were 
unable to stand had their height approximated by measuring their arm span with a tape measure.  
Health-related quality of life questionnaires were completed (severe respiratory insufficiency (SRI), St. 
George’s respiratory questionnaire (SGRQ), Research and Development- 36 questionnaire (RAND-
36), Epworth sleepiness score (ESS), fatigue severity scale (FSS), visual analogue scales for  energy 
levels, sleep comfort, ventilator comfort, patient-ventilator co-ordination, pressure tolerability and  a 
bespoke questionnaire examining the patients assessment of patient-ventilator asynchrony levels 
(PVIQ).   
These assessments were repeated at six weeks and again with a repeat overnight assessment on 
ventilation at 3 months.  (See trial schematic appendix 3).  
 
Nocturnal measurements 
Night 1: sEMGpara was measured whilst patients self-ventilated without supplemental oxygen.  Each 
breath during a 2 minute epoch, measured every 10 minutes, over seven hours (or as long as the 
patient slept) was analysed.  This technique was used as previously described by Steier et al. to 
assess sEMGpara nocturnally in asthmatic patients.(125)  Signals with movement artefact were 
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excluded and the closest 2 minute epoch that was artefact free was assessed.  Respiratory 
inductance plethysmography bands were applied to measure concurrent chest wall and abdominal 
excursion and nasal pressure measurements were obtained confirming inspiratory flow.  Sp02 and 
TcCO2 measurements (TOSCA 500, Radiometer, Crawley, West Sussex, UK) were used to assess 
the adequacy of nocturnal ventilation.  
Night 2: sEMGpara was measured in a similar manner on ventilation over the same time period.  PVA 
was analysed over the same 2 minute epochs, every 10 minutes over seven hours (or as long as the 
patient tolerated HMV).  To standardise the data the asynchrony are expressed as the percentage of 
breaths analysed allowing for variable HMV use overnight.  PVA were reported in accordance with 
standardised definitions described in the Methods section of the thesis. (Section 2.9/Pages 71-78). 
Respiratory inductance plethysmography bands were applied to measure concurrent chest wall and 
abdominal excursion and mask pressure measurements (Pmo) were obtained to evaluate patient 
ventilator synchronisation.  SpO2 and TcCO2 measurements (TOSCA 500, Radiometer, Crawley, 
West Sussex, UK) were again used to assess the adequacy of nocturnal ventilation.  
At 3 months post HMV therapy, sEMGpara and PVA were measured again and analysed as during 
night 2 during NIV set up. 
 
4.2.7 Analysis and statistics 
sEMGpara, respiratory inductance plethysmography and pressure data were recorded on LabChart  
v7.3 software (AD Instruments Ltd, Oxford, UK) and saved on a password protected DELL desktop 
computer (Dell Corporation Limited, Bracknell, UK).  Analysis of anonymised data was then 
performed offline on a password protected HP laptop (Hewlett-Packard Ltd, Bracknell, UK).  
 Anthropometric data, were normally distributed and are presented as mean and standard deviation.  
All other data were non-parametric and are presented as median value with the inter-quartile range.  
Statistical comparisons were performed as described in Materials and Methods Section 1.10.3. 
For all analyses, a p-value <0.05 was considered statistically significant. 
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Power Calculation 
A power calculation was not used.  Neural respiratory drive measures using sEMGpara had not 
previously been used in patient groups with chronic respiratory failure with no effect size data 
available to assess patient ventilator asynchrony levels in these patients.  We were therefore unclear 
as to what levels of reduction in either of these parameters would be clinically meaningful. We 
therefore conducted a pilot randomised controlled study to determine any differences; with the aim of 
recruiting 40 patients.  This would allow us to power any future trial. 
 
4.3 Results 
4.3.1 Recruitment  
40 patients (25 male) were enrolled in the trial.  This included 16 patients with COPD, 13 patients with 
ORRF and 11 patients with NMD-CWD.  Overall 119 patients were screened for eligibility, with a 
majority excluded because although referred for home mechanical ventilation these patients did not 
demonstrated daytime or nocturnal hypercapnia.  Twenty one patients were randomised to the 
physiological HMV set up and these comprised of 9 COPD patients, 6 ORRF patients and 6 NMD-
CWD patients.  Nineteen patients were randomised to the physician led set up including 7 COPD 
patients, 7 ORRF patients and 5 MND-CWD patients.  Six patients were lost to follow up from the trial; 
one was withdrawn immediately post the intervention due to a sudden life threatening exacerbation of 
COPD, 3  did not attend follow-up or no longer wished to attend, 1 patient died prior to the 6 week 
follow up and 1 declined to continue with HMV therapy.  In addition, 1 patient was unable to attend for 
a 3 month overnight study but otherwise remained compliant with the trial protocol and attended for a 
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4.3.2 Detailed baseline patient anthropometrics  
Table 12: Initial patient baseline characteristics: categorised by physiological and physician 
led HMV set up 
Characteristics Total cohort 
(n=40) 
Physiological  
led HMV set 
up (n=21) 
Physician 






Age (yrs) 58                 
(± 17) 
55                      
(± 17) 
60                 
(± 18) 
p=0.3 
BMI (kgm-2 ) 33.4                
(± 9.6) 
33.7                        
(± 11.0) 
33.0                 
(± 8.0) 
p=0.8 
FEV1 (%pdt) 38.4               
(± 18.5) 
38.2                 
(± 19.6) 
38.6                 
(± 17.7) 
p=0.9 
FVC (%pdt) 48.7               
(± 21.5) 
51.0                 
(± 24.4) 
46.0              
(± 18.1) 
p=0.5 
FEV1/ FVC (%) 67.3               
(± 21.7) 
65.4                 
(± 22.7) 
69.4                 
(± 21.0) 
p=0.6 
SNIP (cmH2O) 45.6              
(± 22.5) 
46.3                  
(± 23.9) 
44.7              
(± 21.5) 
p=0.8 
MIP (cmH2O) 41.3               
(± 23.6) 
45.0                  
(± 25.7) 
37.2              
(± 21.0) 
p=0.3 
MEP (cmH2O) 66.4              
(± 39.8) 
74.5                   
(± 44.6) 
58.0              
(± 33.3) 
p=0.2 
pH  7.38               
(± 0.02) 
7.38                  
(± 0.03) 
7.38              
(± 0.01) 
p=0.9 
PaO2 (kPa) 8.17               8.08                  8.27              p=0.7 
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(± 1.76) (± 2.14) (± 1.28) 
PaCO2 (kPa) 7.36               
(± 1.19) 
7.50                 
(± 1.34) 
7.22             
(± 1.00) 
p=0.5 
cHCO3 (mmol/l) 31.8               
(± 4.2) 
32.3                 
(± 4.8) 






15.5         
(9.9-25.5) 
12.9           
(10.6-26.3) 
16.9              
(8.0-25.3) 
p=0.8 
Abbreviations: yrs= years, BMI= body mass index, FEV1= forced expiratory volume in 1 second, 
FVC= forced vital capacity, SNIP= sniff nasal inspiratory pressure, MIP= maximal inspiratory 
pressure, MEP= maximal expiratory pressure, PaO2 =arterial oxygenation, PaCO2 = arterial carbon 
dioxide level, cHCO3 =corrected bicarbonate level, tidal sEMGpara%max= surface second intercostal 
parasternal electromyogram during 2 minutes of tidal breathing normalised to the maximum 
inspiratory electromyogram, HMV= home mechanical ventilation. 
 
There were no between group differences in baseline characteristics observed between physiological 
and physician led HMV set up.  In addition, there were no within group changes from baseline in lung 
function, respiratory muscle function or resting neural respiratory drive following 3 months of HMV in 
either group.   
Table 13: Patient baseline characteristics:  categorised by disease group 
 










disease groups    
(p-value) 
Age (yrs) 63                       
(± 11) 
63                        
(±16 ) 
43                      
(± 19) 
p=0.02 
 BMI (kgm-2 ) 31.4                    40.1                    26.6                    p<0.01 
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(± 8.8) (± 7.5) (± 8.4) 
FEV1 (L/s) 0.84                   
(± 0.40)  
1.48                           
(± 0.65) 
0.79                    
(± 0.28) 
p=0.001 
FVC (L) 1.85                   
(± 0.53) 
1.87                       
(± 0.83) 
0.92                   
(± 0.36) 
p<0.001 
FEV1 /FVC (%) 43.8                    
(± 10.5) 
79.4                    
(± 8.3) 
86.9                     
(± 9.2) 
p<0.0001 
SNIP (cmH2O) 54.3                   
(± 18.8) 
53.0                    
(± 18.7) 
24.2                    
(± 18.5) 
p<0.001 
MIP  (cmH2O) 51.7                    
(± 21.7) 
44.5                     
(± 22.8) 
22.4                    
(± 16.1) 
p<0.01 
MEP (cmH2O) 79.9                   
(± 36.3) 
80.9                     
(± 36.8) 
33.6                     
(± 26.0) 
p<0.01 
pH 7.38                    
(± 0.03) 
7.38                    
(± 0.03) 
7.38                    
(± 0.02) 
p=0.7 
PaO2 (kPa) 7.11                    
(± 1.17) 
8.53                    
(± 1.51) 
9.18                    
(± 2.13) 
p<0.01 
PaCO2 (kPa) 7.53                    
(± 1.00) 
7.35                    
(± 1.22) 
7.19                   
(± 1.49) 
p=0.8 
cHCO3 (mmol/l) 32.8                      
(± 3.5) 
31.0                   
(± 4.2) 





10.7               
(7.8-16.0) 
16.0                 
(10.6-19.5) 
27.3           
(16.5-39.1) 
p<0.01 
Abbreviations: yrs= years, BMI= body mass index, FEV1= forced expiratory volume in 1 second, 
FVC= forced vital capacity, SNIP= sniff nasal inspiratory pressure, MIP= maximal inspiratory 
pressure, MEP= maximal expiratory pressure, PaO2 =arterial oxygenation, PaCO2 = arterial carbon 
dioxide level, cHCO3 =corrected bicarbonate level, tidal sEMGpara%max= surface second intercostal 
parasternal electromyogram during 2 minutes of tidal breathing normalised to the maximum 
inspiratory electromyogram, COPD= chronic obstructive pulmonary disease, ORRF= obesity related 
respiratory failure, NMD-CWD= neuromuscular and chest wall disease. 
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NMD-CWD patients were significantly younger with lower FVC, inspiratory and expiratory muscle 
strength measures than the other disease groups.  The neural respiratory drive was also significantly 
higher during tidal breathing in the NMD-CWD disease group.  As expected, the COPD patients had 
significantly lower FEV1/FVC ratio as reflective of their obstructive airways disease but these were 
also the most hypoxic patient group.  The obese patient group as predicted had the largest BMI. 
No significant changes were observed in the tidal neural respiratory drive in any disease group 
considering all patients that completed the trial between the baseline level, 6 weeks and 3 months 
post HMV therapy (COPD patients (p=0.5), ORRF patients (p= 0.5), NMD-CWD patients (p=0.6)).    
 
4.3.3  Ventilator settings between the physiological HMV set up and physician led HMV set up  
Table 14: HMV ventilator settings post set up at hospital discharge: categorised by 




HMV       set up 
(n=21) 
Physician led HMV 
set up (n=19) 
Statistical 
difference  between 
treatment groups    
(p-value) 
IPAP (cmH2O) 24                            
(22-26) 
24                            
(20-28) 
p=0.9 
EPAP (cmH2O)  8                                  
(4-10) 
8                                  
(3-10) 
p=0.5 
Ti (s) 1.2                                  
(1.0-1.2) 
1.2                                 
(1.0-1.2) 
p=1.0 
BUR (breath/min) 14                                      
(12-14) 
14                                      
(14-16) 
p=0.1 
Trig insp 3                                           
(2-4) 
4                                        
(4-4) 
p=0.02
Trig exp 4                                 
(3-5) 
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Patient triggered 
breaths (%) 
39.1                          
(16.7-65.4) 






43.7                     
(23.8-71.0) 
33.1                    
(22.0-58.9) 
p=0.3 
Abbreviations: IPAP= inspiratory positive airways pressure, EPAP= expiratory positive airways 
pressure, Ti= inspiratory time, BUR= back up rate, Triginsp= inspiratory trigger, Trigexp= expiratory 
trigger, cmH2O= centimetres of water, s = seconds, HMV= home mechanical ventilation. 
 
The only statistically significant difference between the ventilator settings in the physician led HMV set 
up and the physiological led set up was a lower inspiratory trigger in the physiological led set up.  
Despite this, no statistically significant difference in the percentage of patient triggered breaths was 
observed.  




COPD patients ORRF patients NMD-CWD 




disease groups    
(p-value) 
IPAP (cmH2O) 19.0            
(18.0-25.8) 
20.0            
(18.0-24.5) 
20.0            
(16.0-24.0) 
p=0.7 
EPAP (cmH2O)  7.0                          
(4.0-8.0) 
8.0                         
(6.0-9.0) 
3.0                  
(3.0-6.0) 
p=0.04 
Ti (s) 1.1                       
(1.0-1.2) 
1.2                 
(1.2-1.3) 





14.0             
(10.5-15.5) 
14.0                    
(14.0-14.0) 
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Trig insp 4.0                  
(3.0-4.0) 
4.0                    
(3.0-4.0) 
4.0                        
(2.0-4.0) 
p=0.9 
Trig exp 4.0                 
(4.0-4.8) 
4.0                       
(4.0-4.8) 






47.6                   
(32.4- 74.8) 
48.9                 
(29.3-62.6) 







28.2                    
(13.3-52.5) 
33.1                 
(22.6-52.6) 
67.9                 
(41.4-81.7) 
p<0.01 
Abbreviations: IPAP= inspiratory positive airways pressure, EPAP= expiratory positive airways 
pressure, Ti= inspiratory time, BUR= back up rate, Triginsp= inspiratory trigger, Trigexp= expiratory 
trigger, cmH2O= centimetres of water, s = seconds, COPD = chronic obstructive pulmonary disease, 
ORRF= obesity related respiratory failure, NMD-CWD= neuromuscular and chest wall disease.  
 
As expected, the levels of EPAP were significantly lower in the NMD-CWD group.  The inspiratory 
time was significantly lower in the COPD patient group as is common practice to facilitate lung 
emptying.  Patients with neuromuscular disease were significantly more likely to receive a higher 
percentage of non-triggered breaths and a lower percentage of triggered breaths at initiation of 
ventilation.  
 
4.3.4 Prevalence of patient-ventilator asynchrony 
 
No significant difference was observed in the frequency of PVA between the physician led set up and 
the physiological led set up of HMV at initiation or 3 months (28.4 (17.4-37.6)% vs 25.6 (14.0-30.4)%; 
p=0.6 and 22.4 (13.3-37.1)% vs 23.3 (15.2-41.5)% p=0.7, respectively).  
Overall, PVA affected 25.6 (16.4-35.7)% breaths at initiation of HMV, with ineffective efforts as the 
predominant type of PVA accounting for 10.9 (4.6-23.7)% of breaths. Of clinical importance, there 
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was no improvement observed in PVA 3 months post HMV therapy with 22.8 (14.6-37.1)% affected 
(p=0.6).  (Figure 40). 
 
 
Figure 38: Prevalence of patient ventilator asynchrony during a) the initiation of HMV and b) 







































































































































































































































No significant difference was observed in the total amounts of asynchrony between the patient 
disease groups on the first night of HMV and 3 months post HMV therapy (First night: COPD 28.2 
(20.6-41.5)%, ORRF 26.7 (12.3-37.6)%, NMD-CWD 18.7 (11.4-21.5)%; p=0.06, 3 months: COPD 
30.6 (14.7- 44.5)%, ORRF 23.7 (19.6-44.5)%, NMD-CWD 17.6 (11.3-27.9)%; p=0.3).   
COPD patients had higher proportions of delayed cycling than NMD-CWD patients on the first night of 
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Figure 39: Prevalence of patient ventilator asynchrony at initiation of HMV and 3 months post 
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4.3.5 Primary outcome: Adherence to HMV therapy at 3 months  
There was no significant difference observed in the mean daily adherence to non-invasive ventilation 
between the physiological led HMV set up group and the physician led HMV set up group at 3 
months.  (Table 16). 
Table 16: Comparison between adherence to HMV in the physiological sEMGpara led set up of 
HMV and the physician led set up of HMV  
Assessment period Physiological led HMV 
set up                   
(n=19- 6 weeks,       
n=17 -3 months) 
Physician led HMV 
set up                
(n=16 -6 weeks,   




groups    (p-value) 
6 week  3hr40                      
(1hr43-6h38) 
5hr26                 
(1hr48-7hr31) 
p=0.48 
3 month  4hr27                       
(2hr15-7hr02) 
6hr34                           
(1hr57-7hr24) 
p=0.39 
  Daily adherence 
over 3 months 
4hr01                      
(3hr03-7hr00) 
5h50                   
(1h42-7hr31) 
p=0.86 
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Overall, the daily adherence to HMV therapy was satisfactory at 5hrs 58 minutes (2hrs 02 minutes-
7hrs 09 minutes) at 3 months.  There was a significant improvement in adherence at 3 months 
compared to the 6 week adherence of 5hrs 00 minutes (2hrs 02 minutes-7hrs 03 minutes) in the 
whole cohort (p=0.02).   
No significant difference was observed in the adherence to HMV at 3 months between the different 
disease groups (p=0.4).   COPD patients had the lowest mean daily adherence to HMV at 4hrs 
52minutes (1hrs 09minutes -6hrs 59minutes) and ORRF patients the highest mean daily adherence 
with 6hrs 31minutes (3hrs 46 minutes-8hrs 02 minutes).  
There was no relationship observed between the amount of asynchrony at 3 months and patient 
mean daily adherence to HMV at 3 months. (Figure 42). Furthermore, there was no relationship 
observed between the change in asynchrony levels over the 3 months of HMV therapy and the mean 
daily adherence at the 3 months assessment. (Figure 43).  
 
Figure 40: Relationship between patient ventilator asynchronous breaths at 3 months and 
average daily adherence to HMV at 3 months (n=32) 
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Figure 41: Relationship between the change in patient ventilator asynchronous breaths and 
the average daily adherence to HMV at 3 months (n=32) 

































4.3.6 Secondary outcome: Gas exchange at 3 months  
There was no significant difference between the improvements in gas exchange in the physiological 
set up and the physician led set up of HMV following 3 months of HMV therapy. (Table 17).   
Considering the total cohort that completed the trial, daytime gas exchange significantly improved 
following 3 months of HMV therapy as measured by arterial blood gases. Oxygenation increased from 
8.3kPa (6.5-9.2) at baseline to 8.4kPa (7.5-9.6); p<0.01. Hypercapnia significantly reduced from 
7.1kPa (6.4-8.1) to 6.5 (6.0-7.1); p<0.0001.  
Nocturnal gas exchange also significantly improved over the whole group completing the trial 
following 3 months of HMV therapy.  Mean overnight oxygen saturations (SpO2) improved from 90% 
(82-94) to 94% (92-97%); p<0.0001. Mean overnight transcutaneous carbon dioxide (TcCO2) 
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Table 17: Change in gas exchange between the physiological sEMGpara led set up and the 
physician led set up of HMV during 3 months of therapy. 
Gas exchange 
parameters  
Physiological led HMV 
set up                    
(n=17- ABG data,      
n=16 -nocturnal data)  
Physician led 
HMV set up  
(n=17) 
Statistical 
difference  between 
treatment groups    
(p-value) 
Δ  PaO2 (kPa) 0.92                               
(-0.14 - 1.23)  
0.33                         
(-0.20- 1.20) 
p=0.72 
Δ  PaCO2 (kPa) -0.65                              
(-1.24 - -0.20) 
-0.34                         
(-0.92- -0.08) 
p=0.45 
Δ Nocturnal mean 
SpO2 (%) 
2.8                                 
(-0.4-11.7) 
4.7                           
(0.9-10.0) 
p=0.73 
Δ Nocturnal mean 
TcCO2 (kPa) 
-0.9                                
(-1.4- -0.5) 
-1.08                              
(-2.13- -0.53) 
p=0.64 
Abbreviations: ABG-arterial blood gas, ΔPaO2-change in arterial oxygen levels following 3 months of 
home mechanical ventilation therapy, ΔPaCO2- change in arterial carbon dioxide levels following 3 
months of home mechanical ventilation therapy, Δ nocturnal mean SpO2-change in the mean 
overnight oxygen saturation levels following 3 months of home mechanical ventilation therapy. Δ 
nocturnal mean TcCO2-change in the mean overnight transcutaneous carbon dioxide levels following 
3 months of home mechanical ventilation therapy, kPa- kilopascals. 
 
There was no significant difference in the improvements observed in gas exchange between the 
different disease groups. 
There was no relationship observed between the changes in gas exchange and the change in levels 
of PVA following 3 months of HMV therapy. (Figures 44 and 45).  No relationship was observed 
between the proportion of the night spent with SpO2 less than 90% or TcCO2 levels above 7kPa and 
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Figure 42: Relationship between the changes in daytime arterial oxygenation and the changes 
in patient ventilator asynchrony with 3 months of HMV 
 













Figure 43: Relationship between the changes in daytime arterial carbon dioxide and the 
changes in patient ventilator asynchrony with 3 months of HMV 
 














Abbreviations: ΔPaO2-change in arterial oxygen levels following 3 months of home mechanical 
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Figure 44: The relationship between patient ventilator asynchrony and nocturnal oxygen 
saturations at a) initiation and b) 3 months post HMV therapy 

























































Abbreviations: SpO2-oxygen saturations. 
 
Figure 45: The relationship between patient ventilator asynchrony and nocturnal 
transcutaneous carbon dioxide levels at a) initiation and b) 3 months post HMV therapy 
a)                                                                             b)  


























Median percent of night with TcC02 >7kPa                                                                                                               
77(1-98)% 
Abbreviations: TcCO2-transcutaneous carbon dioxide levels, kPa-kilopascals 
 
No statistically significant relationship was observed between ineffective efforts and the percentage of 
time overnight spent with oxygen saturations below 90% at 3 months of HMV therapy (rs=0.18, 
p=0.33).  A weak relationship was observed at initiation of HMV (rs=0.33, p=0.04).  No association 
Median percent of night with SpO2 <90%     
8 (1-47)% 
 
Median percent of night with TcC02 >7kPa
13 (0-80)% 
 
Median percent of night with SpO2 <90%     
5 (1-21)% 
 
rs = 0.04, p=0.85 
rs = 0.15, p=0.41 
rs = 0.14, p=0.40 
rs = 0.04, p=0.79 
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was observed between gas exchange and any other type of PVA.  These findings are in keeping with 
those previously published by our group in a similar cohort of patients. (79) 
 
4.3.7 Secondary outcome: Changes in respiratory muscle loading measured by 
sEMGpara%max at 3 months  
Patients in the physician led set up group had higher levels of neural respiratory drive than the 
physiological led set up group during tidal breathing awake in the daytime; p=0.02.    Neural 
respiratory drive was significantly reduced in both groups following NIV therapy and this was 
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Table 18: Changes in neural respiratory drive between the physiological led HMV set up group 




HMV set up 
(n=21 Initial tidal, 
self-ventilating, first 
night HMV, n=16 3 
months post HMV 
and change over 3 
months HMV) 
Physician led HMV set 
up 
(n=19 Initial tidal, self-
ventilating, first night 
HMV, n=17 3 months 
post HMV and change 





9.2                               
(5.0-14.1) 







16.6                                
(9.7-23.1) 
12.9                                  
(10.6-18.6) 
p=0.8 





7.6                                 
(4.0-13.1) 
10.1                                 
(6.9-16.1) 
p=0.3 





8.0                                
(5.1-11.1) 








ventilation and 3 
months HMV 
therapy (%) 
-8.6                                     
(-16.1 to -2.9) 
-5.6                                      
(-12.0 to -2.5) 
p=0.7 
Abbreviations: HMV-home mechanical ventilation, sEMGpara%max-surface second intercostal 
parasternal electromyogram normalised to a maximal inspiratory manoeuvre, 
 
The first night of HMV demonstrated greater respiratory muscle unloading in the physiological led set 
up compared to the physician led set up that approached significance (median reduction in 
sEMGpara%max of -4.7 (-8.8 to -0.7)% in the physiological led set up vs. -1.7 (-3.2 to -0.1)% in the 
physician led set up; p=0.06).  However, at 3 months, there were no between group difference in 
respiratory unloading (median reduction in sEMGpara%max of -5.6 (-12.0 to-2.5)% in the 
physiological led set up compared to -8.6 (-16.1 to -2.9)% in the physician led set up; p=0.7). 
Importantly, both HMV set up methods over 3 months achieved significant unloading of the respiratory 
muscles and reduction in neural respiratory drive overnight between self-ventilating and 3 months of 
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Figure 46: Changes in neural respiratory drive as measured by sEMGpara%max between the 







































Abbreviations: sEMGpara%max-surface parasternal electromyogram normalised to a maximal 
inspiratory manoeuvre. 
 
Although there was no between group difference at baseline and 3 months of HMV treatment, the 
total cohort demonstrated nocturnal respiratory muscle loading and a reduction in neural respiratory 
drive following 3 months of HMV.  Mean nocturnal neural respiratory drive reduced from 13.2% (10.3-
22.1) during self-ventilation to 7.8% (4.8-13.8) 3 months post HMV (p-value <0.0001).   
 
This observation held when data was analysed by disease group.  The COPD and ORRF group 
achieved significant respiratory muscle unloading on the first night of HMV therapy (p=0.01 and 
p<0.001, respectively). The NMD-CWD group achieved significant muscle unloading by 3 months only 
(p<0.01).  
There was no association observed between respiratory muscle unloading and patient ventilator 
asynchrony during the first night of HMV therapy (rs=0.14, p=0.4) or 3 months post HMV therapy 
(rs=0.24, p=0.2).  No significant relationship was observed between the changes in respiratory muscle 
loading and the changes in patient ventilator asynchrony levels following 3 months of HMV therapy.  
(Figure 49).  




a) Physician led HMV set up 
 
 












p<0.01 p=0.31 p<0.01 p=0.46
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There was no association between the incidence of ineffective efforts and neural respiratory drive at 
initiation of HMV or at 3 months post treatment (rs=0.17, p=0.3 and rs=0.16, p=0.4). 
 
Figure 47: Relationship between the change in respiratory muscle unloading and patient 






























Abbreviations: ΔsEMGpara%max-change in surface parasternal electromyogram normalised to a 
maximal inspiratory manoeuvre over 3 months of home mechanical ventilation therapy, Δ 






4.3.8  Secondary outcome: Health related quality of life measures   
There were no differences in health related quality of life outcomes observed between the 
physiological set up of HMV group and the physician led set up of HMV group following 3 months of 





rs=0.06, p= 0.76 
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Table 19: Change in health related quality of life following 3 months of HMV therapy: 
comparison of physiological HMV set up and physician led HMV set up 
 
Health related 
quality of life score 
(total) 
Physiological HMV 
set up (n=17) 
Physician led HMV 
set up (n=17) 
           p-value 
SRI (/100) 8.7                         
(4.8-24.4) 
11.3                             
(-2.9-18.2) 
p=0.6 
SGRQ (/100) -3.7                              
(-8.9-5.7) 
-4.6                              
(-15.3-6.2) 
p=0.7 
RAND-36 175                              
(-8-410) 
85                                
(-13-258) 
p=0.5 
HAD (/24) -1.0                               
(-6.5-2.5) 
-1.0                              
(-5.0- -0.5) 
p=0.7 
ESS (/24) -2.0                              
(-8.0-1.5) 
-4.0                               
(-12.0- -0.5) 
p=0.8 
FSS (/70) -2.0                              
(-16.0-6.5) 
-7.0                               
(-12.0-2.0) 
p=0.8 
Abbreviations: SRI=severe respiratory insufficiency questionnaire, SGRQ= St. George’s respiratory 
questionnaire, RAND-36= research and development short form 36 questionnaire, HAD= hospital 
anxiety and depression scale, ESS= Epworth sleepiness scale, FSS= fatigue severity scale, HMV= 
home mechanical ventilation.  
 
There was no difference between physiological HMV set up and physician led HMV set up in patient 
perception of HMV scores or the patient assessment of patient ventilator asynchrony levels post 3 
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Table 20: Change visual analogue scales and patient perception of patient ventilator 
asynchrony questionnaire following 3 months of HMV therapy: comparison of physiological 





set up (n=17) 
Physician led HMV 
set up (n=17) 
Statistical 
significance             
(p-value) 
Energy level VAS 
(/100) 
4.0                                
(-5.5-22.0) 
9.0                        
(0.0-36.5) 
p=0.4 
Sleep comfort VAS 
(/100) 
6.0                         
(1.5-36.0) 





-1.0                             
(-13.5-9.5) 




HMV  VAS(/100) 
-6.0                              
(-22.0-6.5) 
10.0                             
(-27.0-23.5) 
p=0.2 
Pressure tolerability      
VAS (/100) 
-3.0                              
(-12.5-4.0) 






0.0                                
(-9.0-4.5) 
0.0                              
(-6.0-4.5) 
p=0.6 
Abbreviations: VAS= visual analogue scale, PVA= patient ventilator asynchrony, HMV= home 
mechanical ventilation, HRQL = health related quality of life. 
 
 
4.3.8.1 Tolerability of HMV set up 
All patients were naïve to HMV.  At initiation, the patient perception of co-ordination with the ventilator 
was greater in the physiological HMV set up group compared to the physician led HMV set up group 
(81.5 (72.8-91.5) vs 63.0 (56.0-78.0); p<0.01).  All other assessments of ventilator comfort, tolerability 
of pressures and awareness of PVA levels were not significantly different.  There were no differences 
observed between patient disease groups considering initial perception of HMV set following the first 
night of therapy except in the perception of pressure tolerability.  COPD patients reported the 
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4.3.8.2 Changes in health related quality of life measures in the total cohort completing the trial 
Overall, a significant improvement was observed in health related quality of life scores using the SRI, 
the RAND-36, the ESS and the HAD following 3 months of HMV therapy.  Using these health related 
quality of life measures, an improvement in HRQL was apparent from 6 weeks post HMV therapy with 
no further significant increase at 3 months.  No significant improvements were observed using the 
SGRQ or the FSS, although the latter approached significance at 3 months (p=0.06). (Table 21). 
 







Initiation of  

















initiation and 3 
months   (n=34) 
SRI (/100) 54.9      
(44.2-62.8) 
65.2 *     
(42.3-78.2) 
64.8 *     
(54.3-74.2) 





59.4      
(34.9-72.9) 
52.9      
(39.5-70.9) 
52.4      
(36.0-65.6) 





1193      
(1005-1724) 
1490*     
(1055-1955) 
1473*    
(1064-2006) 
145                 
(-11.3-361.3) 
p=0.003* 
HAD (/24) 12.0        
(7.3-18.0) 
10.0*        
(7.0-19.0) 
9.0*          
(4.0-14.3) 
-1.0                 
(-6.0-2.0) 
p=0.01* 
ESS (/24) 10.5        
(6.3-15.0) 
7.0*          
(3.0-12.0) 
7.0*          
(3.0-11.5) 
-3.0                 
(-6.0-1.0) 
p=0.007* 
FSS (/63) 51.0      
(34.5-59.0) 
43.0        
(26.0-52.0) 
42.5      
(30.0-50.8) 
-5.5                 
(-13.0-6.0) 
p=0.06 
*indicates a significant statistical change from baseline HRQL measures, p-value for 3 month changes 
only is shown. 
Abbreviations: SRI=severe respiratory insufficiency questionnaire, SGRQ= St. George’s respiratory 
questionnaire, RAND-36= research and development short form 36 questionnaire, HAD= hospital 
anxiety and depression scale, ESS= Epworth sleepiness scale, FSS= fatigue severity scale.    
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Statistically significant improvements in patients’ perception of energy levels and sleep comfort were 
observed following 3 months of HMV in the total cohort of patients receiving HMV therapy.  (See 
Table 22).  No significant improvements were observed in patients’ perception of ventilator comfort, 
co-ordination of their breathing with the ventilator or asynchrony levels following 3 months of HMV.  
Furthermore, patients noticed a reduction in the tolerability of ventilator pressures over the 3 months 
which approached significance (p=0.06).  








follow up          
(n=35) 
3 month 

















32.0         
(23.3-53.8) 
45.0    
(27.0-59.0) 
52.5*       
(33.0-69.3) 






44.5         
(23.5-64.0) 
62.0*     
(51.0-77.0) 
69.0*      
(50.0-79.3) 






64.5        
(42.0-88.0) 
74.0   
(42.0-82.0) 
73.0       
(45.5-84.3) 




with HMV         
VAS (/100) 
76.5         
(58.0-86.0) 
77.0    
(56.0-84.0) 
71.5       
(52.5-88.0) 




tolerability      
VAS (/100) 
86.5         
(83.0-96.8) 
77.0    
(56.0-84.0) 
81.5      
(63.3-88.3) 








40.0         
(37.3-43.8) 
40.0   
(35.0-43.0) 
40.5      
(33.3-45.0) 
0.0                    
(-6.3-4.3) 
p=0.57 
*indicates a significant statistical change from baseline HRQL measures, p-value for 3 month changes 
only is shown. 
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Abbreviations: VAS= visual analogue scale, PVA= patient ventilator asynchrony, HMV= home 
mechanical ventilation, HRQL = health related quality of life. 
 
4.3.8.3 Heath related quality of life measures comparing the different disease groups receiving 
HMV therapy 
No significant differences were observed in the HRQL outcome measures using the generic HRQL 
questionnaires between the different disease groups following 3 months of HMV. (Table 23). 
Table 23: Changes in HRQL measures comparing the different disease groups post 3 months 
of HMV 
Health related 










SRI (/100) 11.9               
(5.0-20.5) 
8.9                      
(-3.5-18.1) 
10.2                    
(-1.9-16.4) 
p=0.6 
SGRQ (/100) -3.7                     
(-12.6-1.7) 
-8.8                     
(-18.2- -1.9) 





40                       
(-15-408) 
145                 
(39-305) 
275                  
(30-385) 
p=0.9 
HAD (/24) -4.0                      
(-9.0-2.0) 
-1.0                     
(-4.5-2.0) 
-2.0                     
(-3.0-0.0) 
p=0.6 
ESS (/24) -2.5                      
(-5.5-1.8) 
-5.0                      
(-9.3- -1.0) 
0.0                      
(-4.0-2.0) 
p=0.2 
FSS (/63) -11.0                   
(-15.0- -3.0) 
-4.0                      
(-10.0-6.0) 
5.0                      
(-12.0-10.0) 
p=0.2 
Abbreviations: SRI=severe respiratory insufficiency questionnaire, SGRQ= St. George’s respiratory 
questionnaire, RAND-36= research and development short form 36 questionnaire, HAD= hospital 
anxiety and depression scale, ESS= Epworth sleepiness scale, FSS= fatigue severity scale, COPD= 
chronic obstructive pulmonary disease, ORRF= obesity related respiratory failure, NMD-CWD= 
neuromuscular or chest wall disease.   
 
There was no difference between patient disease groups in perception of HMV measured through 
VAS scores and the patient ventilator asynchrony questionnaire (PVIQ). 
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4.3.8.4 Relationship between patient ventilator asynchrony levels and health related quality of 
life measures with HMV therapy 
 
There was no correlation between PVA and HRQL questionnaires scores observed at initiation of 
HMV or 3 months post HMV therapy.  No significant correlations were observed with the changes in 
HRQL measures using total SRI scores, RAND-36, HAD, ESS, FSS and changes in patient ventilator 
asynchrony levels. A weak correlation was observed with the changes in SGRQ scores and the 
amount of patient ventilator asynchrony (rs= -0.42, p=0.02).  (Figure 50).  A correlation was also 
observed in changes of anxiety domain of the SRI questionnaire and the amount of patient ventilator 
asynchrony (rs=-0.50, p=<0.01).  (Figure 51).  This association did not remain using the changes in 
the anxiety domain of the HAD and the changes in PVA (rs=0.31, p=0.08). 
Figure 48: The relationship between changes in the SGRQ scores and changes in patient 
ventilator asynchrony levels following 3 months of HMV therapy 
 


















Abbreviations: ΔSGRQ score- change in St. George’s respiratory questionnaire score following 3 
months of home mechanical ventilation therapy, Δ asynchronous breaths- change in asynchronous 









rs= -0.42, p=0.02 
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Figure 49: The relationship between changes in the anxiety domain of the SRI questionnaire 







































Abbreviations: Δ SRI anxiety domain score- change in the severe respiratory insufficiency 
questionnaire (anxiety domain) with 3 months of home mechanical ventilation, Δ asynchronous 
breaths- change in asynchronous breaths with 3 months of home mechanical ventilation therapy.  
 
The proportion of PVA at both initiation and 3 months post treatment did not correlate with patient 
reported synchronisation to the ventilator using a VAS scale (rs= -0.01,p=0.9 and rs=0.03, p=0.9). 64% 
of patients were unable to correctly identify the dominant asynchrony occurring overnight when 
questioned the following morning.  
4.3.9   Nocturnal ventilator titration to set up HMV 
 
The number of ventilator parameter manipulations required by nursing staff and physicians prior to 
initial discharge was significantly greater in the physician led HMV set up group then the physiological 
led set up, p<0.001. (Table 24).  The majority of alterations to the ventilator required in the 
physiological group at baseline (60.6%) were to increase the EPAP levels to control of upper airway 
obstruction.  The majority of manipulations required in the physician led group were to titrate pressure 
support and increase the levels of IPAP (70%).  
 
 
rs= -0.5, p<0.01 
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Table 24: Comparison of the number of ventilator alterations:  comparison of the physician led 
HMV set up and the physiological led set up of HMV over the 3 months of HMV therapy 
 
Observation period Physiological HMV 
set up (n=17) 
Physician led HMV 
set up (n=17) 
          p-value 
First night of HMV 1.0                           
(0.0-3.5) 
6.0                               
(3.0-12.0) 
p<0.001 
Post first night to 3 
months of HMV 
0.0                                  
(0.0-3.0) 





3 months HMV  
0.0                                   
(0.0-3.3) 
4.0                                     
(0.5-9.5) 
p<0.001 
Abbreviations: HMV-home mechanical ventilation. 
 
4.3.10  HMV set up length of hospital stay 
 
Hospital length of stay was reduced by one day in the physiological set up HMV group compared to 
the physician led set up of HMV (Table 25). 
 
Table 25: Comparison of the length of hospital stay for initiation of HMV between the physician 
led HMV set up and the physiological set up of HMV 
 
 Physiological HMV 
set up (n=17) 
Physician led HMV 
set up (n=17) 
p-value 
Length of stay for 
HMV initiation 
(days) 
2                                              
(2-2) 
3                             
(2-3) 
p=0.04 
Abbreviations: HMV- home mechanical ventilation. 
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4.4 Discussion 
4.4.1 Main findings 
Clinical 
This is the first pilot randomised trial to investigate the clinical effectiveness of physiological HMV set 
up, targeting neural respiratory drive, compared with standard physician led HMV set up.  Although 
there was no between group difference in the primary outcome of daily ventilator adherence, there 
was shorter length of hospital admission for HMV set up as well as less requirement for ventilator 
setting alterations in the physiological set up group.  In addition, all the patients tolerated physiological 
targeted set up of HMV.  As there was no difference in ventilator adherence between the groups, it is 
not surprising that there were no differences observed in gas exchange and respiratory muscle 
unloading at 3 months between the intervention and control group. 
Physiological 
The data from this trial have shown a high prevalence patient-ventilator asynchrony during the 
initiation of HMV.  Indeed, these data have demonstrated that almost a quarter of all breaths are 
asynchronous during set up of HMV.  More importantly, these data have shown that there was no 
attenuation in the amount of PVA following 3 months of HMV therapy.  Similarly to Carlucci et al, we 
have demonstrated that the proportion of PVA during HMV was not associated with a particular 
underlying specific disease group.(146)  Furthermore, there was no association observed between 
the proportion of PVA during HMV and ventilator adherence, gas exchange, respiratory muscle 
unloading or patient perception of patient ventilator co-ordination. 
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4.4.2  Critique of the Method 
Due to practical constraints of a single clinical researcher (MR) conducting this RCT and performing 
the analysis, the scoring of the PVA could not be performed blinded to the intervention.  Although 
every effort was made to ensure accurate reporting of the PVA consistent with the pre-defined 
definitions, there may be unintentional bias.  However, when testing the reliability of the scoring 
method, adequate inter-observer agreement was achieved on traces reported in this study with a 
second scorer (SM) who was blinded to the intervention (Methods 2.10). 
Measuring sEMGpara overnight is prone to signal disturbance during periods of patient movement 
introducing artefact.  Severe episodes of PVA may result in patient arousal from sleep which often 
manifest in movement of the patient.(70)  It is therefore possible that the proportions of PVA in this 
study are under-represented as these periods of severe asynchrony and patient movement were 
excluded from the analysis. 
Although every effort was made to balance the groups in terms of disease group, age and body 
composition using standard minimisation techniques at randomisation, differences in neural 
respiratory drive were observed in the patients during self-ventilating trials both during the daytime 
and overnight.  Indeed, these differences may represent different phenotypical characteristics 
between patients from within a similar disease group in terms of the respiratory load and capacity 
balance of the respiratory system.  Those patients with higher neural drive overnight may have more 
severe sleep disordered breathing, whereas those with lower neural drive may have spent more of the 
night awake.  As polysomnography was not used for all patients, we are not able to comment on this 
fully. 
Despite the intention of improving PVA using a novel physiological biomarker of inspiratory effort 
(sEMGpara) to maximally unload the respiratory muscles, we were unable to demonstrate a reduction 
in PVA in the interventional arm.  Currently, there is no definitive method known to enhance 
asynchrony and correction methods are likely to vary between disease groups and with the changing 
upper airway resistance observed between wake and sleep.  We have adopted a pragmatic clinical 
approach to addressing PVA (See appendix 2 for sEMGpara set up protocol), which has major 
limitations in that the current manually titrated modification of the ventilator settings lacks a much 
needed dynamic approach, albeit there are more advanced automated ventilator technologies being 
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developed that could be expected control for PVA.  As ventilatory support impacts on pulmonary 
mechanics and the pattern of breathing, PVA is a dynamic phenomenon that will change over time 
and hence there is a requirement to provide a technology that can both monitor PVA and well as 
modify the ventilator settings to reduce asynchrony.  This is further likely to be affected by different 
sleep stages.  Rapid eye movement sleep has been shown to be associated with reduced neural 
respiratory drive, which would be expected to reduce asynchrony as the mandatory pressure 
controlled ventilation becomes more prominent (147).  The main target of using sEMGpara was to 
maximise respiratory muscle unloading and optimise ventilator set up as evidenced by a reduction in 
sEMGpara%max.  However, reducing neural respiratory drive with increased levels of pressure 
support may have adverse impacts on the amount of asynchrony, in particular, ineffective efforts. (77, 
148)  Despite this, the proportion of ineffective efforts during the first night of HMV was actually lower 
in the physiological led set up group compared with the physician led group (7.0 (3.6-22.3)% vs. 14.1 
(8.1-24.1)%). 
PVA may also be related to the operating characteristics of the home mechanical ventilator (NIPPY 
3+, B&D Electromedical, Stratford-upon-Avon, UK) used in this study.  Despite optimising the 
ventilator triggering sensitivity during HMV set up, as shown by the greater trigger sensitivity in the 
physiological set up group, the proportion of PVA and type of PVA was similar in each group.  The 
NIPPY 3+ has an inspiratory and expiratory flow trigger with a sensitivity scale of 0-10, with 10 being 
the most difficult.  This scale is non-linear and information is not provided to the operator as to how 
each trigger setting alters the flow triggering threshold.  The NIPPY 3+ also delivers positive pressure 
by a turbine and so despite the most sensitive trigger setting there is maybe an intrinsic delay 
between the detection of inspiratory flow and the blower output to deliver ventilator support impacting 
on delayed inspiratory triggering and ineffective efforts.  Flow cycle triggering into expiration can also 
adversely impact on the interaction between the patient and the ventilator.  Particularly in obstructive 
airways disease when flow rates may reach a lower peak value and decrease slowly following 
inspiration.(13)  An extended inspiratory time in COPD may result in breath stacking, hyperinflation 
and further increase difficulties in triggering the ventilator.(13)  Furthermore, flow expiratory triggers 
have been associated with more PVA than a time cycled mode of switching to expiration.(13)  This 
study may therefore have been limited by the operating characteristics of the ventilator.   As only one 
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type of home mechanical ventilator was used to provide assisted ventilation in this study.  The 
proportion of PVA identified in this study may not apply to other ventilators.  
 
In this study, as with many clinical studies, we were not able to measure and quantify the level of 
mask leak that would have contributed to PVA, in particular cycling PVA.  The NIPPY3+ (B&D 
Electromedical, Stratford-upon-Avon, UK) similar to other home mechanical ventilators does not 
provide accurate leak measurement as recently shown by Contal et al.(149)  Despite our best efforts 
to minimise leak with time spent carefully fitting the mask interface, it is wholly possible that mask leak 
would have increased the proportion of PVA observed despite optimal setting of the ventilator.   
 
Lastly, the physiological optimisation of the ventilator settings was undertaken in the awake state but 
HMV is used during sleep.  The titration of the ventilator settings may therefore have underestimated 
the pressures required to optimise purely sleep associated phenomenon such as upper airways 
obstruction.  Where further titration was required in the physiological set up group this was to enhance 
EPAP settings to alleviate this. From our experience, a better estimate of the EPAP required based 
on baseline investigations during sleep could be employed for future studies using this technique.  
 
Methods of assessment 
The effectiveness of the ventilator setting was assessed by the physician in charge of the patient’s 
care having reviewed the patient’s clinical history, examination and investigations, including the 
nocturnal oximetry and capnography measurements.  The current gold standard assessment of 
ventilator titration includes extended polysomnography to assess sleep quality and confirm sleep 
staging.  However, this is not routine practice in the UK.  As the primary goal of HMV is to manage 
chronic respiratory failure, previous studies have shown that overnight monitoring of SpO2 and TcCO2 
are a clinical useful method to titrate HMV.(150, 151)  
Throughout the overnight studies, the measurement of flow, and therefore mask leak, was not 
possible for two main reasons. Firstly, as the pneumotachograph is heated and thus it cannot be left 
unattended and continuous observation overnight by the research team at the bedside was of 
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concern as this would impact on sleep quality.  Secondly, the Hans-Rudolph pneumotachograph we 
have previously used in our studies, needs to be supported overnight as the weight pulls on the mask 
interface resulting in unintentional leak.  It was impossible to support the pneumotachograph at the 
mask and allow the patient to move freely in the bed overnight plus have adequate sleep quality.  
Spontaneous breathing was measured by nasal cannula and ventilator delivered pressure was 
measured at the mask.  The measurement of inspiratory pressure change at the nasal cannula has 
been validated against face mask pneumotachography.(152)  
 
Patient ventilator asynchrony 
In this trial, we were not able to significantly reduce PVA overnight using a novel physiological 
approach that was targeted to maximise respiratory muscle unloading and optimise the ventilator 
settings.  As discussed above, this supports the concept that PVA is a dynamic process that requires 
continuous monitoring and adjustment of the ventilator settings to adapt to changes in pulmonary 
mechanics and sleep stage.  A previous observational study that employed physiological set up of the 
ventilator during wakefulness did not reduce PVA during sleep, although some improvement in 
ineffective efforts overnight was achieved by a physiological titration of EPAP.(75)  
Many of the previous studies have investigated the prevalence of PVA in an acute setting in patients 
receiving invasive ventilation.  Few studies, prior to the current study, have focussed on those in 
chronic respiratory failure requiring HMV.  Furthermore, there are even fewer studies that have 
considered all types of PVA (cycling and triggering) as part of extended overnight monitoring. (77, 89, 
93)  Thille et al. reported that 24% of invasively ventilated patients exhibited severe levels of 
asynchrony (>10% of all ventilator breaths delivered) when commencing assisted ventilation.(77)  
Vignaux et al. demonstrated that 43% of patients on non-invasive ventilation for acute respiratory 
failure had severe PVA.(89)   In contrast, Carteaux et al. reported that few patients had severe PVA 
on HMV  whereas Carlucci et al. observed 30% patient on HMV had severe PVA.(80)  In this trial, we 
observed that severe PVA affected 88% of the patients at initiation of HMV and 94% of patients 
following 3 months of HMV, using the standard 10% asynchrony index cut off.  The higher prevalence 
in the current study may be related to the longer observation period as all of these previous studies 
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investigated patient-ventilator interaction over a maximum of 30 minutes and it is unclear if this 
included any periods of sleep.   
The current cut off level of severe asynchrony was based on work by Vitacca et al. that investigated 
ineffective efforts only over a minute under different levels of pressure support in patients weaning 
from invasive ventilation.  This therefore has limited usefulness in the HMV group receiving a fixed 
level of pressure support overnight.   Furthermore, ineffective efforts were measured by the 
assessment of the ventilator waveform, which has since been shown to under report PVA particularly 
when PVA has a high prevalence.(153)  This questions both the reliability and applicability of the 10% 
asynchrony index in the HMV group. 
Type of patient ventilator asynchrony 
Similarly to previous studies, we have confirmed ineffective efforts are the most common type of PVA 
in patients receiving HMV affecting approximately 10% of breaths at initiation and 6% of breaths at 3 
months.  Auto-triggering was the next most frequent type of PVA affecting 3% of breaths during HMV 
set up and but with a significant increase to 6% of breaths at 3 months.  Auto-triggering has been 
related to mask leak and so this increase may relate to increase in mask leak due to wear and tear of 
the mask seal over time.(154)  All other asynchronous events affected <2% of breaths at both HMV 
initiation and 3 months of HMV use. 
In this trial, we have standardised PVA definitions to facilitate reproducible assessments.  There has 
been ambiguity in the literature regarding the current PVA nomenclature.  We have based the current 
definitions on those used defined by Vignaux et al.(89)  We have further clarified the difference 
between auto-triggering, which represents a single non-triggered breath, and auto-cycling, which 
reports more than 3 non-triggered breaths in a row separated by less than 1 second.  This has 
previously been described as the delivery of non-triggered breaths over and above the back-up rate 
associated with high trigger sensitivity.(155)  We have also observed an infrequent type of PVA with 
HMV that was previously not defined but represents a single sustained patient inspiratory effort that 
triggers 3 or more ventilator delivered breaths before the patient exhales.  We have termed this as 
multiple triggering. Multiple triggering was observed in 23% of patients at initiation of HMV and 30% of 
patients at 3 months, but affected < 0.1% of breaths overall at each assessment.  It therefore remains 
unclear as to whether its impact on patient ventilator interaction is of clinical significance. 
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HMV Adherence 
Adherence to HMV at 3 months in the physiological led HMV set up was similar to the physician led 
HMV set up with both groups achieving a mean daily adherence of more than 4 hours.  NIV use has 
been shown to correlate with reduction in daytime PaCO2 with a nocturnal adherence of 4 hours 
required to control daytime hypercapnia in obese, NMD-CWD and possibly COPD patients.(39, 56, 
156)  HMV use of greater than 4 hours also led to an increase in physical activity and weight loss in 
obese patients and a reduction the Epworth sleep score in NMD-CWD patients at 3 months. 
There was no relationship observed between the PVA and hours of adherence to HMV in the current 
trial.  Although other studies have reported that severe asynchrony was associated with a poorer 
tolerance of non-invasive ventilation, these studies were performed in the acute setting, over a 30 
minute period and no long term measurements of adherence have been reported.(89, 146)   
Adherence to ventilation may be very variable and impacted by commonly described disadvantages 
of HMV, such as claustrophobia, anxiety, requirement for patient motivation, inconvenience, gastric 
distension, noise or interface discomfort.(157-160)  Although every attention was given to optimise the 
interface for all patients in this trial, 41.2% of patients reported persistent interface discomfort on 
direct questioning at 3 months.  Patients in this study also reported increased levels of anxiety, as 
measured by the anxiety component of both the HAD and the SRI questionnaires, at initiation.  
Anxiety levels are important factor determining quality of life in patients on HMV and have been 
related to increased severity of pulmonary disease in COPD patients.(102)  Ultimately, it is likely that 
patient adherence to HMV is multi-factorial and a combination of all of these factors play a role in the 
individual patient. 
Gas exchange  
This pilot randomised controlled trial demonstrated that physiological HMV set up had similar 
physiological efficacy, in terms of gas exchange at 3 months, to the physician led HMV set up.  This 
was shown as a reduction in daytime PaCO2 and nocturnal mean TcCO2 with an increase in daytime 
PaO2 and nocturnal mean SpO2 levels in both the intervention and control groups.  These 
improvements in gas exchange were not disease specific, but realised in all patient groups.  
Furthermore, there was no relationship demonstrated between PVA and gas exchange.  Specifically, 
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there was no association between total PVA and the time spent with oxygen saturations < 90% 
overnight.  There was a weak relationship between ineffective efforts and the time spent with oxygen 
saturations <90% but this was only observed during the initiation of HMV (rs=0.33, p=0.04), which was 
a similar finding to that of Fanfulla et al. (r= 0.39).(76).  
Home mechanical ventilators have improved performance characteristics over the last decade and 
are commonly used in pressure support mode with a set back up rate as in our trial.  Interestingly, 
there is no mention of a back-up rate being used overnight in the study by Fanfulla et al. that reported 
the relationship between ineffective efforts and nocturnal oxygen saturations.(76)  It may be 
hypothesised that as long as the patient receives a sufficient back-up rate from the ventilator then gas 
exchange will occur regardless of patient ventilator synchronisation.  In support of our findings, and 
more recently, Bertrand et al. compared neurally adjusted ventilator assist (NAVA) with pressure 
support ventilation (PSV) in patients with acute respiratory failure with a respiratory rate above 25 
breaths per minute requiring non-invasive ventilation.(141) This study demonstrated that the use of 
NAVA led to a reduction in severe PVA, however, no improvement in gas exchange was reported 
over the 30 minute assessment period.(141)  Furthermore, there was no association reported 
between PVA and nocturnal TcCO2 and SpO2 in stable patients with obesity hypoventilation receiving 
HMV overnight.(70)   
 
Respiratory muscle unloading  
This is the first study to demonstrate non-invasive evidence of respiratory muscle unloading with HMV 
using sEMGpara%max. Both the physiological HMV set up and the physician led set up achieved 
respiratory muscle unloading after the first night of HMV and at 3 months post initiation of HMV 
therapy.  No significant difference was observed between the proportion of respiratory muscle 
unloading achieved at 3 months with either approach.  This may have been explained, in part, by the 
differing levels of neural respiratory drive demonstrated by the two groups during the self-ventilating 
trials prior to starting HMV.  Despite randomising patients by minimisation on the basis of lung 
function, age and body composition in an attempt to evenly distribute the different patient disease 
groups, when examining neural respiratory drive, patients in the physiological led HMV set up 
demonstrated an increase in sEMGpara%max during nocturnal ventilation.  The same was not seen 
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in the physician led HMV set up group and may represent phenotypical differences within disease 
categories in terms of pulmonary mechanics, patient reserve and nocturnal respiratory muscle loading 
between the two groups.  Despite the differences in neural drive characteristics post the first night of 
HMV, there was a median reduction in sEMGpara%max of -4.7 (-8.8 to -0.7)% in the physiological led 
set up compared to -1.7 (-3.2 to +0.1) in the physician led set up which approached significance 
(p=0.06). 
Unlike previous studies, we did not demonstrate a relationship between respiratory muscle loading 
and PVA.(8, 86, 88)  These studies investigated respiratory muscle loading in acutely unwell patients 
or patients recovering from acute illness who were fully dependent on receiving invasive ventilation.  
A similar effect on respiratory muscle unloading may not occur in patients requiring nocturnal non-
invasive ventilation only.  Furthermore, it is not reported in these studies if the patients were 
investigated whilst asleep.  In the study by Leung et al. patients were asked to rate their sensation of 
dyspnoea using a Borg score strongly supporting that they were awake.  Sleep, and different stages 
of sleep, is known to reduce neural respiratory drive, in particular, during rapid eye movement sleep 
and therefore the effects of an increase in respiratory muscle loading from an asynchronous event 
may not be so easily observed.(161, 162) 
Health related quality of life 
Health related quality of life (HRQL) improvements are fundamental to successful HMV set up as one 
of its main clinical goals is for symptom control in patients with progressive disease.  Over 3 months of 
HMV therapy, improvements were observed in HRQL measures, including the SRI sum score, RAND-
36 sum score, HAD score and ESS. A statistically significant improvement was not observed in the 
SGRQ questionnaire however in minimally clinically importance difference for improvement was 
achieved.  Our study supports the previous finding that HMV improves quality of life in patients with 
COPD, obesity, NMD and CWD.(40, 51, 67, 133, 163, 164).  However, in this study no disease group 
benefited significantly more than another following 3 months of HMV therapy.  These improvements in 
health related quality of life, patient comfort and patient perception of PVA were similar between 
patients set up on HMV using protocol led and the physician led HMV set up at 3 months.  Of interest, 
though not statistically significant patients in the physiological-led set up did report improved patient 
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ventilator co-ordination following the first night of HMV, although this benefit was lost over the 3 
months of therapy. It is unclear whether this represents a contemporaneous  effect of the intervention. 
The impact of patient ventilator asynchrony on health related quality of life from longitudinal studies 
has never been addressed. There is, however, some limited evidence to suggest that patient 
ventilator asynchrony in the form of ineffective efforts adversely impacts on patient comfort and 
dyspnoea on ventilation.(89, 90, 135, 146)  In the current trial, we could not identify any significant 
correlation between PVA and patient perception of comfort whilst receiving HMV.  None of the 
previous studies were performed on elective patients using HMV, outside of an acute setting, where 
anxiety levels and the perception of comfort and dyspnoea may be different.  These studies also 
assessed patients whilst awake and during ventilator therapy as opposed to recall post nocturnal 
ventilation, which may also explain this difference.   We could not identify a difference in comfort 
scores using a severity cut off for asynchrony levels, but this may reflect the high prevalence of PVA 
as a majority of patients had PVA affecting >10% breaths. 
Of interest, we observed an inverse correlation between the anxiety component of the SRI 
questionnaire following 3 months of HMV and the proportion of PVA.  This may suggest that patients 
perceive PVA overnight but report this as anxiety as they struggle to describe the patient ventilator 
asynchrony.  A component question of the SRI anxiety score details patient anxiety at night asking the 
patient to rate if they are ‘afraid of having breathing difficulties at night’, which may explain an 
association with PVA.  Furthermore, these data suggest that if patient anxiety levels fail to improve a 
comprehensive physiological overnight assessment may be warranted to elucidate any issues with 
PVA.   
An inverse relationship between PVA frequency and improvement in the SGRQ was observed over 3 
months of HMV therapy.  Although validated in obstructive airways disease, this association may be 
apparent as the largest disease group studied were those with COPD.  Examining the SGRQ more 
closely there are questions again related to anxiety levels and sleep disturbance such as ‘my cough 
or breathing disturbs my sleep’ and ‘I get afraid or panic when I cannot get my breath’ which may 
manifest as patient perception of PVA.  This warrants further investigation. 
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Hospital length of stay during HMV set up 
Hospital length of stay was reduced in patients who were initiated on HMV using physiological led set 
up.  In addition, there was reduced requirement of ventilator modifications required in this group prior 
to hospital discharge.  These observations would support the suggestion that physiological led HMV 
set may have additional cost benefits.  In view that the physiological led set up involved a daytime set 
up with a majority of patients requiring limited modification of the settings suggests that this approach 
to initiating HMV could be employed in future studies in the outpatient setting leading to further cost 
benefits.   
 
4.4.3 Clinical significance of the findings  
The current trial is the first to assess PVA overnight at initiation of HMV and at 3 months post initiation 
of HMV therapy.  We have demonstrated that the high prevalence of PVA at the initiation of HMV is 
sustained at 3 months. No association between the levels of PVA and patient adherence to HMV 
therapy could be demonstrated.  However, we have also shown that despite the high proportion of 
PVA, there is limited adverse impact on respiratory muscle unloading, gas exchange, quality of life or 
ventilator adherence.  There may be an association with the patient’s perception of anxiety 
surrounding the use of HMV, although this must be confirmed.   
We have demonstrated that using the neural respiratory drive, measured from the second intercostal 
space parasternal muscle, in combination with thoraco-abdominal movement and mask pressure we 
can non-invasively identify and categorise PVA at the bedside.  The use of the neural respiratory drive 
can guide the physician to diagnose the different types of PVA, which facilitates a comprehensive 
understanding of patient ventilator interaction and provides information of the possible cause of the 
PVA.  For example, double triggering can occurs when premature cycling affects the first ventilator 
delivered breath and the second ventilator breath is generated because of ongoing inspiratory effort 
from the patient.  Alternatively, double triggering may occur due to an auto-triggered breath occurring 
immediately post a normally triggered breath (as in our definition).  The underlying cause of PVA 
cannot be detected by the measurement of thoraco-abdominal movement alone as the onset of 
inspiratory effort is unclear but the additional measurement neural respiratory drive facilitates the 
diagnosis between them and enables appropriate correction. (Figure 52).  Similarly, ineffective efforts 
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may be underestimated in current practice where the chest and abdominal bands are used to detect 
inspiratory efforts.  In particular, in neuromuscular patients, we have observed low levels of neural 
respiratory drive representing an ineffective effort that did not lead chest wall excursion. (Figure 53).  
A similar observation was noticed by Luo et al. when measuring diaphragm EMG during sleep and 
identified ongoing diaphragm activation without thoraco-abdominal movement. (109)  These authors 
concluded that the presence of patient inspiratory drive confirming obstructive sleep apnoea was, in 
fact, present in a third of cases that were otherwise diagnosed as central sleep apnoea when relying 
on thoraco-abdominal movement.(109) 
However, detailed assessment of PVA is currently manually scored and so very labour intensive.  It is 
clear from the data in this study that the impact of PVA is limited in an HMV setting and not required 
for every patient at initiation. In its current form PVA assessment should be rationed to patients 
struggling to adhere to HMV, those adversely impacted by of PVAs and those that remain very 
anxious of using HMV with no other clear explanation post a trial of HMV therapy.  Future work should 
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Figure 50: Two examples of double triggering occurring when considering only the RIP chest 
and abdominal bands related to two different phenomenon a) A prematurely cycled breath with 
ongoing patient inspiratory effort to trigger a second ventilator delivered breath, b) A patient 
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Figure 51: Two inspiratory efforts apparent with sEMGpara but not with RIP chest and 
abdominal bands each followed by a ventilator triggered breath (obtained from a Duchenne 




We have shown that measuring sEMGpara is a non-invasive assessment of neural respiratory drive 
that can be used to monitor respiratory muscle unloading at the bedside whilst using HMV.  This 
signal could be used to guide the physician to the optimal ventilator settings for the individual patient.  
Carteaux et al. demonstrated benefits of bedside targeting respiratory muscle unloading to assist with 
weaning from invasive ventilation.(165)   A similar approach could be taken when initiating HMV. 
Although physiological led set up did not improve upon an expert tertiary centre physician led set up in 
terms of patient outcomes, significantly less ventilator manipulation was required during initiation 
which resulted in a shorter length of stay.  With the increasing demands for HMV, this technique may 
Represents the point at which inspiratory effort 
is apparent examining the chest and sum RIP 
bands and confirms that there is not an 
acquisition issue from the RIP signal. 
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be particularly useful to assist physicians in district general hospitals who are less familiar with HMV 
set up to provide a local service.   
 
4.5 Conclusion 
This pilot randomised control demonstrated that a physiological led set up of HMV, using neural 
respiratory drive to optimise ventilator set up, has similar efficacy to an expert physician led set up of 
HMV in terms of ventilator adherence, gas exchange, respiratory muscle unloading and health related 
quality of life improvements at 3 months.  However, the physiological led HMV set up resulted in fewer 
ventilator setting modification during overnight titration with a reduced length of inpatient stay for HMV 
set up.  These advantages were achieved without a reduction in the frequency of patient ventilator 
asynchrony during HMV and indeed PVA was high at baseline and remained high after 3 months of 
HMV therapy.  Of clinical importance, there was no relationship observed between PVA and clinical 
outcomes such as ventilator adherence, gas exchange, overnight respiratory muscle unloading and 
patient perception of ventilator comfort.  These current data suggest that the elimination of PVA may 
not be required to successfully set-up HMV, but that a clear understanding of the physiological effect 
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Chapter 5 Impact of Patient Ventilator Asynchrony on Sleep 
Quality 
5.1 Introduction 
Sleep disordered breathing is common in patients with chronic respiratory failure.  Respiratory failure 
results from an imbalance between the loads placed upon the respiratory system and its capacity to 
compensate for that load.  To balance the load on the respiratory system in patients with respiratory 
disease, neural respiratory drive is elevated to activate and recruit muscle to increase the operational 
capacity from the respiratory muscle pump.  Overnight, the natural fall in neural respiratory drive 
during sleep, particularly in rapid eye movement (REM) sleep, exacerbates the respiratory muscle 
load-capacity imbalance.   This occurs in combination with muscle hypotonia of the upper airway 
musculature and a blunted hypercapnic ventilatory response predisposing to alveolar hypoventilation 
and respiratory failure.(166, 167)  Sleep disordered breathing therefore may develop as an early sign 
of chronic respiratory failure leading to poor sleep quality and daytime somnolence.(168, 169) 
The impact of long-term sleep disruption related to sleep disordered breathing on patients with 
chronic respiratory failure is unclear.  Studies in healthy subjects and animal models have shown that 
sleep disruption adversely impacts on cellular and humoral immunity, oxygen consumption and 
carbon dioxide production, respiratory muscle endurance, hypercapnic ventilatory responses and 
thermoregulation. (170-172)  
Effective nocturnal non-invasive ventilation reduces the work of breathing, alleviates upper airways 
obstruction and assists the respiratory muscle pump to improve alveolar hypoventilation and gas 
exchange.  Correcting sleep disordered breathing with non-invasive mechanical ventilation has shown 
to significantly improve both nocturnal ventilation and sleep quality in patients with chest wall 
deformity at 12 months.(173)  
However, poor sleep quality has still been reported during the use of both invasive mechanical and 
non-invasive ventilation although the aetiology of this is not fully understood.(75, 91, 174)  In a study 
by Bergbom- Engberg et al. assessing patient’s experiences of mechanical ventilation, 35% 
retrospectively described significant sleep disruption.(175)  30% reported symptoms of ‘agony/panic’ 
during mechanical ventilation that was associated with difficulties in synchronising the patients 
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breathing to the ventilator.(175)  This has led to the suggestion that patient ventilator asynchrony may 
be directly related with arousals and awakenings resulting in persistent sleep disruption.  Previous 
studies that examined patients with chronic respiratory failure receiving home mechanical ventilation 
(HMV), demonstrated a relationship between increased PVA and poor sleep quality, defined as 
greater sleep fragmentation with reduced stage 3 and REM sleep.(70, 75, 176)   Bosma et al. 
compared proportional assist ventilation to pressure support ventilation in patients weaning from 
mechanical ventilation and reported that proportional assist ventilation improved sleep disruption as a 
consequence of a reduction in PVA.(91)   
There are no longitudinal studies investigating the relationship between the patient ventilator 
asynchrony and sleep quality in patients with chronic respiratory failure receiving HMV.  We 
hypothesised that (1) patient ventilator asynchrony negatively impacts on sleep quality and (2) patient 




This study was approved by the local ethics committee and all patients provided written informed 
consent.  
10 patients with chronic respiratory failure (7 males) recruited to the randomised controlled trial, 
described in Chapter 4, agreed to additional polysomnography assessment overnight.  Chronic 
respiratory failure was defined as patients with evidence of daytime PaCO2 greater than 6kPa with a 
normal arterial blood pH range of 7.35-7.45. 
The inclusion and exclusion criteria are described in Chapter 4 1.2. 
5.2.2 HMV set-up  
All patients were admitted for nocturnal set up and titration of HMV (NIPPY3+ ventilator; B&D 
Electromedical, Stratford-upon-Avon, UK).  Two patients were initiated on HMV using a physician led 
nocturnal titration set up protocolised according to their underlying pathophysiological condition 
(described in Appendix 2) as is standard practice in our unit.  Eight patients were initiated on HMV 
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using a physiological set-up to address patient ventilator asynchrony and optimise respiratory muscle 
unloading (described in detail in Chapter 4).  As there were no between group differences observed in 
PVA and gas exchange, the patients from both groups were combined as a single cohort.  All patients 
received a pressure support mode with a fixed back up rate set at 2 breaths below their resting 
breathing rate. 
 
5.2.3 Nocturnal polygraphy assessment 
Respiratory polygraphy was performed overnight to include assessments of sEMGpara, RIP and 
mask pressure (as described in Chapter 4). Each breath during a 2 minute epoch, measured every 10 
minutes, over seven hours (or as long as the patient slept) was analysed for synchronisation between 
the patient and ventilator according to our standardised definitions.  Signals with movement artefact 
were excluded and the closest 2 minute epoch that was artefact free was assessed.  Pulse oximetry 
and transcutaneous capnography measurements (TOSCA 500, Radiometer, Crawley, West Sussex, 
UK) were used to assess the adequacy of nocturnal ventilation.   Assessments were performed 
overnight at both the initiation of HMV and post 3 months of HMV therapy.  
sEMGpara, respiratory inductance plethysmography and mask pressure data were recorded on 
LabChart  v7.3 software (AD Instruments Ltd, Oxford, UK) and saved on a password protected DELL 
desktop computer (Dell Corporation Limited, Bracknell, UK).  Analysis of anonymised data was then 
performed offline on a password protected HP laptop (Hewlett-Packard Ltd, Bracknell, UK).  
 
5.2.4 Sleep analysis 
Sleep was evaluated by limited polysomnography (PSG) using Alice 5® (Respironics®, Murrysville, 
PA, USA), as described in Chapter 2, during both the first night initiation of HMV and at 3 months post 
HMV therapy.  All PSG recordings were scored manually in 30 second epochs both by myself and 
independently analysed by an expert sleep technician (ID) blinded to the respiratory polygraphy 
results.  The PSG results following expert analysis were used in this study.  (The levels of agreement 
between myself and the sleep technicians scoring 10 PSG studies can be found in Appendix 5).   
Sleep stages and arousals were scored in accordance to the American sleep medicine manual for the 
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scoring of sleep and associated events: rules, terminology and technical specification (2007).(117)   
Sleep and respiratory events scored with standard terminology are described in Chapter 2 (2.10.3).  
Terminology to explain our definitions of sleep disruption related to PVA are described below: 
Arousal index (AIpsg) was defined as the number of electroencephalogram (EEG) identified arousals 
from sleep lasting greater than 3 seconds that occurred per hour from full PSG analysis. 
Arousal index (AItotal) was defined as the calculated arousal index per hour incorporating only the 2 
minute epochs that were screened for PVA throughout the overnight study. 
PVAwake index was defined as the number of patient ventilator asynchrony events occurring per hour 
of wakefulness calculated from the 2 minute epochs. 
PVAsleep index was defined as the number of patient ventilator asynchrony events occurring per hour 
of sleep calculated from the 2 minute epochs. 
Patient ventilator asynchrony arousal index (AIpva) was defined as the number of patient ventilator 
asynchronous events that events that preceded an arousal within 3 seconds per hour of sleep 
overnight calculated from the 2 minute epoch assessments, 
 
5.2.5 Integrating polysomnography and respiratory polygraphy: electroencephalogram and 
parasternal electromyogram 
To synchronise the analysis of overnight PSG from the Alice 5® equipment (Respironics®, Murrysville, 
PA, USA) and respiratory polygraphy recorded on to LabChart v7.3 (AD Instruments, Ltd, Oxford, UK) 
we applied two sets of abdominal and chest RIP bands.  A maximal inspiratory manoeuvre was 
performed by the patient as part of the PSG calibration at the start of the overnight recording and at 
the end of the night study.  From these assessments we could accurately match the configuration of 
the RIP bands from the two systems.  We did not observe a discrepancy in the computer clocks over 
a night of recording using our computing systems but this was verified for each individual study.   
Post manual scoring of the respiratory polygraphy in 2 minute epochs every 10 minutes overnight, the 
corresponding PSG epochs were manually compared to identify the stages of sleep patients were in 
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when PVA occurred.  The frequency of arousals occurring during the 2 minute epoch respiratory 
polygraphy assessments was reported and PVA events preceding an arousal were identified. 
 
5.3 Statistical Analysis 
Anthropometric data, were normally distributed and are presented as mean and standard deviation. 
Otherwise, non-parametric tests were performed, given the small number of patients. Comparisons 
between disease groups were descriptive only.  Ventilator settings and sleep quality measures were 
expressed as medians (interquartile range) and compared over time, using the Wilcoxon-matched 
pairs test.  Comparisons of PVA levels in the same patient between different sleep stages were 
performed with a repeated measures Friedman test.  The frequency of PVAs occurring in different 
sleep levels and leading to arousals were compared using a Kruskal-Wallis test.  Finally, correlations 
between PVAs and sleep efficiency measures were performed with a Spearman correlation.  For all 
analyses, a p-value <0.05 was considered statistically significant.   
 
5.4 Results 
Of the 10 patients recruited, 1 patients had chronic obstructive pulmonary disease (COPD), 2 patients 
had obesity related respiratory failure (ORRF), 3 patients had overlap syndrome (COPD with 
obstructive sleep apnoea (OSA)), 2 patients had neuromuscular disease (NMD) and 2 patients had 
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Table 26: Patient baseline characteristics  
No.      Disease    Phys set-up       Age       Sex      BMI    FEV1%      FVC%       FEV1/FVC                                                                                                      
(n)        Group           (Y/N)            yrs        (M/F)    kg/m2  predicted       ratio (%) 
1       COPD/OSA           Y                61          F          41.6        35.0          83.7           35.0 
2       COPD/OSA           Y                68         M         26.8         19.0          31.8           46.2 
3       OHS/OSA              Y                42         M         37.2         81.5          88.7           75.3 
4       OHS                       N                84         M         34.7         35.8          36.2           72.1 
5       COPD/OSA           Y                46         M         40.5         30.6          43.9           57.6 
6       COPD                    Y                59         F           16.9         37.8          94.6            33.3 
7        NMD/OSA           Y                32        M           37.1        23.4         21.1             96.2 
8        NMD/OSA           Y                69         F           39.1        48.9         54.7             73.2 
9        NMD                    N                41       M           20.3        12.3          12.1             89.0 
10      NMD                    Y                21       M           16.8        20.1          17.8             98.7 
  Mean                                               52                      31.1       34.4           48.5            67.7 
   SD                                                ±19                     ±9.9      ±19.7         ±30.7          ±23.9 
Abbreviations:Phys-Physiological led set-up of ventilation (interventional arm) COPD-chronic 
obstructive pulmonary disease, OHS-obesity hypoventilation syndrome, OSA-obstructive sleep 
apnoea, NMD-neuromuscular disease, BMI- body mass index, FEV1- forced expired volume in 1 
second, FVC- forced vital capacity, SD-standard deviation, Y-yes, N-no, yrs-years, M-male, F-female, 
kg/m2-kilograms per metre squared. 
 
As expected, patients with obesity related respiratory failure and/or obstructive sleep apnoea had 
higher levels of expiratory positive airway pressure (EPAP) than non-obese patients (11 (7-13) 
cmH2O and 4 (3-4) cmH2O, respectively). Pressure support levels at initiation of HMV were similar 
between the disease groups with COPD patients receiving 18 (14-20) cmH2O, ORRF patients 17 (12-
22) cmH2O and NMD patients 18 (16-21) cmH2O.  Back up rate was also similar between the disease 
groups with COPD patients receiving 14 (13-16) breaths per minute, ORRF patients 14 (14-14) 
breaths per minute and NMD patients 14 (14-16) breaths per minute.  Only patients receiving 
physiological led set up of HMV had changes to the ventilator trigger settings.  The most frequent 
change in ventilator settings in this group was a reduction inspiratory trigger sensitivity to address 
ineffective ventilator triggering.  Inspiratory trigger was slightly more sensitive in patients with COPD 
and NMD than ORRF patients (3(2-4) and 3(2-4) vs. 4(4-4), respectively). The expiratory trigger was 
less sensitive in ORRF patients than COPD patients and NMD patients (7 (4-10) vs 4(2-4) and 5 (3-6), 
respectively) but this was led by a single patient with a high expiratory trigger of 10.  (Table 27) 
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Table 27: Ventilator settings at initiation and 3 months post HMV 
                            First night NIV                  3 months post NIV therapy  
No.     IPAP      EPAP     BUR    Triginsp    Trigexp      IPAP      EPAP     BUR    Triginsp    Trigexp 
         (cmH20)  (cmH20)  (/min)    (0-10)    (0-10)    (cmH20)  (cmH20)  (/min)    (0-10)    (0-10)   
1              30          12         14           2            4            30             12         14            2            4                                  
2              25           5          14           3            1            27              7          14            3            1         
3              24          12         14           4           10           n/a        
4              25           3          14           4            4            25              3          14            4            4        
5              32          14         16           4            4            30             10         16            4            4     
6              16           4          12           3            4            16              4          12            3            4                         
7              28           7          14           3            3            28               8          18           3            3                         
8              26           9          14           3            6            26              12         14           3            6                             
9              22           3          16           4            4            24               3          16           4            4                
10            20           4          14           2            5            16               4          14           2            5                                      
Median    25           6          14           3            4            26               6          14           3           4           
IQR     (22-30)    (4-12)   (14-15)  (3-4)      (4-5)      (20-29)       (4-11)   (14-16)    (3-4)    (4-5)                                                                
Abbreviations: IPAP= inspiratory positive airways pressure, EPAP= expiratory positive airway 
pressure, BUR= mandatory back up breath rate, Triginsp= Inspiratory trigger setting, Trigexp= Expiratory 
trigger setting, n/a= not applicable (patient failed to attend follow up 3 month study), IQR= Interquartile 
range. 
 
There was no difference in ventilator settings observed between initiation of HMV and 3 months post 
initiation of HMV.  Pressure support was increased in 2 patients and reduced in 3 patients mainly in 
relation to increases in EPAP which was increased in 4 patients.   
 
Data from full polysomnography 
There was no significant difference observed in the sleep quality, determined from the full overnight 
polysomnography data, between the initiation of HMV and 3 months post therapy initiation. (Table 
28).  Two patients slept for less than 4 hours at both the initiation of HMV and 3 months post HMV 
therapy.  Median sleep efficiency was 77.3% on the first night and this decreased further at 3 months 
to 68.4% in line with previous studies.(176) The median arousal index at initiation was high 26.7 (11-
38) per hour with 4 patients experiencing over 30 arousals per hour.  The arousal index did not 
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change with time on HMV and was 23.4 (14-30) per hour following 3 months of treatment, although 
the number of patients that experienced greater than 30 arousals per hour was only 2.  There was no 
significant difference observed between percentage of time spent in stage 1 and 2, stage 3 or REM 
sleep stages at initiation and 3 months post HMV therapy initiation. (Figure 54). 
 
 
Table 28: Sleep quality measures recorded from full overnight polysomnography at 
initiation and 3 months post NIV therapy  
                            First night NIV            3 months post NIV therapy  
No.   TST        SL        SE      WASO      AIpsg            TST        SL        SE       WASO       AIpsg 
          (min)     (min)     (%)       (min)       n/hr              (min)     (min)     (%)       (min)       n/hr 
1           376       13       74.7        115        13.4               351         45       68.4         118       43.8 
2           237      28        44.6        266        38.5               200         42       35.5         321       31.2 
3           304      32        57.1       196         27.6               n/a 
4           129     146       22.5       297          6.1               220         76       42.6        220        18.0 
5           477     14         88.3       50          12.2              403          22       80.8         74          7.5 
6           486     15         93.6       18          34.3              387          11       80.7         82         23.4 
7           381     32        81.5        55          25.7              301          52       69.5         81         15.7  
8           457     36        88.1        26          3.0                302         49        64.0        121        12.1 
9           274     68       49.9        207         44.7              383       144        60.6        105        28.1 
10         421    36        79.9         71          37.2              494         27        91.5         20         27.8     
Median  379    32       77.3          93          26.7              351        45         68.4       105         23.4  
IQR (265-462)(15-44)  (49-88)  (44-222)  (11-38)  (261-395) (25-64)  (52-81) (78-171) (14-30)                                   
Abbreviations: TST = total sleep time, SL= sleep latency, SE= sleep efficiency, WASO= wake time 
after the first onset of sleep, AIpsg= arousal index determined from full polysomnography data, min-
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Figure 52: Box Plots showing the changes in sleep stage between first night and 3 months 
post HMV therapy initiation 
 
Data are expressed as median and the interquartile range for the percentage of nocturnal 
sleep time spent in light stage sleep (stage N1-2), deep sleep (stage N3) and rapid eye 
movement (REM) sleep.  
 
Following 3 months of HMV therapy a reduction of 0.5 (1.7-0.1)kPa in overnight TcCO2 was observed. 
Oxygen saturations overnight improved by 2.6 (-0.2-6.9) % following 3 months of HMV therapy.  Two 
COPD patients received oxygen therapy that remained constant over the 3 month period.  Post 
completion of the trial at 3 months, one patient had oxygen removed and one patient received a 
reduction in oxygen prescription (2L/min to 1L/min overnight) due to improvements in nocturnal 
hypoxia.  COPD patients (n = 4) had the greater improvement in mean nocturnal TcCO2 of 1.2 (2.2- 
0.6) kPa compared to 0.6 (1.2-0.2) kPa in the NMD group (n = 4).  COPD patients also had a greater 
improvement in mean nocturnal oxygenation of 4.9 (-0.8- 21.3) % compared to 2.8 (0.5-3.8) % in the 
NMD patients.  ORRF patients were not included as only one patient completed the study.   
No significant changes were observed in the apnoea hypopnea index (AHI) and 4% oxygen 
desaturation index (ODI) between initiation and 3 months of HMV therapy (p=0.79 and p=0.08, 
respectively). There was an increase in AHI 1.7(-4.2-2.4) events per hour following 3 months of HMV 
therapy and a reduction in 4% ODI of 1.8 (28-2.7) events per hour. COPD patients demonstrated the 
greatest reduction in 4% ODI of 18.2 (57.2- 3.8) events per hour and a small increase in AHI 2.2 (-4.2-
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both AHI and 4% ODI with time on HMV (1.0 (6.2-1.6) events per hour and 2.4 (15.4-7.4) events per 
hour, respectively).  
 
Table 29: Nocturnal Respiratory Parameters 
                            First night NIV            3 months post NIV therapy  
No.     TcCO2              SpO2            AHI       4% ODI        TcCO2               SpO2               AHI        4% ODI 
       mean, max        mean, min        n/hr         n/hr          mean, max       mean, min            n/hr          n/hr   
            (kPa)                (%)                                                   (kPa)              (%)                  
1         8.8,  9.5           67.4,  28.0       0.6          78.3          6.8,  7.6          92.6,  78.0            12.6         14.3 
2         7.5,  8.3           89.4,  71.0       9.1          29.6          8.4,  9.6          88.4,  61.0            10.8         34.4 
3         5.5,  6.9           99.8,  93.0       9.7           0.6           n/a 
4        7.0,  7.7           95.4,  76.0        2.3          14.9         6.5,  7.1           95.2,  79.0             4.4          13.1 
5        8.4,  10.3         81.8,  46.0        7.7          48.5         6.1,  6.5          91.5,  78.0              1.5          11.6  
6        6.9,  7.1           92.3,  89.0        2.7           0.5          6.5,  6.8           92.3,  88.0             5.4           1.1 
7        8.6,  9.5           95.6,  79.0        2.2          21.1         7.3, 8.0            98.6,  90.0             0.0           2.1 
8        6.6,  6.9           91.0,  80.0        0.0          2.9           5.6,  6.1           95.0,  72.0             0.2          12.7  
9        7.5,  9.5           96.3,  86.0        7.9          3.2           7.3,  8.5           98.9,  85.0            10.0          3.2 
10      5.4,  6.5           99.1,  81.0       27.2         6.5           5.7, 6.5            98.9,  84.0            19.7          1.8 
M      7.3    8.0           93.8   79.5        5.2         18.0         6.5   7.1            95.0   79.0             5.4        11.6 
IQR (6-8)  (7-10)    (88-97) (65-87)   (2-9)     (3-34)       (6-7)  (7-8)     (92-99) (75-87)     (1-11)    (2-14)                            
Abbreviations: M= Median, IQR =intra quartile range, TcCO2= transcutaneous carbon dioxide level, 
SpO2 =oxygen saturations, AHI= apnoea, hypopnea index, 4% ODI= 4% oxygen desaturation index, 
n/a= not applicable (patient failed to attend for 3 month follow up), n/hr-number of events per hour, 
max-maximum, min-minimum. 
 
Overall, PVA was more frequent during wake with approximately twice as many events occurring than 
during sleep although with marked individual variability and so a significant difference was not 
achieved.   There was no change in PVA occurring during wake between initiation of HMV and 3 
months post HMV therapy initiation (18 (-189-153) events per hour; p=0.9).  Similarly, there was no 
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Table 30 : Integrated 2 minute respiratory polygraphy and 10 minute polysomnography data 
                            First night NIV                  3 months post NIV therapy  
No.  Anls  % PVA   PVAwake   PVAsleep  AItotal AIPVA           Anls  % PVA   PVAwake   PVAsleep  AItotal   AIPVA 
    (hr:min)   breaths         (events/hr)         (n/hr)             (hr:min)  breaths      (events/hr)            (n/hr)                                    
1      1:10      45          576         546         14        5              1:12       18        198          162           43     18 
2      1:04      22          138         306         31       26             1:10       20        162          294          31      14 
3      1:16      16          192          90          32       14              n/a   
4      0:42      52          492         552         14       14              0:30       61        846          912         13      9 
5      1:12      17          288         120          9         8               1:00       4         162           36           7        3 
6      1:12      29          168         216         37       17              1:12       32       234          258         18       8   
7      1:14      21          432         108         26       20              1:08       24       414           90           21      9 
8      1:12      21          300         204          2          1              1:12       11       318          18             3        1 
9      1:08      22          306          90          47        35            1:12       38       546          216         19      10 
10    1:12      11          504          54          35        14             1:12       14       252          102          31     17 
 M   1:12       22          303         162         29        14            1:12       20       252          162        19        9                                                          
IQR(1:07-1:13) (17-33)   (186-495)    (90-366)   (13-35)      (7-25)      (1:04-1:12) (13-35) (180-480)     (63-276)   (10-31)   (6-16)                                                             
Total data are represented as median (M) and interquartile range (IQR).   Abbreviations: Anls = total 2 
minute detailed analysis time per patient, %PVA breaths=percentage of breaths affected by all patient 
ventilator asynchrony, PVAwake=number of total patient ventilator asynchrony observed per hour 
during wake, PVAsleep=number of total patient ventilator asynchrony observed per hour during sleep, 
AItotal = analysis total arousal index, AIPVA= arousal index during detailed analysis within 3 seconds of 
a patient ventilator asynchronous event, hr-hour, min-minutes, n/hr-number per hour.  
 
COPD patients demonstrated less PVA during wake than NMD patients at both initiation of HMV and 
3 months post HMV initiation (initiation: COPD 228 (146-504) events per hour and NMD 369 (302-
486) events per hour, 3 months post HMV therapy: COPD 180 (162-225) and NMD 366 (269-513)).  
However,  NMD patient had less frequent PVA during sleep than COPD patients both at initiation of 
HMV and following 3 months of HMV therapy (initiation: COPD 261 (144-486) and NMD 99 (63-180), 
3 months post HMV therapy: COPD 210 (68-285) and NMD 96 (36-188)).  Arousals preceded by PVA 
were similar in both patient groups.  
A reduction in the frequency of PVA occurring in both wake and sleep was observed in the COPD 
patients (51 (-315- 56) events per hour and 48 (-309-29) events per hour, respectively) following 3 
months of HMV therapy.  No change was observed in the frequency of PVA occurring in wake in NMD 
patients following 3 months of HMV therapy.  A small increase was observed in PVA occurring during 
sleep 15 (-144-107) in patients with NMD. 
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5.4.1 Patient ventilator asynchrony and sleep stages 
The majority of PVA occurred during stages 1 and 2 sleep both during the first night of NIV and 3 
months post NIV therapy with a PVAsleep index of 269 (202-382) events per hour and 186 (134-421) 
events per hour, respectively. PVA persisted during REM sleep in this study and we observed no 
significant attenuation in NRD with a PVAsleep index of 192 (51-370) events per hour at initiation and 
209 (32-310) events per hour post 3 months of HMV therapy.  The lowest PVA occurred during stage 
3 sleep with a PVAsleep index of 105 (38-504) events per hour at the initiation of HMV and 135 (42-
299) events per hour 3 months post HMV initiation.  Although there was no significant difference 
observed in the number of asynchronous events occurring in the different sleep stages at initiation of 
HMV, by 3 months of therapy the PVAsleep index was higher in stage 1 and 2 sleep compared to stage 
3 at 3 months post therapy (p=0.02). (Figure 55).   
Despite this, there was no overall statistically significant difference observed in PVA frequency at any 
sleep stage between the initiation of NIV and 3 months post therapy (stage 1 and 2 p=1.0; stage 3 
p=0.6; REM p=1.0).  
 
Figure 53: Box Plots showing the changes in total PVA with sleep stages between first night 
NIV and 3 months post NIV therapy  
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There was no difference observed in the frequency of ineffective efforts, premature expiratory cycling 
or delayed expiratory cycling across the sleep stages at the initiation of HMV (ineffective efforts 
p=0.97, premature cycling p=0.52, delayed cycling p=0.75). 
First night NIV 3 months post NIV 
p=0.02 
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 Auto-triggering occurred more frequently sleep stages 1 and 2 than in deep stages of sleep at 
initiation of HMV (p=0.02). (Figure 56) 
There were no significant differences in the frequency of ineffective efforts, auto-triggering, premature 
expiratory cycling and delayed expiratory cycling between the different sleep stages at 3 months post 
NIV therapy (ineffective efforts p=0.69; auto-triggering p=0.40; premature expiratory cycling p=0.44; 
delayed expiratory cycling p=0.91). (Figure 57).  
 
 
Figure 54: Box Plots demonstrating the changes in the most frequent triggering (ineffective 
efforts (IE) and auto-triggering (AT)) and cycling (premature cycling (PC) and delayed 
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Figure 55: Box Plots demonstrating the changes in the most frequent triggering (ineffective 
efforts (IE) and auto-triggering (AT)) and cycling (premature cycling (PC) and delayed 
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No correlation was observed between PVAsleep and the percentage of sleep time spent in stage 3 or 
REM sleep at initiation of HMV (rs=0.46, p=0.19 and rs=0.47, p=0.18; respectively).  Neither was a 
correlation observed between PVAsleep and stage 3 sleep or REM sleep at 3 months post HMV 
therapy (rs =0.15, p=0.71 and rs =-0.43, p=0.25). 
 
5.4.2 Patient ventilator asynchrony and sleep disruption  
PVA preceded 48% of the total arousals at initiation of HMV and 47% post 3 months of HMV. There 
was no significant reduction in the number of arousals preceded by PVA between baseline HMV set 
up and 3 months post therapy (14 (7-21) events per hour vs. 9 (6-16) events per hour; p=0.98).  
Although the prevalence of PVA during sleep is high, only 8 (2-24)% of PVAsleep at initiation of HMV 
and 6 (4-11)% of PVAsleep at 3 months preceded an arousal. No difference in the small proportion of 
asynchronous events resulting in sleep disruption was observed following 3 months of HMV therapy 
(p=0.6). Similarly, no significant reduction in non-PVA induced arousals was observed with 3 months 
of HMV (8 (1-14) events per hour vs 10 (4-16) events per hour; p=0.5). (Table 30). 
Ineffective efforts were most frequently associated with  arousals 3 (1-4) per hour on the first night of 
HMV set up and 3 (1-3) per hour 3 months post HMV therapy. The next most frequent PVA 
IE AT PC DC 
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associated with arousals were premature cycling events which led to 2 (1-4) arousals per hour on the 
first night of HMV and 1 (0-3) at 3 months post therapy.  All the other asynchrony preceded less than 
1 arousal per hour on both the first night of NIV and 3 months post NIV therapy.  (Figures 58 & 59). 
Ineffective efforts were significantly more likely to precede an arousal at both initiation and 3 months 
than a multiple asynchronous event (p<0.01 at initiation and p<0.001 at 3 months).  
The majority of arousals preceded by PVA occurred in sleep stages 1 and 2, 76% at initiation and 
78% at 3 months post HMV therapy.  In contrast, few arousals occurred in slow wave sleep (16% at 
initiation of HMV, 21% at 3 months) and REM sleep (8% at initiation of HMV, 1% at 3 months). 
Only a small proportion of the asynchronous events that occurred during sleep led to arousals and 
very few of these arousals resulted in an awakening, total awakenings preceded by PVA were 1.0 
(0.8-3.3) event per hour at initiation and 2.0 (1.0-2.0) events per hour at 3 month assessment. 
 
Figure 56:  Box plots indicating the number of arousals per hour related to the individual types 
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Figure 57: Box plots indicating the number of arousals per hour related to the individual types 








































PVAsleep levels were not significantly correlated with the arousal index overnight at initiation of HMV or 
3 months post HMV therapy (initiation: rs= -0.5, p=0.2, 3months: rs=0.3, p=0.4). 
 
5.4.3 Patient ventilator asynchrony and sleep quality 
No significant relationship was observed between the PVA levels occurring during sleep and overall 
sleep efficiency, WASO or total sleep time at either initiation of HMV or 3 months post therapy. 
(Figures 60 & 61).  No significant relationship was observed between the amount of PVA during wake 
and sleep latency at initiation of HMV.  However, a significant relationship was observed between the 








- 180 - 
Figure 58: Spearman correlation between PVAsleep and a) sleep efficiency, b) WASO and c) total 
sleep time during the first night of HMV  






























































Abbreviations: Total PVA- patient ventilator asynchrony (whole night study), PVAsleep-patient ventilator 
asynchrony occurring during sleep periods only, WASO- wake after sleep onset.  
 
Figure 59: Spearman correlation between PVAsleep and a) sleep efficiency, b) WASO and c) total 
sleep time 3 months post HMV therapy 









































a) rs= -0.2, p= 0.6 
c) rs=-0.2, p= 0.5 
b) 
rs= 0.2, p= 0.6 b) rs=0.2, p= 0.6 
b) 
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Abbreviations: Total PVA- patient ventilator asynchrony (whole night study), PVAsleep-patient ventilator 
asynchrony occurring during sleep periods only, WASO- wake after sleep onset.  
 
Figure 60: Spearman correlation between PVAwake and sleep latency at a) first night NIV and b) 
3 months post NIV therapy  

























































a) b) rs=0.2  p= 0.6 
 
rs=0.8   p= 0.02 
 
c) rs=-0.4, p= 0.3 
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Table 31: Clinical impact of PVA on arousals and awakening during HMV set up and at 3 
months  






At HMV Initiation 162 (90-366) 14 (7-25) 8 (2-24) 1 (1-3) 
3 months Post 
Initiation 
162 (63-276) 9 (6-16) 6 (4-11) 2 (1-2) 
Abbreviations: PVAsleep-patient ventilator asynchrony occurring during sleep periods only, PVA 
arousal- patient ventilator asynchronous events preceding an arousal. 
 
Although the total PVA during sleep was high, the PVA arousal index was significantly lower at 
initiation of HMV (162 (90-366) per hour vs 14 (7-25) per hour; p<0.0001).  A similar observation was 
made a 3 months post HMV therapy (162 (63-276) vs 9 (6-16); p<0.0001).  The PVA arousal index 
when normalised for the total PVA during sleep was only 8 (2-24) % at initiation which did not change 
significantly after 3 months of HMV 6(4-11) %; (p = 0.60).  Furthermore, there was a low conversion 
rate between PVA induced arousals and awakenings at initiation of HMV and 3 months post HMV 
therapy.  No relationship was observed between PVA arousal index and measures of sleep quality 
such as sleep efficiency (r = -0.35; p = 0.32), WASO (r = 0.37; p = 0.29) and total sleep time (r = -
0.39; p =0.27) at initiation of HMV.  Similarly, no correlation was observed between PVA arousal index 
and measures of sleep quality such as sleep efficiency (r = -0.10; p = 0.80), WASO (r = 0.04; p = 
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5.5 Discussion 
5.5.1 Main findings 
All patients in this small detailed physiological study, using a novel method to assess patient ventilator 
asynchrony overnight, were shown to have a high frequency of asynchronous events.  Patient 
ventilator asynchrony was observed in over a fifth of breaths analysed during initial set up of HMV 
therapy and this did not change after 3 months post HMV therapy.  Sleep quality in patients receiving 
HMV was reduced and this did not significantly improve following 3 months of HMV therapy in terms 
of changes in sleep efficiency, total sleep time, wake after sleep onset and sleep latency.  
Interestingly, there was no relationship between total PVA during sleep and measures of sleep 
quality, which is not unexpected as there was no relationship between total PVA during sleep and the 
PVA induced arousal index at either initiation or post 3 months of HMV therapy.  Furthermore, there 
was no relationship observed between PVA during sleep and the time spent overnight in slow wave 
(stage 3) sleep and REM sleep. 
5.5.2 Critique of the Method 
All patients in this study, were ventilated in pressure support mode using the NIPPY3+ home 
mechanical ventilator (B&D Electromedical, Stratford-upon-Avon, UK).  As mentioned previously, the 
results from this study may be related to the operating characteristics of this ventilator and the 
frequency of PVA may not be applicable to other brands of home ventilator.  However, we considered 
it more important in this small detailed physiological study to accommodate for confounders, such as 
the triggering and pressure delivery system of the ventilator, by using only one brand of home 
ventilator. 
All patients were naïve to HMV and so the first night of HMV therapy is likely to be highly disruptive 
with patient being unfamiliar with the interface and pressure support along with increased anxiety 
levels impacting on sleep.  Due to the nature of initiation of HMV at the Lane Fox respiratory unit in a 
busy NHS service, patients have a short length of stay, but it may have been preferable to investigate 
the changes in sleep disruption relating to HMV following a short acclimatisation period, such as one 
week.  However, this was the first such study to investigate the relationship between patient ventilator 
asynchrony and arousal in patients with chronic respiratory failure and therefore it was most important 
  
- 184 - 
to establish the technique to integrate electroencephalography with electromyography to quantitatively 
assess PVA and arousal index. 
As the equipment burden on the patient was cumbersome, and at the request of the patient, we 
performed polysomnography without the pre-tibial electromyogram.  We acknowledge that although 
the relationship between periodic limb movements (PLMs) and patient ventilator asynchrony has not 
previously been investigated, in the current study it is not possible to confirm that all the arousals 
observed following an asynchronous event were not related to other stimuli, such as PLMs. 
We appreciate that discomfort from the polysomnography monitoring in the hospital environment may 
have impacted on the sleep quality.  This may, in part, explain the lack of improvement in sleep 
quality over the 3 months of HMV therapy.  Indeed, sleep quality measured in patients in the comfort 
of their home environment where this therapy is delivered may not be reflective of the overnight study 
in the hospital.  However, we asked the patients in the morning after each study if they slept 
adequately and the overall response from the patients was that they had achieved adequate sleep 
quality similar to the home environment.  Interestingly, a previous study that compared sleep quality in 
patients in the hospital and at home reported a deterioration of sleep quality in the home environment 
with increased air leaks occurring at the interface.(176) 
One caveat to the changes observed in TcCO2 is that the transcutaneous measurement of carbon 
dioxide may fluctuate from day to day related to skin preparation and limitations of the technology. 
Limited data are available on the natural variability of transcutaneous monitoring between consecutive 
overnight studies.   To overcome drift each overnight study was anchored to the patient’s arterial 
blood gas prior to sleep.  The CO2 sensor (stow-severinghaus electrode) was applied to patient by the 
same operator for all studies.  Furthermore, this method has be validated as a reliable monitoring tool 
in patients receiving HMV.(151)  
Arousals are to some extent arbitrarily defined as lasting more than 3 seconds and so the impact of 
PVA on microarousals (periods of PSG disturbance lasting less than 3 seconds) may be 
underestimated in this study and yet have cardiovascular consequences related to autonomic 
responses such as raised heart rate and blood pressure.(177)  In addition, arousals leading to sleep 
stage shift were not examined in this study which may also have impacted on sleep quality.  
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Relationship between patient-ventilator asynchrony and arousal 
The majority of PVA during sleep did not precede an arousal with only 8 (2-16) % of PVA at initiation 
of HMV and 8 (4-10) % of PVA at 3 months post HMV therapy occurring before an arousal according 
to our definition.  Nevertheless, because of the high frequency of PVA, this resulted in PVA preceding 
48% of all arousals observed at initiation and 47% of all arousals at 3 months post HMV therapy.  
Interestingly, there was no improvement in the frequency of total PVA during sleep or wakefulness 
following 3 months of HMV therapy and there was no change in the number of PVA preceding 
arousals over this period.  However, the proportion of PVA during sleep that resulted in an arousal, 
when normalised for the total PVA during sleep, fell from 8.6% to 5.6% and these data supports that 
although the total PVA during sleep may not fall, as in this study, the arousal threshold changes such 
that the PVA induced arousal index decreased.  This would support the suggestion that the patient 
adapts to the HMV albeit the frequency of asynchronous events remains high. 
We did not find a relationship between PVA occurring during sleep and measures of sleep quality 
including sleep efficiency, total sleep time and WASO at either initiation of HMV or post 3 months of 
HMV therapy.  To our knowledge, no such association has been demonstrated in any previous 
studies.  Work by Guo et al. comparing obesity hypoventilation patients with and without PVA 
overnight did not demonstrate any difference in total sleep time or sleep efficiency.  Neither could we 
demonstrate a correlation with PVA during sleep and the arousal index.  This conflicts with data from 
Bosma et al. and Crescimanno et al. who found a positive correlation between the total arousal index 
per hour and PVA per hour.(91, 176)  Patients in the study by Bosma et al, were weaning from 
invasive mechanical ventilation and examined on an ICU ventilator (Evita 4, Drager, Germany).(91)  
Patient ventilator interaction and threshold for arousals is likely to be very different in recovery from an 
acute illness compared to a stable elective setting. In addition, neither of these earlier studies 
examined electromyography as a marker of patient inspiratory effort.  Both Luo et al. and we have 
demonstrated that patient neural respiratory drive may occur without thorax excursion and so the 
proportion of PVA in both of these studies may have been underestimated.(109)  (See Chapter 4- 
4.4.3 clinical consequences of sEMGpara). 
The relationship between PVA and arousals remains complex.  Data from this study suggest that the 
majority of PVA (92%) do not precede arousals.  However, due to the high frequency of PVA 
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approximately half of all arousals were preceded by PVA with a very variable response between 
individuals.  Ineffective efforts were the most frequent PVA preceding an arousal followed by 
premature cycling and therefore may be the most appropriate PVA to target to improve sleep quality.  
Although very few PVA led to awakenings and no correlation of PVA arousal index with changes in 
sleep efficiency, wake after sleep onset and the total sleep time were demonstrated suggesting that 
overall little measurable related sleep disruption occurred.   However, the clinical impact of arousals 
that do not lead to sleep fragmentation on daytime symptoms is unclear. 
In view of the high frequency of PVA in this study, it is unclear if some of the associations with 
arousals in this study may represent an ‘epi-phenomenon’ and not a direct effect of the PVA.  We are 
also unaware if a single PVA is sufficient to result in an arousal or if many PVA may need to occur in 
quick succession to lead to sleep disruption.   Some studies examining PVA have chosen to only 
consider 3 consecutive breaths affected by PVA and others have stipulated that these must occur 
within a time frame of 10 seconds.(70, 176)  Although there remains no clear evidence, that one 
definition leads to more sleep disruption than another. It has also been suggested that cortical 
arousals may attenuate with recurrent arousing stimuli raising the arousal threshold for example in 
patients with OSA (177, 178).  It is likely that different patients may have different arousal thresholds 
and this may be further influenced by the levels of hypercapnia, sleep stage and underlying disease 
pathology.   In support of a sleep stage effect on arousals, both our work and Guo et al. have 
demonstrated that very few arousals occurred in slow wave and REM sleep.(70)   
Patient ventilator asynchrony in the awake state 
There was no relationship between PVA that occurred during the awake state and markers of sleep 
quality at initiation of HMV.  However, after 3 months of HMV therapy, a correlation was observed 
between the PVA during wakefulness and sleep latency, which suggests that the presence of PVA in 
the awake state may prevent the patient relaxing sufficiently to enter into sleep.  This effect may be 
more apparent post adaption to HMV as other external factors, such as anxiety and interface 
intolerance, are likely to impact on sleep latency on the first night of HMV therapy in naïve patients.  
PVA occurred more frequently during wake than sleep at both initiation and post 3 months of HMV in 
our patients, although this was not statistically different.  To our knowledge this is the first study to 
describe the high prevalence of PVA during wake overnight which was an unexpected finding.  These 
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high levels may relate to alterations in pulmonary mechanics when transitioning from sleep to wake 
with respiratory pathology or reflect patient anxiety when waking on HMV overnight.  
 
Nocturnal gas exchange and respiratory events 
There was no change observed in the 4% ODI or AHI following 3 months of HMV therapy.  As little is 
known about the night-to-night variation of these measurements in patients treated with HMV, the 
small individual fluctuations observed in this study may simply reflect this.  In untreated patients with 
upper airway pathology leading to sleep disordered breathing, 15% were demonstrated to have 
significant variability in AHI between two consecutive polysomnography assessments.(179) A study 
comparing gas exchange between a full face mask and a nasal mask on two consecutive nights in 
patients with hypercapnic respiratory failure did not find significant differences in mean oxygen 
saturations and transcutaneous carbon dioxide level.(180)  COPD patients demonstrated a larger 
reduction in 4% ODI than the NMD patients which is likely to relate to the high prevalence of 
concurrent obesity in COPD patients in this study.  A small increase in the AHI was observed in this 
group, which may represent underlying levels of alveolar hypoventilation that have been unmasked 
following treatment of the upper airway obstruction.  However, the accurate assessment and scoring 
of AHI is challenging in patients receiving HMV (34) and to accommodate for this all PSG studies 
were scored by the same experienced sleep technician (ID) in accordance with the somnoNIV 
definitions. 
Effect of HMV on sleep quality 
Few studies have objectively investigated the effects of HMV on sleep quality.  Most studies have 
been based on patient reported subjective improvements to sleep quality.(98, 181, 182)  Other 
studies have suggested that mechanical ventilation itself may result in severe sleep disruption related 
to ventilator induced central apnoeas and PVA.(70, 75, 174, 176)  One study that assessed sleep 
quality using PSG in ALS patients could not demonstrate improvements in sleep quality following 
HMV.(183)   
In our study, sleep efficiency was reduced at initiation of HMV and at 3 months, but with marked 
variation between individuals. This was similar to the sleep efficiency reported by Guo et al. in obesity 
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hypoventilation patients established on HMV.(70)  Sleep efficiency, total sleep time, sleep latency and 
wake after sleep onset did not improve in our patients following 3 months of HMV therapy.  In fact, a 
reduction in sleep efficiency was observed in 6 of the 9 patients studied.  The change in sleep 
efficiency in these patients was driven by a reduction in the total sleep time related predominantly to 
an increase in wake after sleep onset.  The reduction in sleep efficiency over time may relate to 
baseline sleep deprivation levels in some patients due to sleep disordered breathing prior to the 
initiation of HMV.  In support of this, 3 patients had a sleep latency of less than 15 minutes at initiation 
of HMV compared to 1 patient at 3 months post HMV therapy.  Alternatively, the deterioration in sleep 
efficiency may emphasise the poor sleep quality of patients on HMV which contradicts patient 
perception. 
Relationship between patient-ventilator asynchrony and sleep stage 
In accordance with previous studies, a higher incidence of PVA was observed during stage 1 and 2 
sleep compared to stage 3 slow wave sleep, which reached statistical significance post 3 months of 
HMV therapy.(70, 176)  However, in contrast to other studies we also found a higher prevalence of 
PVA in REM sleep compared to stage 3 sleep, although this did not reach statistical significance.  
There was no relationship observed between sleep stage and the four commonest types of 
asynchrony, with the exception of auto-triggering that was more commonly observed in stage 1 and 2 
light sleep at initiation of HMV.  This is the first study to evaluate the contribution of each asynchrony 
to sleep disruption.  Ineffective efforts led to the most arousals both at initiation of HMV and following 
3 months of HMV therapy followed by premature expiratory cycling.  Ineffective efforts were more 
likely to precede an arousal than multiple triggering which is likely to relate to the higher frequency of 
ineffective efforts observed overall.   
There were no changes observed in time spent overnight in different sleep stages between the first 
night of HMV therapy and 3 months post HMV therapy.  As reported earlier, PVA was more frequently 
observed in light sleep than slow wave sleep.   Similar results were observed by Guo et al, in stable 
obesity hypoventilation patients established on HMV (70), although we observed greater PVA in REM 
sleep than in slow wave sleep.  The latter may be a manifestation of the erratic changes in breathing 
patterns adopted by patients in REM sleep impacting on patient ventilator synchronisation. 
  
- 189 - 
COPD patients experienced more PVA during sleep than NMD patients both at initiation of HMV and 
3 months post HMV therapy.  Whereas, NMD patients experienced more PVA during wake than 
COPD patients.  COPD patients also demonstrated some improvement in PVA levels both during 
wake and sleep over time on HMV which was not observed in NMD patients.   
In agreement with work by Crescimanno et al. in neuromuscular patients, we found more auto-
triggering in light stages of sleep at the initiation of HMV.  PVA including auto-triggering have been 
correlated with increasing leaks on mechanical ventilation.(80, 89)  Crescimanno et al. hypothesised 
that increased amounts of auto-triggering may have resulted from higher levels of leak in non-REM 
sleep although a significant difference in unintentional leaks on NIV between sleep stages has not 
been established.(176, 184)  Adaption to the interface at initiation of HMV including the patient 
learning methods to control unintentional leak overnight may explain the increased levels occurring in 
light sleep in our study.  Interestingly, the proportion of auto-triggering occurring in stage 3 and REM 
increased following 3 months of HMV therapy which may suggest that patients adapt to leaks and 
sleep becomes less disrupted by auto-triggering following time spent on HMV.   
In contrast to Crescimanno et al and Fanfulla et al., we did not find a negative correlation between 
PVA and stage 3 or REM sleep.(75, 176)  However, the prevalence of PVA was higher in our study, 
which may relate to the extended analysis throughout the whole night used to identify PVA in the 
current study.  In addition, both of these earlier studies included only neuromuscular patients, 
whereas our study considered a heterogenous population, which limits comparison. (75, 176)  
5.6 Conclusion and clinical relevance 
These current data have shown that patient-ventilator asynchrony during sleep was high, but that the 
asynchronous events resulting in an arousal were much lower.  Indeed, if the arousals resulting from 
an asynchronous event are normalised for the total number of asynchronous events during sleep the 
proportion is low and falls even further following 3 months of HMV therapy supporting the concept of 
patient adaptation in terms of the arousal index.  In addition, there was a low conversion rate 
demonstrated from between asynchrony induced arousal and awakening, which was itself a very 
infrequent event.  There was no relationship between patient-ventilator asynchrony during sleep and 
sleep quality in terms of sleep efficiency, total sleep time, wake after sleep onset, arousal index or 
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time overnight spent in stage 3 or REM sleep.  This observation was made in the context of severe 
amounts of PVA according to current literature definitions.  
These data are reassuring to the clinician as although patient ventilator synchrony is common, 
arousals and waking overnight during HMV is much less common which supports HMV as a clinically 
useful tool that enhances nocturnal gas exchange, but not at the expense of sleep quality.  This 
challenges the current clinical opinion that patient ventilator asynchrony frequently results in arousal 
and sleep disruption.  Furthermore, these data suggest that detailed physiological or physician led set 
up set up for titrating HMV settings to achieve patient ventilator synchronisation during sleep may not 
lead to an improvement in sleep quality in the majority of patients and possibly should be targeted a 
specific patients who are unable to tolerate HMV.  We have previously shown that there was no 
relationship between patient ventilator asynchrony and overnight gas exchange and that observation 
can be extended to a lack a relationship between patient ventilator asynchrony and sleep quality.(79)  
From these data, it may be more clinically relevant to focus on enhanced patient ventilator 
synchronisation and comfort whilst the patient is awake and using HMV in order to facilitate sleep 
onset and this approach would be supported by the relatively low sleep efficiency in patients receiving 
HMV.  Finally, the clinical impact of arousals that do not lead to sleep fragmentation on daytime 
symptoms requires further investigation. 
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Chapter 6 The impact of inspiratory trigger delay on neural 
respiratory drive and the perception of comfort 
 
6.1 Introduction 
The inspiratory effort required to trigger the ventilator in the pressure support mode represents 10% to 
30% of the total breathing effort of the patient.(8, 44)  In addition, poor patient ventilator synchrony as 
a result of the triggering asynchrony adversely effects respiratory muscle unloading, increasing 
respiratory muscle oxygen consumption and negatively impacting on both the work of breathing and 
comfort of the patient.(8)  Furthermore, triggering asynchrony is common and frequently 
underestimated being associated with poor outcome in invasively mechanically ventilated patients in 
the intensive care unit.(77, 78) 
Trigger delays to ineffective efforts, represent extremes of a spectrum of triggering asynchrony and 
the distinction between meaningful trigger delays and ineffective efforts on clinical outcome is unclear.  
Ineffective efforts represent a triggering asynchrony with complete mismatch between the inspiratory 
effort of the patient and the pressure supported breath delivered by the ventilator and result in an 
increase in work of breathing, time spent with oxygen saturations below 90% and sleep disruption.(8, 
75, 76)  Trigger delay is the time between the onset of neural respiratory drive, demonstrated as the 
inspiratory muscle activity of the patient, and the delivery of a ventilator triggered pressure supported 
breath.  This can be a frequent event in chronic obstructive pulmonary disease (COPD) patients with 
evidence of intrinsic positive end expiratory pressure (PEEPi) and neuromuscular patients who fail to 
generate a sufficient inspiratory effort to trigger the ventilator as a consequence of respiratory muscle 
weakness.  Trigger delay has not been defined as a distinct type of triggering asynchrony, in part, 
because the optimal trigger response prior to an adverse impact on respiratory muscle unloading and 
clinical outcome, such as comfort, remains unclear.  Furthermore, the trigger delay tolerated by 
patients with different disease pathologies causing chronic respiratory failure may vary.  Thus, the 
clinical impact of trigger delay remains under recognised when assessing patient ventilator 
interaction. 
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Non-invasive ventilators vary in their performance characteristics with newer generation ventilators 
reporting enhanced triggering performance compared to older generation piston and turbine based 
ventilators.(185-187)   Stell et al. compared the trigger response of thirteen non-invasive ventilators 
on a lung model designed to reflect obstructive airways disease.(7) Inspiratory trigger delays were 
predominantly in the range of 120ms to 300ms with small proportion of the ventilators tested with a 
triggering delay time of less than100ms or more than 500ms.(7)  Interestingly, all of the studies 
comparing trigger performance of the ventilators have been performed in lung model bench studies 
with the assumption that a faster trigger response is beneficial to the patient resulting in a lower the 
work of breathing and greater patient comfort.(7, 188, 189)  To date there are no clinical studies, 
using subjective comfort and neural respiratory drive, in both healthy subject and COPD patients to 
determine the clinical effect of trigger delay. 
6.1.1 Study aims 
 We aimed to conduct a pilot study to investigate the relationship between trigger delay, self-reported 
comfort and respiratory muscle loading in both healthy subjects and COPD patients.  We also 




This study was approved by the local ethics committee and all patients provided written informed 
consent.  Healthy subjects without underlying lung disease or medical co-morbidities and COPD 
patients established on HMV were enrolled in the study.  All healthy subjects and COPD patients 
underwent spirometry testing, height and weight measurements and maximal inspiratory sniff 
pressure measurements.  Baseline neural respiratory drive measurements (sEMGpara) during stable 
tidal breathing were recorded over two minutes with participants seated in a chair at 45 degrees with 
their arms supported (as described in detail in material and methods chapter 2 -2.7.1).  Neural 
respiratory drive was also measured during a maximal inspiratory sniff manoeuvres.  To enable 
comparison between subjects neural respiratory drive, measurements were reported as a percentage 
of the maximum neural drive obtained from performing a maximal inspiratory manoeuvre 
(sEMGpara%max).  
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6.2.1 Measuring inspiratory trigger delay 
A custom-made NIPPY3+ ventilator (B&D Electromedical, Stratford-upon-Avon, UK) with an externally 
modifiable trigger delay was used.  An analogue signal was outputted from the ventilator when 
inspiratory effort was detected and when the ventilator delivered pressure to the airways. This 
analogue signal was converted to a digital signal using the Powerlab analogue to digital converter (AD 
Instruments, Chalgrove, Oxford) and recorded in concert with the assessment of participant and 
ventilator interaction. (Figure 64).  
Twenty different trigger delay settings were assessed in all participants ranging from 10ms to 
1000ms. Each study participant received non-invasive ventilation with a set trigger delay over a 2 
minute epoch. To ensure reproducibility each participant received the 20 trigger delay settings twice in 
a randomised order.  Sealed envelope randomisation was performed by an independent member of 
the research team.  All participants received non-invasive ventilation for 10 minutes prior to starting 
the study to acclimatise to the ventilator before any trigger delay was imposed.  During this time, 
adjustments to the mask interface were made to maximise comfort and minimise leak.  Leak was 
assessed from close examination of flow traces obtained at the mask during a breath hold performed 
at the end of expiration.  
Second intercostal parasternal surface electromyography was performed throughout the study (as 
described in material and methods chapter 2- 2.7.1). This was used as a marker of both the onset of 
inspiratory effort and the inspiratory muscle load imposed during each trigger delay setting.   Flow 
was measured through a heated Hans Rudolph pneumotach (flow 0-400L/min) (Shawnee, KS, USA) 
that was placed proximal to the exhalation valve in the ventilator circuit adjacent to the mask (Figure 
64).  The pneumotach was calibrated prior to each study using a standardised 3 litre volumetric 
syringe kept to within the recommended ±15ml error margin.(190)  Measurements of tidal volume 
were obtained ensuring less than a 3% variability between breaths as recommended by the ATS/ERS 
task force.(190)  Mask pressure was also recorded throughout the study as a marker of the ventilator 
response to subject triggering.  An example of these recordings obtained from a single subject at two 
trigger delay settings (50ms and 900ms) is demonstrated in Figure 65.   
In addition to measuring the peak sEMGpara%max during each 2 minute trigger delay epoch, the 
traces were closely examined to identify 5 breaths per epoch in which measurements of the time 
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between the onset of sEMGpara contraction and the activation of the ventilator flow trigger could be 
assessed.  
Transcutaneous capnometry and oximetry were measured throughout the study.  Transcutaneous 
carbon dioxide (TcCO2)  and oxygen saturations (SpO2) were controlled by changes in the driving 
pressure of the ventilator (inspiratory positive airways pressure) to maintain the TcCO2 and SpO2 
within the subject’s baseline values with the TcCO2 limit set at 0.5 kPa and SpO2 limit set at 4%.  This 
was primarily to minimise the influence of the hypercapnic and hypoxic drive to breathe. 
 
Figure 61: An example of the analogue delay output from the custom made NIPPY3+ ventilator 
measured in concert with the measures of patient ventilator interaction 
 
Legend:  *start of second intercostal parasternal muscle activity; **start of change in flow at the 
mouth generated by patient  
Abbreviations: sEMGpara- second intercostal parasternal surface electromyogram, RMS- root mean 
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Figure 63: An example of the raw traces obtained from a single COPD subject at a trigger 
delay of a) 50ms and b) 900ms demonstrating both the delay in the ventilator 
pressurisation and the increased parasternal muscle recruitment.  
 
 
Abbreviations: sEMGpara- second intercostal parasternal surface electromyogram, RMS- 
root mean square of the raw parasternal electromyogram signal, mV-millivolts, µV-




Measuring components of trigger delay 
The delay from the initiation of a breath by the patient to the delivery of the breath by the 
ventilator is made up of multiple components that can be measured: i) the intrinsic subject delay: 
from onset of neural respiratory drive to onset of inspiratory flow at the mouth, ii) the trigger 
sensing delay: from flow generation by the patient to ventilator triggering, iii) the enforced trigger 
delay: extrinsic trigger delay inserted for the purposes of this study and iv) the ventilator 
mechanical delay: the delay in delivering the breath to the patient once triggering has occurred.  
(See Figure 66).  Using our bespoke NIPPY3+ ventilator (B&D Electromedical, Stratford –upon-
Avon, UK) adapted to output an electrical signal when the ventilator sensed triggering had 
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delay occurred.  In this way, we could compare delays due to individual pulmonary mechanics or 
ventilator inefficiencies between the participants in our study.  
Figure 64: Components of trigger delay identified 
 
Legend: a-b: intrinsic subject delay; b-c: ventilator trigger sensing delay; c-d: enforced 
trigger delay; d-e: ventilator mechanical delay 
Abbreviations: sEMGpara- second intercostal parasternal surface electromyogram, RMS- root 
mean square of the raw parasternal electromyogram signal, mV-millivolts, µV-microvolts, L/s-litres 
per second. 
 
6.2.2 Non-invasive ventilator settings 
All the healthy subjects received NIV delivered by a modified NIPPY 3+ ventilator (B&D 
Electromedical, Stratford-upon-Avon, UK) in pressure support (PS) mode set with an inspiratory 
positive airway pressure (IPAP) of 12cmH2O and an expiratory positive airway pressure (EPAP) 
of 4 cmH2O.  A back up rate was set at 6 breaths per minute, the lowest possible on the NIPPY 




- 198 - 
all breaths from the ventilator. The inspiratory and expiratory trigger settings were set at 4 and 4 
as is the recommended manufacture settings.  
The COPD patients received NIV delivered by a modified NIPPY 3+ ventilator (B&D 
Electromedical, Stratford-upon-Avon, UK) in PS mode with an IPAP and EPAP set at the usual 
overnight settings of the patient. The back-up rate was also set at 6 breaths per minute, which 
was below the patient’s nocturnal ventilator setting rate to ensure that the patients triggered all 
breaths throughout the study. All COPD patients in this study received non-invasive ventilation 
with inspiratory and expiratory trigger settings set at 4 and 4 to standardise the study. 
 
6.2.3 Participant comfort measurements 
All study participants were blinded to the trigger delay settings asked to assess the perceived 
comfort of each setting using a 100mm visual analogue score (VAS) immediately post receiving a 
set trigger delay.  A score of 100mm represented total comfort and a score of 0mm represented 
total discomfort.  
6.2.4 Statistical analysis 
All data were non-parametric and is presented as median and inter-quartile range. Comparison of 
data between healthy subjects and COPD patients was performed using Mann-Whitney t-test. 
Spearman correlations were performed between trigger delay settings and participant outcome 
measures such as respiratory muscle loading or comfort scores. For all analyses, a p-value <0.05 
was considered statistically significant.   
 
6.3 Results 
6.3.1 Study Participants 
Fourteen healthy subjects were enrolled into the study with the baseline characteristics reported 
in Table 31.  Four COPD patients were enrolled into this study, their demographics are reported in 
Table 32.  COPD patients were older than the healthy controls (65 (61-68)years vs 35 (31-
42)years; p<0.001) with, as expected, more obstructive spirometry (FEV1 21 (15-23)% vs 101 (92-
117)%; p<0.0001), lower sniff nasal pressure (54 (39-69)cmH20 vs 77 (68-90)cmH20; p<0.004) 
and higher resting neural respiratory drive (11.1 (9.0-22.7)%max vs 6.1 (3.9-6.7)%max; p<0.01) 
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(Figure 67). There was no difference in the body mass index (BMI) between the COPD patients 
and the healthy subjects but, again as expected, COPD patients were more hypoxic and 
hypercapnic on room air prior to non-invasive ventilation (SpO2 94 (92-96)% vs 99 (99-100)%; 
p=<0.0001, TcCO2 7.4 (6.7-8.0) kPa vs 4.8 (4.5-5.3) kPa; p<0.0001, respectively). 
Table 31 Demographics of healthy subjects 
Results are expressed as median and standard deviation.  Abbreviations: yrs =years, FEV1= 
forced expiratory volume in 1 second, FVC= forced vital capacity, SNIP= sniff nasal inspiratory 
pressure, EMG= second intercostal parasternal electromyogram, TcCO2 =transcutaneous carbon 




Table 32: Demographics of COPD patients 
 
 
Results are expressed as median and interquartile range. Abbreviations: yrs =years, FEV1= 
forced expiratory volume in 1 second, FVC= forced vital capacity, SNIP= sniff nasal inspiratory 
pressure, EMG= second intercostal parasternal electromyogram, TcCO2 =transcutaneous carbon 
dioxide, M-male, F-female, kPa-kilopascals, kg/m2-kilogram per metre squared. 
 
No. Age Sex BMI FEV1% FVC% FEV1/FVC SNIP tidal EMG tidal EMG   Oxygen TcCO2
(n) yrs (M/F) kg/m2 ratio (%) cmH2O raw (mV) (%max) (%) (kPa)
1 32 F 24 127 139 79 79 5.4 4 99 4.5
2 27 F 20 83 93 78 60 2.6 6.2 100 4.6
3 28 F 20 92 100 81 67 14.3 8.4 100 4.8
4 63 F 30 145 148 81 91 2.8 6.7 100 4.8
5 32 M 27 109 106 80 73 4.3 6.4 99 4.8
6 49 F 19 101 114 76 70 4.6 7.1 99 4.9
7 59 M 25 133 120 87 93 5.7 4.4 99 5.3
8 28 M 22 114 107 91 96 5.9 6.7 100 4.2
9 34 M 25 94 94 83 68 4.1 5.9 99 5.4
10 39 M 23 82 73 93 64 2.3 3.3 100 5.5
11 32 F 22 113 128 77 84 4.4 6.6 100 4.5
12 36 M 23 100 90 75 88 2.7 3.7 99 4.5
13 39 F 21 100 93 94 74 4.6 2.8 99 5.1
14 35 M 26 92 97 79 89 6.4 4.7 98 5.4
Median 35 23 101 103 81 77 4.5 6.1 99 4.8
IQR (31-42) (21-25) (92-117) (93-122) (78-88) (68-90) (2.8-5.8) (3.9-6.7) (99-100) (4.5-5.3)
No. Age Sex BMI     FEV1% FVC% FEV1/FVC   SNIP tidal EMG tidal EMG   Oxygen TcCO2
(n) yrs (M/F) kg/m2 ratio (%) cmH2O raw (mV) (%max) (%) (kPa)
15 64 M 22 23 37 44 65 12.0       12.9          92 8.0       
16 69 M 26 23 45 47 43 23.1       9.3            94 7.0       
17 65 M 19 19 37 39 70 7.9         8.9            96 6.6       
18 60 M 24 14 37 31 38 28.5       25.9          93 7.8       
Median 65 23 21 37 42 54 17.6       11.1          94 7.4       
IQR (61-68) (20-26) (15-23) (37-43) (33-46) (39-69) (8.9-25.1) (9.0-22.7) (92-96) (6.7-8.0)
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Figure 65: Box and Whisker plots comparing sEMGpara%max in 4 COPD patients and 14 
































Data are represented with the mid line as the median, the box length representing the interquartile 
range and the whiskers as the minimum and maximum values. Abbreviation: sEMGpara%max-
surface second intercostal parasternal electromyogram normalised to a maximal inspiratory 
manoeuvre. 
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All COPD patients tolerated the full protocol of the study.  13 of the 14 healthy subjects managed 
the full study protocol; one subject discontinued due to claustrophobia 20 minutes into the study. 
Of the remaining 13 healthy subjects that completed the study protocol, all provided self-reported 
comfort data using a visual analogue scale, however, only 7 subjects had a sEMGpara signal that 
was analysable above noise levels throughout the whole study on ventilation; (#1, #3, #5, #6, #11, 
#13 and #14).  The healthy subjects that had an analysable signal throughout the study had a 
higher raw sEMGpara signal during tidal breathing compared to those healthy subjects where the 
raw sEMGpara signal was not able to be analysed when non-invasive ventilation was started,  
(17.6 (8.9-25.1) mV vs. 4.5 (2.8-5.8) mV; p=0.07). 
 
6.3.2 The effect of trigger delay on sEMGpara%max  
There was no difference observed in the sEMGpara%max between round 1 and round 2 in either 
the healthy subjects or COPD patients (p=0.99 and p=0.99, respectively).  In view of this the data 
presented in this chapter are the combined sEMGpara%max for both round 1 and 2 at each of the 
20 different delay settings. 
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Figure 67:  sEMGpara%max measured with increasing trigger delay settings in healthy subjects 





















































Table 33: Individual sEMGpara%max in response to increasing trigger delay in healthy subjects  
No. (n) 10 20 50 70 100 120 150 170 200 250 300 350 400 450 500 600 700 800 900 1000
1 2.2       2.4       2.4       3.2       2.4         2.9       2.4       2.7       2.5       2.5       3.0       2.9       3.2       2.4         3.1       2.8         2.8         3.0         3.1         2.8         
3 8.5       8.6       7.9       7.5       6.4         8.2       7.5       5.4       6.8       7.9       8.5       7.2       6.3       9.9         10.4     9.4         11.2       11.9       9.7         10.1       
5 6.1        8.9 6.9       7.0       11.3       10.0     7.4       7.3       9.9       6.8       7.2       7.5       6.2       8.5         7.4       13.0       6.5         8.5         9.9         8.7         
6 7.6       6.8       10.5     7.5       11.7       8.5       7.9       10.0     6.9       8.4       6.6       10.0     6.3       12.4       7.7       10.2       15.1       13.8       11.8       14.6       
11 8.8       9.9       9.9       10.5     8.1         8.9       8.4       8.7       8.8       9.4       10.9     13.4     8.9       11.1       13.1     11.2       10.3       14.1       11.7       20.8       
13 2.0       1.8       1.9       1.8       1.7         1.8       1.7       1.9       1.7       1.6       1.5       1.9       1.7       1.9         2.3       1.9         1.8         1.8         2.0         2.0         
14  3.2 3.2 4.5 3.5   3.8  3.3 3.3  3.4  3.6  3.4  3.9   3.6 3.6       3.8 3.6 3.3         4.6  3.9  3.8  3.9
Median 5.9       6.8       5.9       5.9       6.4         7.4       6.3       5.4       6.7       5.4       5.8       5.8       5.5       8.4         7.3       8.0         6.5         8.5         8.1         6.9         
IQR (2.5-8.1) (2.5-8.1) (2.4-9.7) (3.2-8.6) (2.5-10.5) (2.9-9.4) (2.6-8.2) (2.8-8.6) (2.6-7.8) (2.6-8.6) (3.1-8.7) (3.1-9.7) (3.1-7.1) (2.5-10.7) (2.9-9.2) (3.0-11.1) (2.8-10.8) (3.2-13.2) (3.3-11.6) (2.8-14.5)
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Table 34:  Detailed individual sEMGpara%max response to 20 increasing trigger delay settings (ms) in 4 COPD patients combined 
 
No statistically significant difference was observed between neural respiratory drive between any of the 20 trigger delay settings in healthy subjects (p>0.99).No 
statistically significant difference was observed in this study between neural respiratory drive levels at any of the 20 trigger delay settings in COPD patients (p>0.99). 
No 10           20             50           70            100        120          150        170        200           250        300         350          400        450          500          600          700          800          900          1000
15 53.7        41.0          35.6        49.7         29.5       42.4         36.5       46.3       44.0          39.7       42.6        40.4         43.1       51.4         45.6         47.8         42.0         55.1         67.2         61.1         
16 15.8        15.0          10.4        14.7         14.1       17.5         13.9       12.3       13.8          13.2       16.1        15.8         16.4       17.6         14.3         15.1         17.5         19.7         19.2         22.1         
17 5.9          8.4            7.4          10.7         6.0         8.3           6.6         9.5         9.1            8.8         8.0          9.0           7.9         10.2         8.3           13.0         10.7         13.2         12.9         10.7         
18 23.0        26.7          27.0        25.0         30.6       30.5         20.3       25.8       30.2          28.6       33.1        29.1         29.1       28.9         31.6         28.2         35.1         40.5         37.0         42.0         
Median 18.3        20.8          16.7        20.2         15.7       23.6         17.9       19.2       21.5          20.4       25.3        22.2         23.1       24.7         23.7         23.5         23.6         31.9         30.3         33.1         
IQR  (7.9-45.3)  (11.8-36.4)  (8.4-33.2) (12.8-40.9) (8.8-31.0) (12.1-33.2) (8.4-26.3) (9.4-39.4)  (12.9-37.9) (9.4-34.4)  (9.4-34.4) (10.4-31.8) (9.7-36.0) (11.1-40.2) (10.7-40.7) (12.4-40.2) (12.6-36.0) (13.0-36.0) (12.8-58.4) (10.8-43.5)
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6.3.3 Respiratory muscle loading in healthy subjects and COPD patients with increasing 
trigger delay  
 
Compared with self-ventilating healthy subjects increased respiratory muscle loading was 
consistently demonstrated with inspiratory trigger delays above 450ms.  More variability in 
respiratory muscle loading was observed in round 1 than round 2.  (Figure 71). 
Figure 69: Respiratory muscle loading and unloading in healthy subjects on non-invasive 
ventilation with increasing trigger delay 
 































































































































Patients with COPD did not achieve respiratory muscle unloading on non-invasive ventilation with 
trigger delay. Even with small trigger delays COPD patients demonstrated an increased in 
respiratory muscle recruitment compared with self-ventilation.  (Figure 72). COPD patients 
experienced increased respiratory muscle loading than healthy subjects at all trigger delays. 
a) Round One  
b) Round Two  
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Furthermore, as expected, the longer the trigger delay the larger the increase in respiratory 
muscle loading observed, although this did not reach statistical significance.  
 
Figure 70: A graph of respiratory muscle loading and unloading in COPD patients on non-

































































































































































a) Round One  
b) Round Two  
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6.3.4 The effect of trigger delay on comfort scores 
 
Healthy Subjects 
There was no significant difference observed between the comfort scores obtained in healthy 
subjects in round 1 and round 2 at any of the ventilator delay settings.  Combining the comfort 
scores from both rounds together, a peak median comfort scores of 84 (62-92) and 84 (67-88) 
were measured at 120ms and 150ms trigger delay, respectively.  Longer and shorter trigger 
delays were increasingly more uncomfortable.  The least comfortable trigger delay setting was 
measured at 1000ms with a combined median comfort score of 58 (33-76). (Figure 73a). 
. 
A significant difference was shown between the comfort settings (1-way ANOVA, p<0.001). 
Comfort scores at 50ms, 120ms, 170ms and 200ms trigger delays were significantly more 




There was no difference observed between the comfort scores recorded by COPD patients at 
different trigger delay settings in round 1 and round 2. Combining the comfort scores for round 1 
and 2 together, COPD patients perceived increased comfort at shorter trigger delay settings, with 
a peak median comfort score of 84 (66-91) at a trigger delay of 10ms.  A reduction in comfort 
scores was observed at longer trigger delays in COPD patients with maximal discomfort detected 
at 1000ms trigger delay.  
A statistically significant difference was shown in combined comfort scores between the trigger 
delay settings (p<0.0001), investigating the differences (Dunn’s multiple comparisons tests) this 
was driven by a difference between comfort scores at 10ms; comfort score 84 (66-91) and 
1000ms; comfort score 26 (19-59) respectively. (Figure 73b). 
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Data shown as median and IQR 
6.3.5 The relationship between respiratory muscle loading and perception of comfort 
When considering which factors are driving the perception of comfort or discomfort in this study, 
we analysed the relationship between respiratory muscle loading (defined as increasing 
sEMGpara%max) and comfort scores.  Analysing those subjects for which respiratory muscle 
electromyography was available, respiratory muscle loading (mean sEMGpara%max) was shown 
to be negatively correlated with mean comfort perception in both healthy subjects and patients 
with COPD.  (Figures 74 and 75). 
 
Figure 72: Relationships between mean comfort perception and respiratory muscle loading 
in healthy subjects during a) round one and b) round two 
 















































Abbreviations: sEMGpara%max-surface parasternal electromyogram normalised to a maximal 
inspiratory manoeuvre.   
p<0.0001, rs= -0.77 p=0.0003, rs= -0.73 
a) b) 
p<0.0001 
p<0.001 a) b) 
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Figure 73: Relationships between mean comfort perception and respiratory muscle loading 
in COPD patients during y a) round one and b) round two 
















































Abbreviations: sEMGpara%max-surface parasternal electromyogram normalised to a maximal 
inspiratory manoeuvre.   
 
 
6.3.6 Considering the components of the trigger delay 
Intrinsic subject delay was significantly longer in patients with COPD than healthy subjects.  
However, trigger sensing delay was significantly longer in healthy subjects compared to patients 
with COPD.  Overall, this led to a longer total delay between the initiation parasternal muscle 
electrical activity and the delivery of pressure support by the ventilator in healthy subjects.  There 
was no significant difference between the ventilator mechanical delay between COPD patients 








p=0.04, rs= -0.46 p<0.0001, rs= -0.85 
a) b) 
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Table 35: Breakdown of trigger delay (excluding enforced trigger delays) in both healthy 
subjects and COPD patients 
                                    Healthy Subjects           COPD patients                     p-value 
Component of 
trigger delay  
Time (ms) Time (ms)  
i) Intrinsic subject 
delay 
115 (78-144) 129 (104-156) p<0.001 
ii) Trigger sensing 
delay 
177 (109-266) 112 (96-122) p<0.001 
iv) Ventilator 
mechanical delay 
50 (30-70) 36 (30-48) p=0.21 
Total delay 362 (274-432) 279 (248-308) p<0.001 
 
 
279 (248-308) milliseconds of the total inspiratory time of the COPD patients was made up of 
delays in interacting with the ventilator. This is equivalent to 16 (13-19) % of the time that the 
parasternal inspiratory muscles are activated, during which time there is no pressure support 
being provided from the ventilator.  The largest component of inspiratory delay in COPD patients 
was related to the intrinsic delay between initiation of the parasternal muscle electrical activity and 
generating inspiratory airflow at the patient’s mouth 7 (6-9)% of inspiratory time. (Table 36).  
Healthy subjects have less overall delay 14 (11-19)% as a proportion of time that the parasternal 
muscles are activated.  For healthy subjects the longest inspiratory delay is related to the trigger 
sensing delay which is responsible for 7 (4-11)% of the total neural inspiratory time.  
Reassuringly, the ventilator mechanical delay was similar in both COPD patients and healthy 
controls, responsible for just 2% of the overall neural inspiratory time.  
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Table 36: Impact of trigger delays on the total inspiratory time: percentage of time for 
which unrewarded parasternal respiratory muscle activity occurs 
 Healthy Controls COPD patients 
Trigger delays as a 
percentage of the total 
neural inspiratory time  
  
Intrinsic delay (%)  4 (3-6) 7 (6-9) 
Trigger sensing delay (%)  7 (4-11) 6 (5-8) 
Ventilatory mechanical 
delay (%)  
2 (1-3) 2 (1-3) 
Total delays (%)  14 (11-18) 16 (13-19) 
 
In an effort to explain the differences observed between the intrinsic delay and the trigger sensing 
delay between healthy subjects and COPD patients further we investigated the breathing 
characteristics of each study participant whilst on non-invasive ventilation.  We could demonstrate 
that COPD patients had a statistically significant shorter neural inspiratory time than healthy 
subjects during the study (p<0.001), despite the enforced extension of inspiratory time related to 
trigger delay.  In keeping with this the respiratory rate of the COPD patients was faster than the 
healthy subjects whilst receiving NIV (p=0.02).  The rate of change of inspiratory flow generated 
by COPD patients was greater than that achieved by healthy subjects (p<0.001). The 
unintentional leak recorded at the mask was not significantly different between the groups of 
participants.   
Neuroventilatory efficiency was significantly reduced in COPD patients indicating that increased 
respiratory muscle recruitment is required to generate a tidal volume (p<0.0001).  However, the 
percentage of neural time used to generate inspiratory flow was similar between participants.  
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2368 (2021-2902) 1783 (1540-2072) <0.001 
Inspiratory flow 
time per neural 
inspiratory time 
(%) 
80 (68-90) 82 (73-93) 0.06 
Inspiratory flow 
rate (L/s) 




136 (98-161) 34 (25-99) <0.0001 
Mask leaks 
(mL/s) 
25 (19-50) 26 (19-57) 0.80 
Respiratory rate 
(n/min)  
11 (11-12) 13 (12-14) 0.02 
Abbreviations: COPD=chronic obstructive pulmonary disease, ms-milliseconds, L/s-litre per 
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Figure 74:  Change in a) inspiratory flow rate b) tidal volume and c) inspiratory time 





































































































1 0 0 0
1 5 0 0















































1 0 0 0
2 0 0 0
3 0 0 0









Abbreviations: copd-chronic obstructive pulmonary disease patients, healthy- healthy subjects, 
ms- milliseconds, ml-millilitres, L/s-litres per second. 
  
A significant reduction flow rate was observed in COPD patients between 10ms and 1000ms 
inspiratory trigger delays (p=0.008).  This was driven by the increase in inspiratory time rather 
than any limitation of the tidal volume.  Healthy subjects had much slower inspiratory flow rates at 
10ms trigger delays compared to COPD patients (p<0.0001). 
There was no difference in the coefficient of variation between healthy and COPD subjects in 
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three-fold difference was observed between the coefficient of variation in tidal volume between 




6.4.1 Main findings 
The current study was supportive of previous data in the literature suggesting that 
sEMGpara%max is higher in COPD patients than healthy controls during resting breathing.(132)  
In addition, this study demonstrated that respiratory muscle activity is not effectively unloaded 
whilst on non-invasive ventilation with trigger delay in COPD patients, whereas healthy subjects 
achieve consistent respiratory muscle loading only when a trigger delay of 450ms was imposed.  
There was no difference in neural respiratory drive, as measured by sEMGpara%max, with 
increasing trigger delays in healthy subjects with only a 1% increase in neural respiratory drive 
between 10ms and 1000ms trigger delay.  Furthermore, there was no difference observed in 
respiratory muscle loading with increasing trigger delay in COPD patients, albeit the neural 
respiratory drive increased from 18.3% (7.9-45.3%) at 10ms delay to 33.1% (10.8-43.5%) at 
1000ms delay.  These findings suggest that COPD patients that already have substantial loading 
of the respiratory muscles are less able to cope with the extra workload placed upon the 
respiratory system from an inspiratory trigger delay than healthy subjects. 
Comfort scores were inversely related to neural respiratory drive in both healthy and COPD 
subjects, supporting the hypothesis that that increased respiratory muscle loading causes poorer 
perception of comfort whilst receiving non-invasive ventilation.  Previous studies have 
demonstrated a close direct correlation between exercise induced perception of breathlessness 
and the levels of neural respiratory drive measured by respiratory muscle electromyography in 
patients with COPD and cystic fibrosis as well as healthy controls.(127, 191, 192)  As a simple 
bedside monitoring tool, measuring sEMGpara%max could be used to assess patient comfort 
whilst receiving non-invasive ventilation overnight and assist the physician in tailoring settings to 
improve individual patient-ventilator interaction.  Such an approach has recently been 
demonstrated in patients on the general intensive care unit receiving invasive mechanical 
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ventilation and could conceivable act as a physiological biomarker of patient comfort on non-
invasive ventilation.(193)  
6.4.2 Critique of the method 
Measurement of neural respiratory drive, using sEMGpara, in healthy individuals receiving non-
invasive ventilation is challenging.  In this study, we have demonstrated that measurable raw 
sEMGpara signals above the level of electrical noise were only possible in half of the healthy 
subjects recruited following application of non-invasive ventilation.  The small number of 
participants with fully analysable sEMGpara data could have resulted in a type 2 error in the 
neural respiratory drive analysis with increasing trigger delays.  This study was, however, 
performed as a feasibility study to identify if COPD patients could tolerate being subjected to 
trigger delays whilst receiving non-invasive ventilation and to better understand the components 
of trigger delay facing patients during their interaction with non-invasive ventilation. 
Every effort was made to ensure that participants were seated comfortably at 45 degrees with 
their arms and back well supported during the study in a posture that has previously been 
validated when obtaining sEMGpara%max measurements.(124)  Due to the 2.5 hour length of the 
study, it is possible that posture varied slightly, which may have influenced the parasternal signal 
recordings. The electrodes were not removed between the two runs of the protocol and the 
recordings were visually inspected to exclude motion artefact in the analysis.  
Although a thirty minute break from the ventilator was taken by each participant between round 1 
and round 2 of the trigger delay protocol, the levels of neural respiratory drive observed in the 
second round may have been influenced by the previous hour on non-invasive ventilation.  
Reassuringly, there were no differences in the neural respiratory drive measured at the different 
20 trigger delay settings between the two rounds in either health controls or COPD subjects. For 
this reason, it was reasonable for the results from round 1 and round 2 to be combined.  
Although the trigger delay settings were randomly assigned, it is possible that comfort perceived 
by the subjects participating in this study was influenced by the previous trigger settings.  
Furthermore, healthy subjects may have acclimatised more to non-invasive ventilation in the 
second round impacting on their perception of comfort.  For this reason, we repeated the study 
twice and reassuringly found that there was no difference in the comfort scores obtained between 
round one and round two when the order of trigger delay settings were different. 
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As discussed previously, the sEMGpara%max is based on the peak EMG activity of the 
parasternal muscle normalised for the EMG activity during a maximum sniff manoeuvre.  This 
may not be wholly reflective of the total parasternal inspiratory muscle activity.  An improvement 
on the current measurement would be to measure the area under curve of the EMG, however 
currently the electrocardiogram (ECG) artefact makes this not possible.  Developments are 
currently underway with complex signal processing to remove ECG artefact from the parasternal 
signal but this is beyond the scope of this thesis. 
Unintentional mask leak was measured in all subjects at the beginning of each round of trigger 
delay settings.  The mean of three independent measurements obtained during a breath hold 
manoeuvre in end expiration were reported in this study.  Every effort was made to ensure that 
leaks from the mask were addressed by the research team throughout the studies as they 
occurred.  Leak is a dynamic process and so it is possible that higher levels of leak may have 
occurred during the study that would have independently interfered with the ventilator inspiratory 
trigger sensing.  
The ventilator pressure support applied to all healthy subjects was the same.  As not all healthy 
subjects were the same age and height similar pressures may have resulted in either suboptimal 
tidal volumes or overinflating the respiratory system.  For a future study it may be more 
appropriate to use a set ml/kg ideal body weight for each participant.  Finally, we must 
acknowledge that the healthy subjects were not age and gender matched to the COPD patients.  
Thus, differences in neural respiratory drive observed in the COPD patients may have been, in 
part, as a result of the healthy subjects being younger and female, than their COPD counterparts.   
 
6.4.3 Respiratory muscle response to increasing inspiratory trigger delays on non-invasive 
ventilation 
COPD patients experience expiratory flow limitation with associated static and dynamic 
hyperinflation and intrinsic positive end expiratory pressure.  These adverse pulmonary 
mechanics lead to respiratory muscle mechanical disadvantage and increased loading of the 
respiratory muscles, which in turn leads to increased neural respiratory drive as more muscle 
fibres are recruited to cope with the load placed upon them.(45, 46, 194)  Direct output from the 
respiratory centres in the brainstem is difficult to measure but neural respiratory drive can be 
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measured indirectly through the respiratory muscle electromyogram that provides a method of 
assessing the level of muscle activation and recruitment required to meet the load placed upon 
the respiratory muscles. 
The main aims of non-invasive ventilation include the correction of hypoventilation and to assist 
the respiratory muscle unloading.(53, 195)  Inappropriate ventilator settings, may result in ‘under-
assistance’ of the respiratory muscles or ‘over-assistance’ which can lead to PVA.(13, 148)  Both 
of these situations may counterproductively increase the load upon the respiratory muscles and 
lead to an increase in neural respiratory drive in the extra-diaphragmatic respiratory muscles.  
This is often a dynamic process and so monitoring the levels of neural respiratory drive can guide 
the physician in optimising ventilator settings on an individual patient basis.(13)   
Examining the change in neural respiratory drive between baseline self-ventilating and whilst on 
non-invasive ventilation suggests that healthy subjects achieve enhanced respiratory muscle 
unloading on non-invasive ventilation  at trigger delays below 450ms, whilst all the COPD patients 
experienced an increase in respiratory muscle loading on non-invasive ventilation  with even a 
short trigger delay. It is most likely that healthy subjects have increased capacity within their 
respiratory system to better tolerate the increasing load of trigger delay placed upon them.  COPD 
patients are already facing considerable loads upon their respiratory system related to the 
underlying pathophysiology and so would naturally tolerate further unrewarded inspiratory efforts 
less well.   
A final important consideration when understanding why COPD patients failed to effectively 
unload the respiratory muscles on non-invasive ventilation is the operating mechanics of the 
NIPPY3+ ventilator (B&D Electromedical, Stratford-upon-Avon, UK).  The NIPPY3+ ventilator 
(B&D Electromedical, Stratford-upon-Avon, UK) is triggered in inspiration by the patient 
generating a threshold level of ‘a rate of change of flow’ at the mouth. The trigger settings on the 
ventilator range from 1-10 (10 most difficult) and are not a linear scale.(196)  The trigger 
sensitivity settings for this study were set at the manufactures default of 4 for both inspiratory and 
expiratory triggering for consistency, which are also the settings used in our clinical practice.  The 
rate of change of flow required to trigger the ventilator at different settings remains proprietary 
information.  It is therefore possible that an inspiratory trigger setting of 4 is too insensitive for 
COPD patients resulting in the increasing sEMGpara%max whilst on NIV.  
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6.4.4 Patient comfort with increasing inspiratory trigger delays on non-invasive ventilation 
Previous work by Vignaux et al, in acute respiratory failure suggested an association between 
impaired patient comfort as measured by a visual analogue scale and increased amounts of PVA 
on NIV.(89)  Ventilator inspiratory trigger delays are known to increase the work of breathing, as 
respiratory muscles are activated for an extended period without receiving ventilatory support 
from the ventilator.(8)  This would intuitively be less well tolerated by the patient resulting in the 
perception of discomfort.  Patient comfort on NIV is often dependent on many factors such as 
mask tolerability, humidification, anxiety levels, the rate of ventilator pressurisation as well as 
patient ventilator synchronisation.(89, 197-199)   
 
Healthy subjects were most comfortable on NIV with inspiratory trigger delays in the range of 120-
150ms. Comfort declined with increasing trigger delays to a maximal discomfort at 1000ms. 
Interestingly, very short trigger delays were also more uncomfortable for healthy participants.  
Trigger delay was well tolerated in healthy subjects, perception of comfort only fell 10 points 
below the peak comfort score when the inspiratory trigger delay exceeded 450ms. As the trigger 
delay increased, a wider IQR was observed suggesting more individual variability between in 
comfort perception at longer trigger delays. 
COPD patients were most comfortable at the shortest inspiratory trigger delay setting of 10ms 
and as expected most uncomfortable at the longest trigger delay setting of 1000ms.  An 
inspiratory trigger delay of 1000ms was much less well tolerated by COPD patients than by 
healthy controls with a median comfort score of 26 (19-59) vs 58 (33-76).  Post an inspiratory 
trigger delay setting of 150ms comfort scores declined with increasing trigger delay settings. 
For both healthy subjects and COPD patients comfort scores were negatively correlated with 
increasing sEMGpara%max signals.  This finding demonstrates that increased respiratory muscle 
loading is related to a poorer perception of comfort whilst on non-invasive ventilation and 
importantly could be used as a tool to review the impact of changes in ventilator settings to 
optimise comfort for awake patients on non-invasive ventilation. 
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Patient comfort on non-invasive ventilation has not previously been directly associated with the 
levels of neural respiratory drive and respiratory muscle recruitment. Breathlessness has been 
closely linked to levels of neural respiratory drive in COPD and cystic fibrosis patients which may 
well explain the close link with comfort scores.  However, this is the first study to suggest that 
sEMGpara%max may also be a biomarker for patient comfort on non-invasive ventilation.  
 
6.4.5 Components of trigger delay  
In this study, both healthy subjects and COPD patients spent approximately 15% of their neural 
inspiratory time made up of delays in interacting with the ventilator, excluding the enforced trigger 
delays imposed by the research team.  In this way, for almost a sixth of the time parasternal 
inspiratory muscles are activated, there is no ventilatory support being provided to the respiratory 
system from the ventilator. This results in an increase in the work of breathing without assistance 
in gas exchange. This is similar to work by Aslanain et al, that demonstrated in PSV mode of 
ventilation the effort required to trigger the ventilator represents 10–20% of the total breathing 
effort.(44)  COPD patients had shorter inspiratory trigger delays than healthy controls in terms of 




The inspiratory trigger delay in healthy subjects was driven predominantly by an increase in the 
ventilator trigger sensing delay, accounting for 7% of the neural inspiratory time. (Table 36). The 
NIPPY3+ employs a flow inspiratory trigger which detects inspiratory effort when the inspiratory 
flow rate exceeds a level set by the inspiratory trigger.(196)  The individual flow rates for different 
trigger settings are not in the public domain.  
Examining the healthy subjects’ interaction with the ventilator in more detail we were able to 
demonstrate that measured leak from the mask was similar in COPD patients and healthy 
controls, excluding this as a significant cause of the trigger sensing delay observed. However, 
inspiratory flow rates on NIV were much slower in healthy subjects (Table 37) hence crossing the 
threshold to trigger the ventilator may have been more challenging, increasing the inspiratory 
triggering delay at this stage.  
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Inspiratory flow rates in healthy subjects, did not significantly change between 10ms and 1000ms 
trigger delay settings (Figure 76).  
Intrinsic patient delays were as expected shorter in healthy subjects than in COPD patients due to 
improved pulmonary mechanics and accounted for 4% of the neural inspiratory time.  
Ventilator mechanical delays were longer in healthy subjects in terms of time than the COPD 
patients. Excluding any interference from dynamic leak, this suggests that there is some variability 




COPD patients had longer intrinsic patient delay compared to healthy subjects. (Table 36).  This 
is explained by the complex pulmonary mechanics observed in COPD patients.  Pulmonary 
hyperinflation results from gas trapping in the small airways due to the obstructive airways 
disease in COPD, which consequently leads to flattening of diaphragm and mechanical 
disadvantage of the respiratory muscles.(194, 200)  For inspiratory flow to occur and trigger the 
ventilator, the pressure at the alveolar must be lower than the pressure at the mouth. 
Mechanically disadvantaged inspiratory muscles leads to a delay in those muscles achieving the 
change in volume in the thorax required by muscle contraction to generate flow at the mouth. In 
addition, COPD patients also have a threshold load of intrinsic positive end expiratory pressure 
place upon them which must be overcome, leading to yet more delays.(194)   Consequently, the 
respiratory muscle pump must work much harder and often contract for longer prior to generating 
a negative alveolar pressure and facilitating the start of inspiratory flow.(8, 57)   
These findings also suggests that our focus as physicians, should be in correctly off-setting 
intrinsic positive end expiratory pressure (PEEPi) with appropriate levels of EPAP and using 
pharmacotherapeutics such as bronchodilators to optimise obstructive airways disease in COPD 
patients.  Thereby reducing, the mechanisms contributing to intrinsic patient delays. Alternative 
strategies are to avoid ‘over-assistance’ with high levels of pressure support which can increase 
tidal volumes, dynamic hyperinflation and elevate intrinsic PEEP levels(13).  A balance of all 
these factors when setting up NIV is hard to achieve and demonstrates the role of non-invasively 
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monitoring NRD which can provide us with a unique visual feedback of the balance we are 
achieving.  
Lastly, when considering the interaction with the patient and the inspiratory trigger it is important 
to ensure that the optimal triggering mechanism is employed.  Conventional non-invasive 
ventilators now use flow-based inspiratory triggers following work that suggested it shortened time 
delays compared to earlier pressure-based inspiratory triggers.(201) However, further studies 
have shown that replacing pressure-based triggers with flow-based triggers did not reduce wasted 
patient efforts.(58)  Studies have recently shown that analysing interruptions in flow signals ‘the 
shape-signal’ trigger method resulted in less wasted efforts by the patient than flow-based 
triggering systems.(202) Although the cost of this heightened inspiratory trigger sensitivity, was 
more auto-triggered breaths.(202)  Neurally based triggers using electromyography may be a real 
alternative to the traditional triggers and have shown to substantially reduce inspiratory triggering 
asynchrony during non-invasive ventilation.(141) 
 
Patient ventilator Interaction during trigger delay 
Healthy subjects demonstrated longer overall neural inspiratory times and slower inspiratory flow 
rates than COPD patients on non-invasive ventilation. In keeping with this, respiratory rates on 
NIV were also slower in healthy subjects.   
Inspiratory flow was generated at the mouth by both COPD patients and healthy controls for 
approximately 80% of the total neural inspiratory time.  This suggests however, that for 20% of 
parasternal muscle activity no detectable inspiratory flow occurred indicating significant 
inefficiencies in both subject groups. Inspiratory flow rates generated by COPD patients also 
decreased with increasing inspiratory trigger delays. This was driven predominantly by the 
increase in inspiratory time rather than any limitation of the inspiratory volume. (Figure 76).  
However, examining the coefficient of variation in tidal volume between COPD patients and 
healthy controls suggest that the tidal volume is related fixed in COPD patients whereas healthy 
subjects have a substantially increased capacity to vary their tidal volume.  
The reduction in flow rates at increased trigger delays in COPD patients acts as a double 
disadvantage.  These patients already have a substantial intrinsic delay and a lower flow rate will 
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increase the trigger sensing delay.  Inspiratory triggering will therefore become more difficult at a 
point when the external enforced trigger delay is longest.   
Neural-ventilator efficiency has been defined as the tidal volume generated per microvolt of 
electrical activity detected from the respiratory muscles.(203) It equates to the efficiency of the 
respiratory system and the ability of a subject to convert neuromuscular activity into tidal 
volume.(204)  Neural-ventilator efficiency on non-invasive ventilation was significantly greater in 
healthy patients. This was to be expected due to the many threshold loads placed upon the 
COPD patient in relation to airways obstruction and positive end expiratory pressure described 
above that were not overcome by non-invasive ventilation in the presence of inspiratory trigger 
delay.  
No difference in unintentional leak at the mask measured at the end of expiration was 
demonstrated between healthy subjects and COPD patients.  
 
6.4.6 Applicability of measuring sEMGpara%max in healthy subjects 
This study is similar to the study findings in Chapter 3, and demonstrates that measuring 
sEMGpara may not be achievable in all healthy subjects.  Clearly using non-invasive ventilation in 
healthy subjects that do not require ventilatory assistance is an unnatural state.  The sEMGpara 
signal therefore appears to be most useful when elevated in subjects with an impairment in load 
capacity balance. Unloading a respiratory system that is not stretched is likely to reduce 
parasternal activity to an unreportable signal below noise levels. Being unable to define the 
sEMGpara ranges for the normal population may limit the applicability of this as an assessment of 
lung function for the future.  It is clear that we must define the upper limits of a ‘normal sEMGpara 
signal’ as it is an elevated signal that is most suggestive of a deleterious outcome.  The main 
utility of sEMGpara%max is likely to be in longitudinal monitoring of an individual.   
 
6.4.7 Clinical significance of the findings 
COPD patients were most comfortable at the shortest inspiratory trigger delay of 10ms.  A 
reduction in comfort scores was observed at longer trigger delays in COPD patients with maximal 
discomfort detected at 1000ms trigger delay.  Healthy subjects tolerated inspiratory trigger delay 
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better than COPD patients and were most comfortable at trigger delays of 120-150ms.  Similarly 
to COPD patients, maximal discomfort was observed in healthy subjects at an inspiratory trigger 
delay of 1000ms.  Every effort should therefore be made to minimise inspiratory trigger delays in 
COPD patients to maximise patient comfort whilst on NIV.  
Patient comfort on NIV in this study was negatively correlated with increasing sEMGpara%max.  
This suggests that sEMGpara%max could be used as a useful non-invasive marker in awake 
patients on NIV to monitor both respiratory muscle unloading and patient comfort.  
COPD patients in this study did not achieve respiratory muscle unloading compared to self –
ventilation in the presence of inspiratory trigger delays.  Physicians should therefore focus on 
minimising inspiratory trigger delays to reduce the work of breathing for COPD patient on NIV.  
The largest component of inspiratory trigger delay in COPD patients related to intrinsic subject 
delay accounting for 7 (6-9)% of neural inspiratory time.  All those facilitating the setup of NIV in 
COPD patients must therefore take time to ensure that obstructive airways disease and EPAP 
levels and bronchodilator therapy are optimised first to enable good patient ventilator interaction. 
 
6.5 Conclusion 
In this study, parasternal muscle activity did not increase with increasing inspiratory trigger delay 
in either COPD patients or healthy subjects.  This finding was however limited by the small 
number of participants with analysable sEMGpara%max.   Parasternal muscle unloading was not 
achieved in patients with COPD on NIV in the presence of trigger delay.  Consistent parasternal 
muscle loading occurred at trigger delays above 450ms in healthy subjects.  
Patient comfort was lower with increasing trigger delays in both healthy subjects and COPD 
patients.  Maximal comfort was achieve at the shortest trigger delay (10ms) in COPD patients but 
at longer trigger delays in healthy subjects (120ms and 150ms).  
Finally, patient comfort negatively correlated with respiratory muscle loading in both healthy 
subjects and COPD patients.  sEMGpara%max may conceivably be used as a non-invasive 
marker of patient comfort on NIV.   
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Chapter 7 Conclusion 
7.1 Utility of sEMGpara%max measurements  
7.1.1 sEMGpara%max as a marker of NRD in patients and healthy subjects 
sEMGpara%max as a marker of neural respiratory drive is a useful non-invasive tool to monitor 
patients with respiratory failure and was reliably obtainable overnight in this context.  The signal is 
low in healthy subjects due to the reduced loading of the respiratory system and is less reliable. 
We would not recommend using sEMGpara%max in healthy subjects for monitoring neural 
respiratory drive in lateral postures which may occur in sleep overnight or if unloading the 
respiratory muscle pump with interventions such as non-invasive ventilation.  
7.1.2 sEMGpara%max as a marker of patient comfort  
sEMGpara%max has previously been related to markers of breathlessness as measured on Borg 
scale.(191, 205) We demonstrated that during wake the levels of sEMGpara%max were also 
correlated with patient perception of comfort on non-invasive ventilation.    sEMGpara%max could 
be used to monitor patient comfort and optimise respiratory muscle unloading overnight on non-
invasive ventilation.  
7.1.3 sEMGpara%max as a tool to measure respiratory muscle unloading during HMV  
Both HMV set up techniques achieved a significant unloading of the respiratory muscles on the 
first night of NIV compared to self-ventilation.  A median 5% reduction in second intercostal 
parasternal muscle activity was achieved in the physiological led set up of HMV compared to a 
2% reduction in the physician led control. This suggests that using the parasternal signal to set up 
NIV may lead to faster unloading of the respiratory muscles and improved comfort associated with 
lower levels of NRD.  Enhanced respiratory muscle unloading was preserved in the physiological 
led set up of HMV (9%) compared to the physician led control (6%) following 3 months of HMV 
therapy.  Monitoring sEMGpara%max provides a visual guide to the medical professional initiating 
ventilation to set levels of pressure support that is otherwise difficult to quantify.  sEMGpara%max 
could therefore be a useful tool to guide optimal NIV set up and may enhance respiratory muscle 
unloading.  
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7.1.4 sEMGpara%max to guide the set-up of HMV  
The number of ventilator parameter manipulations required by nursing staff and physicians prior 
to initial discharge was greater in the physician led HMV set up group then the physiological led 
set up.  In addition, hospital length of stay was 1 day less in the physiological set up of HMV.  This 
may have important cost savings in optimising the set-up of HMV quickly by using a visual 
feedback to manipulations in settings.  Reducing patient hospital bed days to improve patient 
access to services is an ever increasing challenge for the NHS.  Reducing the burden on 
overnight staff to manipulate ventilator settings may be an advantage to liberate these staff to 
perform other tasks or to facilitate set ups in an outpatient settings where HMV expertise may not 
be available.  
7.1.5 sEMGpara%max as a marker of patient- ventilator asynchrony  
We found sEMGpara to be a useful marker of patients’ inspiratory effort that can be used to 
identify respiration that becomes asynchronous with a mechanical ventilator. Using this technique 
we could non-invasively identify 7 separate types of patient ventilator asynchrony (PVA).  We 
were able to demonstrate that the prevalence of PVA is high affecting a quarter of all breaths 
when studied during a whole night of non-invasive ventilation.  We observed that identifying the 
different types of PVA was reproducible using 2 independent skilled observers.  The most 
common type of PVA were ineffective efforts that was most concordant.  Due to the time 
consuming nature of visual inspection of each trace this reliability could be automated to provide a 
real-time download of patient ventilator interaction. It was not possible to eliminate PVA overnight 
following accurate identification of PVA using fixed pressure settings.  
 
7.2 Patient-ventilator asynchrony what have we learnt  
7.2.1 Prevalence of PVA 
Patient awareness of PVA was high with 61% of 110 patients surveyed aware of difficulties in 
synchronising with their ventilator. Patients were most able to describe difficulties with ineffective 
efforts (43%) followed by autotriggering events (40%).  Cycling asynchrony were less common.  
Overall, patient reported PVA was less frequent than the data obtained from examination of 
patient-ventilator interaction during overnight sleep studies.  These data demonstrated that 
patients were unable to recall the type of PVA that had occurred overnight when questioned the 
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following morning.  PVA may therefore not be accurately reported by patients suggesting if 
patient-ventilator interaction difficulties are suspected they should be formally examined prior to 
changes in ventilator settings being made in an outpatient review.  
PVA was observed in all patients during overnight assessments.  PVA levels were high affecting a 
quarter of all breaths overall.  As with the patient reported survey, ineffective efforts remained the 
dominant PVA observed affecting 10% of all breaths. These levels exceed those previously 
described during non-invasive ventilation and are likely to represent the prolonged observation 
time.(76, 89) No significant improvement was observed in PVA with time spent on NIV at 3 
months. This suggests that PVA levels remain high and are not related to acclimatisation to 
ventilation.  In support of this a study by Atkeson et al. did not find pressure support levels or the 
duration of NIV use to be predictive of the severity of PVA in ALS patients using a multiple 
regression analysis.(206)  Recently, Virjsen et al. also identified similar proportions of PVA at both 
discharge and 1 month post the set-up of HMV in the same patient group.(207)  
The current PVA index which is widely used to describe the severity of PVA may not be useful in 
patients receiving non-invasive ventilation as the proportions of PVA are high.(77)  A new index is 
required to standardise the reporting of PVA between studies so that the frequency of events can 
be compared. 
7.2.2 PVA in different disease groups  
In this thesis, no difference was observed in the total amounts of asynchrony between the patient 
disease groups on either the first night of HMV set-up or 3 months post HMV therapy.  In support 
of this finding Carlucci et al, have also recently reported no difference in PVA between patients 
with restrictive or obstructive lung disease.(146)   In addition, PVA did not correlated with markers 
of pulmonary mechanics such as the pressure-time product of the diaphragm, tidal volume, 
pulmonary resistance or dynamic compliance.(146)  This may suggest that in ‘real-life’ PVA is 
mainly related to external factors such as leak at the interface rather than the patient disease 
process itself.  
7.2.3 Controlling PVA with fixed bi-level ventilation settings  
Overall we were not able to significantly improve on PVA in the intervention arm of our pilot 
randomised control trial (RCT) compared to the physician led control.  However, half the number 
of ineffective efforts were seen on the first night of HMV in the physiological led set-up of HMV 
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compared to the physician led set-up arm, although this did not reach statistical significance  A 
clinically significant reduction is very difficult to quantify but this would be below the threshold of 
severe asynchrony affecting 10% breaths set by Thille et al.(77) No significant difference in the 
levels of any PVA was observed at 3 months post therapy.  Although, it would be ambitious to 
expect that changes to a ventilator made 3 months earlier would result in a persistent reduction in 
PVA levels. 
PVA is very difficult to control due to the dynamic interplay between patient and the ventilator. In 
terms of pulmonary mechanics breath by breath variability occurs in lung recruitment, increasing 
tidal volumes which may conceivably lead to dynamic hyperinflation. Ventilation is currently 
delivered in the main by fixed pressure settings which do not adapt whereas, pressure support 
requirements may decrease with effective ventilation within hours; by offsetting intrinsic PEEP, 
facilitating lung emptying and improving the pressure volume relationship of the lung.  This may 
result in a relative over assistance from pressure support with time on ventilation and may explain 
some success of newer modes of adaptive ventilation such as average volume assured pressure 
support (AVAPS), average volume assured pressure support with auto EPAP (AVAPS-AE) and 
intelligent volume-assured pressure assist (iVAPS).  All modes maintain a target tidal volume with 
variable pressure support as much as is required to achieve it and the AE addition maintains a 
patient upper airway with a variable EPAP.  The iVAPS mode also adjusts the back-up rate to 
facilitate the maximum number of patient triggered breaths.  In the main studies comparing these 
novel modes of ventilation have demonstrated equivalence with conventional pressure support 
modes of ventilation in both control of nocturnal gas exchange and sleep disruption.(156, 208, 
209)   Of interest in a study of 18 patients Kelly et al, described an improved adherence to 
treatment with iVAPS mode and a patient preference for this mode of ventilation.(210)   It is 
unclear as if this was related to lower pressure support levels used in the intervention arm or if 
this may relate to enhanced patient ventilator interaction.  A confounding factor was also that the 
trial design did not blind participants to the treatment received.  To date, no studies of PVA in 
these auto-titrating modes of ventilation have been conducted to assess if these can suppress 
current levels and improve patient outcomes.  Neurally adjust ventilator assist (NAVA) mode of 
ventilation has been shown to consistently reduce PVAs in both an invasive and non-invasive 
setting. (138, 141, 211) Despite this, no significant impact on patient outcomes has yet been 
reported. In fact, as with the auto-titrating ventilatory modes, NAVA has demonstrated 
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equivalence to pressure support ventilation, in terms of both gas exchange and patient comfort. 
(138, 141) Furthermore, another study by Vrijsen et al. also identified high proportions of PVA 
despite meticulous titration of NIV in ALS patients over 3 nights using a fixed bilevel ventilator 
Trilogy 100 (Philips, Murrysville, PA, USA).(207)  
Leak at the interface plays a large role particularly in disrupting the inspiratory triggering of the 
ventilator which depends on stability of the interface to detect a rate of change of inspiratory 
flow.(176) Leak may vary with different types of interface with different seal integrity, different 
postures adopted by the patient overnight, relative changes in tone of the chin muscles with 
different stages of sleep and be extremely difficult to achieve in those patients with bulbar 
weakness.   
Changes in NRD have been observed between the different sleep stages and wake. Recently Xu 
et al. demonstrated that NRD to the diaphragm fell by 26% in non-REM sleep and 39% in REM-
sleep compared to wakefulness in COPD patients overnight.(212)  These complex changes in 
NRD affect respiratory muscle recruitment and thereby the rate of change of flow achieved at the 
mask which is required to trigger ventilatory support. Trigger sensitivities are fixed in standard bi-
level ventilators and so there is currently no adaption to compensate for changes in pulmonary 
mechanics between lighter stages of sleep, deep sleep and wake.  This again makes achieving 
perfect patient-ventilator synchronisation a challenge.  
7.2.4 PVA and Adherence to HMV 
In this study we did not find any association between the amount of PVA and adherence to HMV 
at 6 weeks or 3 months.  Adherence to HMV is affected by multiple factors; in particular, frequent 
issues are raised surrounding the mask type, mask fit and leak especially into the eyes, 
claustrophobia and the overall comfort or tolerability of the interface.   Other barriers may include 
mouth dryness, too much or too little humidification of the circuit, nasal congestion or skin 
reactions to the mask.(213)   In addition to physical barriers, patient motivation, lifestyle factors, 
symptom burden, perceived benefit of treatment, patient understanding of their underlying 
disease process and need for treatment all contribute to patient adherence.(214)  Furthermore, 
the RCT reported in this thesis has demonstrated that patients were unaware of levels of PVA or 
the types of PVA occurring during sleep suggesting that this would therefore not have a negative 
impact on their experience of NIV. (Section 4.3.9).  
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7.2.5 PVA and Gas Exchange 
Despite higher proportions of asynchrony observed in our cohort, there was no demonstrable 
effect on overnight gas exchange.  This is in contrast to previous data suggesting that ineffective 
efforts are associated with overnight oxygen desaturation (76).  This may, in part, be explained by 
the ventilator back up rate in the current study.  The study by Fanfulla et al,(76) was performed in 
patients already established on HMV and the study used low-level pressure support and rather 
unusually for patients with NMD there was no back-up rate applied.  This would not be the current 
clinical approach, based on the evidence, which supports the use of a mandatory back up rate in 
NMD patients (215), ORRF patients (156, 216) and COPD (54).  These data have demonstrated 
that optimal set up of the inspiratory positive airway pressure, the expiratory positive airway 
pressure and the back-up rate is more important, in terms of control of gas exchange, than PVA. 
7.2.6 PVA and respiratory muscle loading 
No association was observed between respiratory muscle loading and patient ventilator 
asynchrony during the first night of HMV therapy or 3 months post HMV therapy.  Previous work 
has identified that PVAs such as ineffective efforts are associated with an increased work of 
breathing measured by the PTPdi.(8, 88, 217)  The lack of association been PVA (particularly IE) 
and work of breathing was surprising and may relate to our method of analysis.  We measured 
respiratory muscle loading as the peak RMS of the sEMGpara signal and did not consider the 
length of time of overall muscle contraction.  It may be that on HMV with expertise in optimising 
pressure support levels as used in this study that the peak muscle activity levels are supressed 
but the total length of contraction is significant.  Measuring the area under the curve once ECG 
artefact is removed from the signal may be a better method of evaluating this fully. We are 
currently working with biomedical engineers in collaboration with Philips research to identify a 
technique in which to achieve this. 
7.2.7 PVA and Patient Quality of Life Measures 
Over 3 months of HMV therapy significant improvements were seen in patient HRQL measures 
using the SRI sum score, the RAND-36, the HAD score and the ESS.  These improvements were 
observed as early as 6 weeks post initiation of treatment and this benefit was sustained at 3 
months. This is in agreement with previous work demonstrating that HMV improves HRQL 
measures in patients with COPD, obesity, NMD and CWD.(40, 51, 67, 133, 163)  
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No differences were observed in the HRQL outcome measures using the SRI, SGRQ, RAND-36, 
FSS, ESS and HAD questionnaires between the different disease groups following 3 months of 
HMV. 
No correlation was observed with changes in HRQL measures using total SRI scores, RAND-36, 
HAD, ESS, FSS and changes in PVA levels. A weak association was observed with the changes 
in SGRQ scores and levels of PVA.  A correlation was also observed in changes of anxiety 
domain of the SRI questionnaire and the amount of PVA.  This may suggest that patients who are 
more anxious are less likely to synchronise well with NIV.  However, the effect of anxiety was not 
consistent when examining the anxiety component of the HAD.  The challenge is that using 
anxiolytic medication in an effort to demonstrate this association also supresses NRD which may 
directly affect PVA.  It would therefore be very difficult to unpick if it is the change in anxiety itself 
leading to changes in the frequency of PVA.   
PVA therefore may contribute to patient anxiety on HMV and some components of patient 
perception of HRQL although this was not a consistent finding across most common used HRQL 
questionnaires.   
7.2.8 PVA and Sleep Efficiency 
The amount of PVA was not heightened in any sleep stage at the initiation of NIV but at 3 months 
of treatment PVA was more frequently observed in lighter stages 1&2 of sleep than deep stage 3 
sleep.  PVA was not supressed in REM sleep as previously described.(75, 176)  No correlation 
was observed between PVA during sleep and the percentage of sleep time spent in stage 3 or 
REM sleep at initiation or 3 months of HMV therapy.   
PVA was observed to precede approximately 50% of arousals both at the initiation of HMV and 3 
months of treatment with no decrease in events following acclimatisation to NIV. The prevalence 
of PVA is so high affecting a quarter of breaths that is difficult to be clear if it is the PVA itself that 
is responsible.  Indeed less than 10% of all PVA preceded an arousal suggesting that the majority 
of events are definitely not responsible for sleep disruption.   In accordance, with data recently 
published by Vrijsen et al. in patients with ALS we found ineffective efforts to precede most 
arousals which of course is the most prevalent PVA.(207)    Arousals were far more likely to occur 
in the lighter stages of sleep with the fewest arousals occurring in REM sleep despite similar 
amounts of PVA.   Furthermore, PVA during sleep was not correlated to arousal levels overnight.  
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No relationship was observed between the total amounts of PVA or the proportion of PVA 
occurring during sleep and overall sleep efficiency, WASO or total sleep time at either initiation of 
HMV or 3 months post treatment. No relationship was observed between the PVA during wake 
and sleep latency at initiation of HMV.  However, a relationship was demonstrated between the 
PVA levels occurring during wake and the sleep latency at 3 months.  On the first night of HMV, 
we could imagine that multiple factors are affecting sleep latency with patients adapting to a new 
mask and the experience of overnight ventilatory pressures.  Once patients are established on 
HMV at 3 months the impact of these external factors may have diminished and one could expect 
that if the patient is not synchronising well on the ventilator when awake they may not be able to 
relax into a physiological state required for sleep.   
7.3 Inspiratory trigger delay   
Respiratory muscle activity as measured by sEMGpara%max was not effectively unloaded in 
COPD patients whilst on non-invasive ventilation with trigger delay.  Indeed sEMGpara%max 
activity almost doubled from 18% to 33% when increasing the inspiratory delay between 10 and 
1000ms.  Healthy subjects as expected were able to cope with inspiratory trigger delay better and 
only increased NRD in the context of applied pressure support when the inspiratory trigger delays 
were more than 450ms.   
COPD patients were most comfortable at the shortest inspiratory trigger delay setting of 10ms 
and as expected most uncomfortable at the longest trigger delay setting of 1000ms.  Once the 
inspiratory trigger delay setting was longer than 150ms, comfort scores declined with increasing 
trigger delay settings suggesting that in COPD patients trigger delays should be kept below this 
level.  Healthy subjects tolerated trigger delay more easily and achieve maximum comfort at 120 
and 150ms delays. This may be related to the increased reserve of the respiratory system and as 
pressure support was not required to alleviate symptoms a gentler response from the ventilator 
was preferred.  
Both healthy and COPD patients spent approximately 15% of their inspiratory time without 
ventilatory support made up of delays in triggering the ventilator.  Healthy subjects demonstrated 
a reduced rate of change of flow and a slower breathing rate than COPD patients.  They therefore 
exhibited an increased ventilator sensing trigger delay compared to COPD patients (i.e. the 
ventilator took longer to detect the rate of change of flow at the mouth). COPD patients had longer 
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intrinsic patient delay compared to healthy subjects (i.e. the patient took longer to generate a rate 
of change of flow at the mouth).  This is best explained by considering the well described 
‘threshold load’ placed on patients with COPD which results in a delay between the onset of 
respiratory muscle contraction and flow at the mouth.  The current ventilators are triggered by a 
change in the rate of flow detected at the mouth and resulting in a delay in their response.  Future 
modes of triggering the ventilator from the parasternal signal may improve upon these delays and 
reduce the overall work of breathing in this patient group.   In the interim, we should continue to 
look at ways of reducing the ‘threshold load’ with adequate bronchodilators and appropriate levels 
of EPAP to open the airways and facilitate lung emptying.   
 
7.4 Conclusion 
Overall, the data presented in this thesis confirmed that the proportions of PVA are high affecting 
all patients on non-invasive ventilation for approximately a quarter of all breaths.  We were unable 
to demonstrate a significant impact of PVA on patient outcomes such as adherence to home 
mechanical ventilation, gas exchange, patient quality of life measures or sleep quality from these 
studies.  This would suggest that controlling for PVA during sleep may not confer as much benefit 
as previously thought particularly in a non-invasive ventilatory setting.   Clinicians focus should 
remain on achieving improved patient-ventilator synchrony during wake to facilitate sleep onset 
but concentrate on achieving improvements in gas exchange particularly reductions in arterial 
carbon dioxide levels and off-loading the respiratory muscles through appropriate pressure 
support levels and back-up rate where required. 
Measuring sEMGpara during sleep may be a useful tool to guide the optimal levels of pressure 
support for an individual patient.  It is a helpful marker to monitor the interaction between the 
ventilator and the patient and reducing levels of NRD may improve patient comfort on non-
invasive ventilation.  Furthermore, using sEMGpara to facilitate the set-up of HMV may be a cost-
effective way to achieve titration pressures in an outpatient setting rather than requiring a costly 
inpatient overnight stay.   
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7.5 Future work 
Future work should focus on using the sEMGpara for respiratory muscle unloading to optimise 
ventilator pressure support settings in non-expert centres to see if the parasternal signal is easily 
transferrable for general use.   A randomised control trial would be useful to examine the utility of 
using the sEMGpara signal to set–up HMV as an outpatient compared to an inpatient initiation.  
The primary outcome could examine cost-effectiveness of the set-up with secondary outcomes 
examining patient adherence to HMV therapy, adequacy of gas exchange and patient health 
related quality of life measures.  
Although we have attempted a thorough assessment of PVA on patient outcomes, we were 
unable to examine the effect of PVA on the autonomic nervous system and if PVA has an impact 
on critical cardiovascular outcomes mediated through changes in heart rate variability or blood 
pressure.  
Personally I would also like to further examine the significance of identifying NRD via 
sEMGpara%max in REM sleep, to establish if it is persistent finding in patients with chronic 
respiratory failure or diminishes with time on HMV.  I would also like to consider this a predictor of 
improved patient outcome if NRD is preserved in the context of severe chronic lung disease.  
 The future of ventilation is changing rapidly often modes of therapy are available for main stream 
use before clinical trials have deemed them to confer much benefit.  Hopefully following on from 
our collaboration with Philips Research and their bioelectrical engineers we will be close to 
removing ECG artefact from the parasternal signal.  The utility of the sEMGpara signal could then 
be assessed as an automated measure of changes in NRD with adaptive modes of ventilator 
settings as a ‘real-time’ assessment overnight. An automated assessment of PVA would also 
assist the clinician in identifying if using these dynamic modes of delivering ventilation confer any 
additional benefit on reducing the levels of PVA    
Lastly, further work should explore the potential of using the parasternal signal as a trigger for the 
home mechanical ventilator overnight to improve upon neuroventilatory coupling and negate the 
issue of leak at the interface affecting triggering of the ventilator.  We would however recommend 
a standard flow trigger back up for periods of poor sEMGpara signal quality such as during 
periods of movement
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Appendix 2: A case example of sEMGpara led titration of HMV 
 
Patient details: 61 year old female COPD/OSA, FEV1 0.7L (35%), FVC 2.00L (84%),  
Weight 100kg, BMI 41.6 kg/m2, PaO2 5.4kPa, PaCO2 9.4kPa, HCO3 40mmol/L, pH 7.37  
 





































































































































































33:25 33:30 33:35 33:40
A B 
C 
Final settings C): 
1)Titrated IPAP 12 to 28 
2)Titrated EPAP 4-8 (ineffective 
efforts) 
3)Reduced inspiratory trigger from 4 
to 2 
4)Adjusted mask leak 
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Appendix 5: PSG scoring agreement of 10 studies between myself (MR) and an ASA accredited sleep 
technician 
 
PSG studies  Agreement (%) Kappa Score 
1 (9/9/13) 92.8 0.90 Very good 
2 (27/9/13) 92.4 0.90 Very good 
3 (22/8/13) 93.9 0.92 Very good 
4 (26/9/13) 94.9 0.93 Very good 
5 (20/9/13) 93.8 0.92 Very good 
6 (6/9/13) 92.5 0.91 Very good 
7 (20/9/13) 94.5 0.92 Very good 
8 (3/10/13) 93.2 0.91 Very good 
9 (21/10/13) 93.2 0.90 Very good 
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Appendix 6: Patient -Ventilator Asynchrony Questionnaires 




Spirometry: FEV1/ FVC 
Oxygen Sats: 
Date of Starting Ventilation: 
Ventilator model: 
Ventilator Settings: 
Please circle below: 
1) Have you noticed any difficulties in co-ordinating your breathing with your ventilator?      YES            
NO 
If YES please answer question 2- 5.  If NO thank you very much for contribution to this survey.  
 
2) Do you sometimes try to breath in but the ventilator does not respond to you? 
       YES           NO 
3) Does your ventilator sometimes give you a breath unexpectedly or without you asking for one? 
      YES          NO 
4) Do you sometimes try to breathe out but your ventilator continues to give you a breath in? 
      YES          NO 
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5) Does the ventilator stop giving you a breath in whilst you are still trying to finish breathing in? 
      YES          NO 
Appendix 7: Patient Ventilator Interaction Questionnaire (PVIQ) 
Illness perception questions for patients requiring NIV 
Has your doctor and/or nurse explained your particular 






Not at all 






A small amount 
Not at all 






Not at all 
Do you think that using your ventilator machine overnight is 
a useful treatment? 
Yes 
No 
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Patient – Ventilator Interaction Score 
Please circle the answer that best applies to you 
1. Do you feel better since starting on your machine? Yes  
No 














5. Can you get back off to sleep on the ventilator after waking in the Always 
 Probably 






















10. Are the breaths the ventilator gives you sometimes too long?  Never 
Occasionally 
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Often 
Always 








13. Are there times when the machine gives you another breath while 











15. Do you have enough time from finishing one breath before the 
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Never 










18. Is your mask comfortable? Yes 
No  





Please circle which type of mask you use: 
a) Nasal mask                                          d) Total face 
b) Nasal pillows  
c) Full face (nose and mouth) 
Thank you for your help 
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